Hospitalist‐Run Observation Unit

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Implementation of a hospitalist‐run observation unit and impact on length of stay (LOS): A brief report

Hospitalists play key roles in many types of clinical services, including teaching, nonteaching, consultative, and comanagement services.14 While the impact of hospitalist programs on LOS for inpatient medicine services has been studied,58 less work has focused on the impact of hospitalists in other types of service delivery, such as in short‐stay or observation units.

While many hospitals now have short‐stay units to care for observation patients, most are adjuncts of the emergency department. A Canadian hospitalist‐run short‐stay unit that targeted patients with an expected LOS of less than 3 days has been described.9 The experience of a single, chest‐painspecific service has also been reported.10

In August 2005, we introduced a hospitalist‐run observation unit, the Clinical Decision Unit (CDU), at University Hospital, the primary teaching affiliate of the University of Texas Health Science Center at San Antonio (San Antonio, TX). The rationale was that observation‐level care in a dedicated short‐stay unit would be more efficient than in an inpatient general medicine service. Through the creation of this unit, we consolidated the care of all medical observation patients, including patients previously evaluated in a cardiology‐run chest pain unit.

In this brief report, we present a description of the unit as well as a preliminary analysis of the impact of the unit on LOS for the most common CDU diagnoses.

Methods

CDU Structure

University Hospital is the Bexar County public hospital. It contains 604 acute care beds, and averages 70,000 emergency visits annually. The CDU is a geographically separate, 10‐bed unit, staffed with dedicated nurses in 8‐hour shifts and 24/7 by hospitalists in 12‐hour shifts. Four to five hospitalists rotate through the CDU monthly. About 30% of shifts are staffed through moonlighting by hospitalist faculty or fellows.

For admissions, through examining hospital LOS data, we targeted diagnoses for which patients might be expected to stay less than 24 hours. Potentially appropriate diagnoses were discussed by the group, and general admission guidelines were created based on consensus. These diagnoses included chest pain, cellulitis, pyelonephritis, syncope, asthma exacerbation, chronic obstructive pulmonary disease exacerbation, hyperglycemia, and hepatic encephalopathy. Table 1 lists these guidelines.

Guidelines for Admissions to CDU for Most Common Diagnoses
Diagnosis Guidelines
  • Abbreviations: CDU, clinical decision unit; ED, emergency department; EKG, electrocardiography.

Chest pain Patients without EKG changes or positive troponins, but for whom stress test was indicated based on history or risk factors
Asthma Patients with oxygen saturation >90% and demonstrating improvement in with ED nebulizer treatment
Syncope Patients without known structural heart disease based on past medical history or exam findings
Cellulitis Patients without suspicion for abscess or osteomyelitis
Pyelonephritis Patients without change from baseline renal function; kidney transplant recipients excluded

If a patient's stay exceeded 23 hours, the hospitalist could transfer the patient from the CDU to a general medicine team. Formal transfer guidelines were not created, but if patients were expected to be discharged within 12 hours, they generally remained in the CDU to minimize transitions. The census of the general medicine teams could also be a factor in transfer decisions: if they were at admitting capacity, the patient remained in the CDU.

Patients admitted to the general medicine units were cared for by 5 teaching teams, staffed exclusively by hospitalists.

Assessment of CDU Implementation on LOS

To examine the impact of unit implementation on LOS, we performed a retrospective, preimplementation/postimplementation comparison of the LOS of patients discharged 12 months before and after the unit opening on August 1, 2005. To ensure a comparison of similar patients, we identified the top 5 most common CDU discharge diagnoses, and identified people discharged from general medicine with the same diagnoses. Specifically, we compared the LOS of patients discharged from the general medicine units from August 1, 2004 to July 31, 2005, vs. those with the same diagnoses discharged from either the CDU or general medicine units from August 1, 2005 to July 31, 2006.

The 5 most common CDU discharge diagnoses were identified using hospital administrative discharge data. All International Statistical Classification of Diseases and Related Health Problems, 9th edition (ICD‐9) codes associated with CDU discharges were identified and listed in order of frequency. Related ICD‐9 codes were grouped. For example, angina (413.0) and chest pain (786.50, 786.59) were considered related, and were included as chest pain. These ICD‐9 codes were then used to identify patients discharged with these diagnoses in the pre‐CDU and post‐CDU periods. Patients on general medicine units were identified using admission location and admitting attending. Only patients admitted by a hospitalist to a general medicine floor were included. Patients were analyzed according to their admission location. All patients with relevant ICD‐9 codes were included in the analysis. None were excluded. For each patient identified, all data elements were present.

The acuity of patients admitted in the preimplementation and postimplementation periods was compared using the case‐mix index calculated by 3M Incorporated's All Patient RefinedDiagnosis‐Related Group methodology (3M APR‐DRG; 3M, St. Paul, MN). This adjusts administrative data for severity of illness and mortality risk based on primary diagnoses, comorbidities, age, and procedures. Patients are assigned to mortality classes with corresponding scores of 0 or higher.

Statistical Analysis

Statistical analyses were performed using STATA 8.0. LOS and acuity differences were assessed using 2‐sample t tests with equal variances.

Results

Clinical Experience with the CDU

The 5 most common CDU discharge diagnoses accounted for 724 discharges, and included chest pain, asthma, syncope, cellulitis, and pyelonephritis. The ICD‐9 codes, as well as the numbers of patients discharged from the general medicine units and CDU with each diagnosis are listed in Table 2. The average daily census in the unit was 7.2 patients with a standard deviation of 0.8. Overall, 22% of CDU admissions were changed from observation to admission status.

Numbers of Patients Discharged from General Medicine Units and CDU in the 12 Months Pre‐CDU (2004‐2005) and Post‐CDU (2005‐2006) Implementation for the 5 Most Common Diagnoses
Diagnosis ICD‐9 Codes Pre‐CDU Post‐CDU Post‐CDU Admitted to CDU Post‐CDU Admitted to Ward Team
  • Abbreviations: CDU, clinical decision unit; ICD‐9, International Statistical Classification of Diseases and Related Health Problems, 9th edition.

Top 5 diagnoses 2240 2148 724 1424
Cellulitis 681.0, 682.0‐682.9 1002 819 48 771
Asthma 493.02, 493.12 199 176 71 105
Chest pain 786.50, 786.59, 413.0 837 917 520 397
Pyelonephritis 590.1, 590.8 143 163 61 102
Syncope 780.2 59 73 24 49

Impact of CDU Implementation on LOS

The overall LOS for patients with the 5 most common diagnoses decreased from 2.4 to 2.2 days (P = 0.05) between the 12‐month preimplementation and postimplementation periods. A significant decrease was seen for patients with cellulitis (2.4‐1.9 days; P < 0.001) and asthma (2.2‐1.2 days; P < 0.001). Differences in LOS for patients with chest pain, pyelonephritis, and syncope were not statistically significant. These results are summarized in Table 3. The acuity of patients admitted in the pre‐CDU and post‐CDU implementation, shown in Table 4, was not significantly different.

Average Length of Stay and Standard Deviation for All Patients Discharged from Any Location in 12‐Month Periods Before and After CDU Implementation
Diagnosis Pre‐CDU Post‐CDU P Value
  • Abbreviation: CDU, clinical decision unit.

Top 5 diagnoses 2.4 (3.8) 2.2 (2.8) 0.05
Cellulitis 2.4 (3.2) 1.9 (2.6) <0.001
Asthma 2.2 (1.9) 1.2 (0.7) <0.001
Chest pain 1.5 (1.3) 1.6 (2.4) 0.75
Pyelonephritis 3.3 (4.9) 2.7 (2.8) 0.27
Syncope 2.0 (2.9) 2.2 (2.0) 0.68
Patient Case‐mix Index as Assessed by 3M APR‐DRG
Diagnosis All Patients2005 All Patients2006
  • Abbreviation: 3M APR‐DRG, 3M Incorporated's All Patient RefinedDiagnosis‐Related Group methodology.

Top 5 diagnoses 0.6987 0.7240
Cellulitis 0.7393 0.7630
Asthma 0.4382 0.4622
Chest pain 0.7428 0.7545
Pyelonephritis 0.7205 0.6662
Syncope 0.6769 0.6619

Discussion and Conclusions

Implementation of a hospitalist‐run observation unit was associated with an overall decreased LOS for patients with the 5 most common CDU discharge diagnoses of chest pain, cellulitis, asthma, pyelonephritis, and syncope. The lack of statistically significantly differences in patient acuity in the preimplementation and postimplementation periods suggests this result is not due to acuity differences, but rather to unit implementation. We believe this reduction resulted from the greater efficiencies of care that occur from clustering observation patients in a geographically separate unit with dedicated nursing staff and efficient workflow. The reduction of 0.2 days over 2148 patients (total number of postimplementation discharges) led to an additional 429.6 days of capacity without adding additional beds. Thus, what might appear to be a modest LOS reduction has a larger impact when patient volume is considered.

For individual diagnoses, significant differences in LOS were seen for patients with cellulitis and asthma The lack of a difference for chest pain may be related to the fact that these patients were cared for in a chest pain unit prior to CDU creation, which likely fostered similar efficiencies. This finding may suggest that hospitalists are as efficient as cardiologists in assessing patients with chest pain. The lack of a difference in LOS for syncope may have reflected a bottleneck in obtaining echocardiogram tests. Finally, the lack of a difference for pyelonephritis may indicate that it is not a diagnosis for which observation is beneficial.

While our use of administrative data over the year‐long preimplementation and postimplementation periods allows for the inclusion of a large number of discharges, the retrospective study design limits the strength of our results. A prospective study would more definitively reduce the possibility of bias and ensure the validity of our finding of reduced LOS.

The creation of a hospitalist‐run observation unit may represent an alternative to emergency departmentrun units. It allows physicians with greater expertise in inpatient medicine to make admission and discharge decisions, allowing emergency department physicians to concentrate on the care of other patients. This can be particularly critical for high‐volume emergency departments. The CDU also offers an alternative to specialist‐run chest pain units. Because patients either stay for only the observation period or are admitted and typically moved off the unit, there is little need for provider continuity, and the discontinuous shift staffing model works well.

In addition to the geographic localization, several aspects of the CDU model may be critical to the successful implementation of similar hospitalist‐run observation units. Dedicated nursing staff with expertise in caring for high‐turnover patients with a more limited spectrum of diagnoses may be a factor. Another factor may be that the lack of less‐experienced trainees in a nonteaching service leads to more efficient care.

A potential area of further exploration includes understanding the differences between CDU patients who are discharged within 23 hours and those who are later admitted. This understanding may help us better differentiate patients appropriate for CDU admission, allowing the creation of more formal admission criteria.

Acknowledgements

The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.

References
  1. Whitcomb WF,Nelson JR.The role of hospitalists in medical education.Am J Med.1999;107(4):305309.
  2. Wachter RM,Katz P,Showstack J,Bindman AB,Goldman L.Reorganizing an academic medical service: impact on cost, quality, patient satisfaction, and education.JAMA.1998;279:15601565.
  3. Huddleston JM,Long KH,Naessens JM, et al.,Hospitalist‐Orthopedic Team Trial Investigators. Medical and surgical comanagement after elective hip and knee arthroplasty: a randomized, controlled trial.Ann Intern Med.2004;141(1):2838.
  4. Auerbach AD,Wachter RM,Katz P,Showstack J,Baron RB,Goldman L.Implementation of a voluntary hospitalist service at a community teaching hospital: improved efficiency and patient outcomes.Ann Intern Med.2002;137:859865.
  5. Lindenauer PK,Rothberg MB,Pekow PS,Kenwood C,Benjamin EM,Auerbach AD.Outcomes of care by hospitalists, general internists, and family physicians.N Engl J Med.2007;357(25):25892600.
  6. Southern WN,Berger MA,Bellin EY,Hailpern SM,Arnsten JH.Hospitalist care and length of stay in patients requiring complex discharge planning and close clinical monitoring.Arch Intern Med.2007;167(17):18691874.
  7. Everett G,Uddin N,Rudloff B.Comparison of hospital costs and length of stay for community internists, hospitalists, and academicians.J Gen Int Med.2007;22(5):662667.
  8. Meltzer D,Manning WG,Morrison J, et al.Effects of physician experience on cost and outcomes on an academic general medicine service: results of a trial of hospitalists.Ann Intern Med.2002;37:866875.
  9. Abenhain HA,Kahn SR,Raffoul J,Becker MR.Program description: a hospitalist‐run, medical short‐stay unit in a teaching hospital.CMAJ.2000;163(11):14771480.
  10. Myers JS,Bellini LM,Rohrbach J,Shofter FS,Hollander JE.Improving resource utilization in a teaching hospital: development of a nonteaching service for chest pain admissions.Acad Med.2006;81(5):432435.
Article PDF
Issue
Journal of Hospital Medicine - 5(9)
Page Number
E2-E5
Legacy Keywords
asthma, chest pain, clinical, outcomes measurement
Sections
Article PDF
Article PDF

Hospitalists play key roles in many types of clinical services, including teaching, nonteaching, consultative, and comanagement services.14 While the impact of hospitalist programs on LOS for inpatient medicine services has been studied,58 less work has focused on the impact of hospitalists in other types of service delivery, such as in short‐stay or observation units.

While many hospitals now have short‐stay units to care for observation patients, most are adjuncts of the emergency department. A Canadian hospitalist‐run short‐stay unit that targeted patients with an expected LOS of less than 3 days has been described.9 The experience of a single, chest‐painspecific service has also been reported.10

In August 2005, we introduced a hospitalist‐run observation unit, the Clinical Decision Unit (CDU), at University Hospital, the primary teaching affiliate of the University of Texas Health Science Center at San Antonio (San Antonio, TX). The rationale was that observation‐level care in a dedicated short‐stay unit would be more efficient than in an inpatient general medicine service. Through the creation of this unit, we consolidated the care of all medical observation patients, including patients previously evaluated in a cardiology‐run chest pain unit.

In this brief report, we present a description of the unit as well as a preliminary analysis of the impact of the unit on LOS for the most common CDU diagnoses.

Methods

CDU Structure

University Hospital is the Bexar County public hospital. It contains 604 acute care beds, and averages 70,000 emergency visits annually. The CDU is a geographically separate, 10‐bed unit, staffed with dedicated nurses in 8‐hour shifts and 24/7 by hospitalists in 12‐hour shifts. Four to five hospitalists rotate through the CDU monthly. About 30% of shifts are staffed through moonlighting by hospitalist faculty or fellows.

For admissions, through examining hospital LOS data, we targeted diagnoses for which patients might be expected to stay less than 24 hours. Potentially appropriate diagnoses were discussed by the group, and general admission guidelines were created based on consensus. These diagnoses included chest pain, cellulitis, pyelonephritis, syncope, asthma exacerbation, chronic obstructive pulmonary disease exacerbation, hyperglycemia, and hepatic encephalopathy. Table 1 lists these guidelines.

Guidelines for Admissions to CDU for Most Common Diagnoses
Diagnosis Guidelines
  • Abbreviations: CDU, clinical decision unit; ED, emergency department; EKG, electrocardiography.

Chest pain Patients without EKG changes or positive troponins, but for whom stress test was indicated based on history or risk factors
Asthma Patients with oxygen saturation >90% and demonstrating improvement in with ED nebulizer treatment
Syncope Patients without known structural heart disease based on past medical history or exam findings
Cellulitis Patients without suspicion for abscess or osteomyelitis
Pyelonephritis Patients without change from baseline renal function; kidney transplant recipients excluded

If a patient's stay exceeded 23 hours, the hospitalist could transfer the patient from the CDU to a general medicine team. Formal transfer guidelines were not created, but if patients were expected to be discharged within 12 hours, they generally remained in the CDU to minimize transitions. The census of the general medicine teams could also be a factor in transfer decisions: if they were at admitting capacity, the patient remained in the CDU.

Patients admitted to the general medicine units were cared for by 5 teaching teams, staffed exclusively by hospitalists.

Assessment of CDU Implementation on LOS

To examine the impact of unit implementation on LOS, we performed a retrospective, preimplementation/postimplementation comparison of the LOS of patients discharged 12 months before and after the unit opening on August 1, 2005. To ensure a comparison of similar patients, we identified the top 5 most common CDU discharge diagnoses, and identified people discharged from general medicine with the same diagnoses. Specifically, we compared the LOS of patients discharged from the general medicine units from August 1, 2004 to July 31, 2005, vs. those with the same diagnoses discharged from either the CDU or general medicine units from August 1, 2005 to July 31, 2006.

The 5 most common CDU discharge diagnoses were identified using hospital administrative discharge data. All International Statistical Classification of Diseases and Related Health Problems, 9th edition (ICD‐9) codes associated with CDU discharges were identified and listed in order of frequency. Related ICD‐9 codes were grouped. For example, angina (413.0) and chest pain (786.50, 786.59) were considered related, and were included as chest pain. These ICD‐9 codes were then used to identify patients discharged with these diagnoses in the pre‐CDU and post‐CDU periods. Patients on general medicine units were identified using admission location and admitting attending. Only patients admitted by a hospitalist to a general medicine floor were included. Patients were analyzed according to their admission location. All patients with relevant ICD‐9 codes were included in the analysis. None were excluded. For each patient identified, all data elements were present.

The acuity of patients admitted in the preimplementation and postimplementation periods was compared using the case‐mix index calculated by 3M Incorporated's All Patient RefinedDiagnosis‐Related Group methodology (3M APR‐DRG; 3M, St. Paul, MN). This adjusts administrative data for severity of illness and mortality risk based on primary diagnoses, comorbidities, age, and procedures. Patients are assigned to mortality classes with corresponding scores of 0 or higher.

Statistical Analysis

Statistical analyses were performed using STATA 8.0. LOS and acuity differences were assessed using 2‐sample t tests with equal variances.

Results

Clinical Experience with the CDU

The 5 most common CDU discharge diagnoses accounted for 724 discharges, and included chest pain, asthma, syncope, cellulitis, and pyelonephritis. The ICD‐9 codes, as well as the numbers of patients discharged from the general medicine units and CDU with each diagnosis are listed in Table 2. The average daily census in the unit was 7.2 patients with a standard deviation of 0.8. Overall, 22% of CDU admissions were changed from observation to admission status.

Numbers of Patients Discharged from General Medicine Units and CDU in the 12 Months Pre‐CDU (2004‐2005) and Post‐CDU (2005‐2006) Implementation for the 5 Most Common Diagnoses
Diagnosis ICD‐9 Codes Pre‐CDU Post‐CDU Post‐CDU Admitted to CDU Post‐CDU Admitted to Ward Team
  • Abbreviations: CDU, clinical decision unit; ICD‐9, International Statistical Classification of Diseases and Related Health Problems, 9th edition.

Top 5 diagnoses 2240 2148 724 1424
Cellulitis 681.0, 682.0‐682.9 1002 819 48 771
Asthma 493.02, 493.12 199 176 71 105
Chest pain 786.50, 786.59, 413.0 837 917 520 397
Pyelonephritis 590.1, 590.8 143 163 61 102
Syncope 780.2 59 73 24 49

Impact of CDU Implementation on LOS

The overall LOS for patients with the 5 most common diagnoses decreased from 2.4 to 2.2 days (P = 0.05) between the 12‐month preimplementation and postimplementation periods. A significant decrease was seen for patients with cellulitis (2.4‐1.9 days; P < 0.001) and asthma (2.2‐1.2 days; P < 0.001). Differences in LOS for patients with chest pain, pyelonephritis, and syncope were not statistically significant. These results are summarized in Table 3. The acuity of patients admitted in the pre‐CDU and post‐CDU implementation, shown in Table 4, was not significantly different.

Average Length of Stay and Standard Deviation for All Patients Discharged from Any Location in 12‐Month Periods Before and After CDU Implementation
Diagnosis Pre‐CDU Post‐CDU P Value
  • Abbreviation: CDU, clinical decision unit.

Top 5 diagnoses 2.4 (3.8) 2.2 (2.8) 0.05
Cellulitis 2.4 (3.2) 1.9 (2.6) <0.001
Asthma 2.2 (1.9) 1.2 (0.7) <0.001
Chest pain 1.5 (1.3) 1.6 (2.4) 0.75
Pyelonephritis 3.3 (4.9) 2.7 (2.8) 0.27
Syncope 2.0 (2.9) 2.2 (2.0) 0.68
Patient Case‐mix Index as Assessed by 3M APR‐DRG
Diagnosis All Patients2005 All Patients2006
  • Abbreviation: 3M APR‐DRG, 3M Incorporated's All Patient RefinedDiagnosis‐Related Group methodology.

Top 5 diagnoses 0.6987 0.7240
Cellulitis 0.7393 0.7630
Asthma 0.4382 0.4622
Chest pain 0.7428 0.7545
Pyelonephritis 0.7205 0.6662
Syncope 0.6769 0.6619

Discussion and Conclusions

Implementation of a hospitalist‐run observation unit was associated with an overall decreased LOS for patients with the 5 most common CDU discharge diagnoses of chest pain, cellulitis, asthma, pyelonephritis, and syncope. The lack of statistically significantly differences in patient acuity in the preimplementation and postimplementation periods suggests this result is not due to acuity differences, but rather to unit implementation. We believe this reduction resulted from the greater efficiencies of care that occur from clustering observation patients in a geographically separate unit with dedicated nursing staff and efficient workflow. The reduction of 0.2 days over 2148 patients (total number of postimplementation discharges) led to an additional 429.6 days of capacity without adding additional beds. Thus, what might appear to be a modest LOS reduction has a larger impact when patient volume is considered.

For individual diagnoses, significant differences in LOS were seen for patients with cellulitis and asthma The lack of a difference for chest pain may be related to the fact that these patients were cared for in a chest pain unit prior to CDU creation, which likely fostered similar efficiencies. This finding may suggest that hospitalists are as efficient as cardiologists in assessing patients with chest pain. The lack of a difference in LOS for syncope may have reflected a bottleneck in obtaining echocardiogram tests. Finally, the lack of a difference for pyelonephritis may indicate that it is not a diagnosis for which observation is beneficial.

While our use of administrative data over the year‐long preimplementation and postimplementation periods allows for the inclusion of a large number of discharges, the retrospective study design limits the strength of our results. A prospective study would more definitively reduce the possibility of bias and ensure the validity of our finding of reduced LOS.

The creation of a hospitalist‐run observation unit may represent an alternative to emergency departmentrun units. It allows physicians with greater expertise in inpatient medicine to make admission and discharge decisions, allowing emergency department physicians to concentrate on the care of other patients. This can be particularly critical for high‐volume emergency departments. The CDU also offers an alternative to specialist‐run chest pain units. Because patients either stay for only the observation period or are admitted and typically moved off the unit, there is little need for provider continuity, and the discontinuous shift staffing model works well.

In addition to the geographic localization, several aspects of the CDU model may be critical to the successful implementation of similar hospitalist‐run observation units. Dedicated nursing staff with expertise in caring for high‐turnover patients with a more limited spectrum of diagnoses may be a factor. Another factor may be that the lack of less‐experienced trainees in a nonteaching service leads to more efficient care.

A potential area of further exploration includes understanding the differences between CDU patients who are discharged within 23 hours and those who are later admitted. This understanding may help us better differentiate patients appropriate for CDU admission, allowing the creation of more formal admission criteria.

Acknowledgements

The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.

Hospitalists play key roles in many types of clinical services, including teaching, nonteaching, consultative, and comanagement services.14 While the impact of hospitalist programs on LOS for inpatient medicine services has been studied,58 less work has focused on the impact of hospitalists in other types of service delivery, such as in short‐stay or observation units.

While many hospitals now have short‐stay units to care for observation patients, most are adjuncts of the emergency department. A Canadian hospitalist‐run short‐stay unit that targeted patients with an expected LOS of less than 3 days has been described.9 The experience of a single, chest‐painspecific service has also been reported.10

In August 2005, we introduced a hospitalist‐run observation unit, the Clinical Decision Unit (CDU), at University Hospital, the primary teaching affiliate of the University of Texas Health Science Center at San Antonio (San Antonio, TX). The rationale was that observation‐level care in a dedicated short‐stay unit would be more efficient than in an inpatient general medicine service. Through the creation of this unit, we consolidated the care of all medical observation patients, including patients previously evaluated in a cardiology‐run chest pain unit.

In this brief report, we present a description of the unit as well as a preliminary analysis of the impact of the unit on LOS for the most common CDU diagnoses.

Methods

CDU Structure

University Hospital is the Bexar County public hospital. It contains 604 acute care beds, and averages 70,000 emergency visits annually. The CDU is a geographically separate, 10‐bed unit, staffed with dedicated nurses in 8‐hour shifts and 24/7 by hospitalists in 12‐hour shifts. Four to five hospitalists rotate through the CDU monthly. About 30% of shifts are staffed through moonlighting by hospitalist faculty or fellows.

For admissions, through examining hospital LOS data, we targeted diagnoses for which patients might be expected to stay less than 24 hours. Potentially appropriate diagnoses were discussed by the group, and general admission guidelines were created based on consensus. These diagnoses included chest pain, cellulitis, pyelonephritis, syncope, asthma exacerbation, chronic obstructive pulmonary disease exacerbation, hyperglycemia, and hepatic encephalopathy. Table 1 lists these guidelines.

Guidelines for Admissions to CDU for Most Common Diagnoses
Diagnosis Guidelines
  • Abbreviations: CDU, clinical decision unit; ED, emergency department; EKG, electrocardiography.

Chest pain Patients without EKG changes or positive troponins, but for whom stress test was indicated based on history or risk factors
Asthma Patients with oxygen saturation >90% and demonstrating improvement in with ED nebulizer treatment
Syncope Patients without known structural heart disease based on past medical history or exam findings
Cellulitis Patients without suspicion for abscess or osteomyelitis
Pyelonephritis Patients without change from baseline renal function; kidney transplant recipients excluded

If a patient's stay exceeded 23 hours, the hospitalist could transfer the patient from the CDU to a general medicine team. Formal transfer guidelines were not created, but if patients were expected to be discharged within 12 hours, they generally remained in the CDU to minimize transitions. The census of the general medicine teams could also be a factor in transfer decisions: if they were at admitting capacity, the patient remained in the CDU.

Patients admitted to the general medicine units were cared for by 5 teaching teams, staffed exclusively by hospitalists.

Assessment of CDU Implementation on LOS

To examine the impact of unit implementation on LOS, we performed a retrospective, preimplementation/postimplementation comparison of the LOS of patients discharged 12 months before and after the unit opening on August 1, 2005. To ensure a comparison of similar patients, we identified the top 5 most common CDU discharge diagnoses, and identified people discharged from general medicine with the same diagnoses. Specifically, we compared the LOS of patients discharged from the general medicine units from August 1, 2004 to July 31, 2005, vs. those with the same diagnoses discharged from either the CDU or general medicine units from August 1, 2005 to July 31, 2006.

The 5 most common CDU discharge diagnoses were identified using hospital administrative discharge data. All International Statistical Classification of Diseases and Related Health Problems, 9th edition (ICD‐9) codes associated with CDU discharges were identified and listed in order of frequency. Related ICD‐9 codes were grouped. For example, angina (413.0) and chest pain (786.50, 786.59) were considered related, and were included as chest pain. These ICD‐9 codes were then used to identify patients discharged with these diagnoses in the pre‐CDU and post‐CDU periods. Patients on general medicine units were identified using admission location and admitting attending. Only patients admitted by a hospitalist to a general medicine floor were included. Patients were analyzed according to their admission location. All patients with relevant ICD‐9 codes were included in the analysis. None were excluded. For each patient identified, all data elements were present.

The acuity of patients admitted in the preimplementation and postimplementation periods was compared using the case‐mix index calculated by 3M Incorporated's All Patient RefinedDiagnosis‐Related Group methodology (3M APR‐DRG; 3M, St. Paul, MN). This adjusts administrative data for severity of illness and mortality risk based on primary diagnoses, comorbidities, age, and procedures. Patients are assigned to mortality classes with corresponding scores of 0 or higher.

Statistical Analysis

Statistical analyses were performed using STATA 8.0. LOS and acuity differences were assessed using 2‐sample t tests with equal variances.

Results

Clinical Experience with the CDU

The 5 most common CDU discharge diagnoses accounted for 724 discharges, and included chest pain, asthma, syncope, cellulitis, and pyelonephritis. The ICD‐9 codes, as well as the numbers of patients discharged from the general medicine units and CDU with each diagnosis are listed in Table 2. The average daily census in the unit was 7.2 patients with a standard deviation of 0.8. Overall, 22% of CDU admissions were changed from observation to admission status.

Numbers of Patients Discharged from General Medicine Units and CDU in the 12 Months Pre‐CDU (2004‐2005) and Post‐CDU (2005‐2006) Implementation for the 5 Most Common Diagnoses
Diagnosis ICD‐9 Codes Pre‐CDU Post‐CDU Post‐CDU Admitted to CDU Post‐CDU Admitted to Ward Team
  • Abbreviations: CDU, clinical decision unit; ICD‐9, International Statistical Classification of Diseases and Related Health Problems, 9th edition.

Top 5 diagnoses 2240 2148 724 1424
Cellulitis 681.0, 682.0‐682.9 1002 819 48 771
Asthma 493.02, 493.12 199 176 71 105
Chest pain 786.50, 786.59, 413.0 837 917 520 397
Pyelonephritis 590.1, 590.8 143 163 61 102
Syncope 780.2 59 73 24 49

Impact of CDU Implementation on LOS

The overall LOS for patients with the 5 most common diagnoses decreased from 2.4 to 2.2 days (P = 0.05) between the 12‐month preimplementation and postimplementation periods. A significant decrease was seen for patients with cellulitis (2.4‐1.9 days; P < 0.001) and asthma (2.2‐1.2 days; P < 0.001). Differences in LOS for patients with chest pain, pyelonephritis, and syncope were not statistically significant. These results are summarized in Table 3. The acuity of patients admitted in the pre‐CDU and post‐CDU implementation, shown in Table 4, was not significantly different.

Average Length of Stay and Standard Deviation for All Patients Discharged from Any Location in 12‐Month Periods Before and After CDU Implementation
Diagnosis Pre‐CDU Post‐CDU P Value
  • Abbreviation: CDU, clinical decision unit.

Top 5 diagnoses 2.4 (3.8) 2.2 (2.8) 0.05
Cellulitis 2.4 (3.2) 1.9 (2.6) <0.001
Asthma 2.2 (1.9) 1.2 (0.7) <0.001
Chest pain 1.5 (1.3) 1.6 (2.4) 0.75
Pyelonephritis 3.3 (4.9) 2.7 (2.8) 0.27
Syncope 2.0 (2.9) 2.2 (2.0) 0.68
Patient Case‐mix Index as Assessed by 3M APR‐DRG
Diagnosis All Patients2005 All Patients2006
  • Abbreviation: 3M APR‐DRG, 3M Incorporated's All Patient RefinedDiagnosis‐Related Group methodology.

Top 5 diagnoses 0.6987 0.7240
Cellulitis 0.7393 0.7630
Asthma 0.4382 0.4622
Chest pain 0.7428 0.7545
Pyelonephritis 0.7205 0.6662
Syncope 0.6769 0.6619

Discussion and Conclusions

Implementation of a hospitalist‐run observation unit was associated with an overall decreased LOS for patients with the 5 most common CDU discharge diagnoses of chest pain, cellulitis, asthma, pyelonephritis, and syncope. The lack of statistically significantly differences in patient acuity in the preimplementation and postimplementation periods suggests this result is not due to acuity differences, but rather to unit implementation. We believe this reduction resulted from the greater efficiencies of care that occur from clustering observation patients in a geographically separate unit with dedicated nursing staff and efficient workflow. The reduction of 0.2 days over 2148 patients (total number of postimplementation discharges) led to an additional 429.6 days of capacity without adding additional beds. Thus, what might appear to be a modest LOS reduction has a larger impact when patient volume is considered.

For individual diagnoses, significant differences in LOS were seen for patients with cellulitis and asthma The lack of a difference for chest pain may be related to the fact that these patients were cared for in a chest pain unit prior to CDU creation, which likely fostered similar efficiencies. This finding may suggest that hospitalists are as efficient as cardiologists in assessing patients with chest pain. The lack of a difference in LOS for syncope may have reflected a bottleneck in obtaining echocardiogram tests. Finally, the lack of a difference for pyelonephritis may indicate that it is not a diagnosis for which observation is beneficial.

While our use of administrative data over the year‐long preimplementation and postimplementation periods allows for the inclusion of a large number of discharges, the retrospective study design limits the strength of our results. A prospective study would more definitively reduce the possibility of bias and ensure the validity of our finding of reduced LOS.

The creation of a hospitalist‐run observation unit may represent an alternative to emergency departmentrun units. It allows physicians with greater expertise in inpatient medicine to make admission and discharge decisions, allowing emergency department physicians to concentrate on the care of other patients. This can be particularly critical for high‐volume emergency departments. The CDU also offers an alternative to specialist‐run chest pain units. Because patients either stay for only the observation period or are admitted and typically moved off the unit, there is little need for provider continuity, and the discontinuous shift staffing model works well.

In addition to the geographic localization, several aspects of the CDU model may be critical to the successful implementation of similar hospitalist‐run observation units. Dedicated nursing staff with expertise in caring for high‐turnover patients with a more limited spectrum of diagnoses may be a factor. Another factor may be that the lack of less‐experienced trainees in a nonteaching service leads to more efficient care.

A potential area of further exploration includes understanding the differences between CDU patients who are discharged within 23 hours and those who are later admitted. This understanding may help us better differentiate patients appropriate for CDU admission, allowing the creation of more formal admission criteria.

Acknowledgements

The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.

References
  1. Whitcomb WF,Nelson JR.The role of hospitalists in medical education.Am J Med.1999;107(4):305309.
  2. Wachter RM,Katz P,Showstack J,Bindman AB,Goldman L.Reorganizing an academic medical service: impact on cost, quality, patient satisfaction, and education.JAMA.1998;279:15601565.
  3. Huddleston JM,Long KH,Naessens JM, et al.,Hospitalist‐Orthopedic Team Trial Investigators. Medical and surgical comanagement after elective hip and knee arthroplasty: a randomized, controlled trial.Ann Intern Med.2004;141(1):2838.
  4. Auerbach AD,Wachter RM,Katz P,Showstack J,Baron RB,Goldman L.Implementation of a voluntary hospitalist service at a community teaching hospital: improved efficiency and patient outcomes.Ann Intern Med.2002;137:859865.
  5. Lindenauer PK,Rothberg MB,Pekow PS,Kenwood C,Benjamin EM,Auerbach AD.Outcomes of care by hospitalists, general internists, and family physicians.N Engl J Med.2007;357(25):25892600.
  6. Southern WN,Berger MA,Bellin EY,Hailpern SM,Arnsten JH.Hospitalist care and length of stay in patients requiring complex discharge planning and close clinical monitoring.Arch Intern Med.2007;167(17):18691874.
  7. Everett G,Uddin N,Rudloff B.Comparison of hospital costs and length of stay for community internists, hospitalists, and academicians.J Gen Int Med.2007;22(5):662667.
  8. Meltzer D,Manning WG,Morrison J, et al.Effects of physician experience on cost and outcomes on an academic general medicine service: results of a trial of hospitalists.Ann Intern Med.2002;37:866875.
  9. Abenhain HA,Kahn SR,Raffoul J,Becker MR.Program description: a hospitalist‐run, medical short‐stay unit in a teaching hospital.CMAJ.2000;163(11):14771480.
  10. Myers JS,Bellini LM,Rohrbach J,Shofter FS,Hollander JE.Improving resource utilization in a teaching hospital: development of a nonteaching service for chest pain admissions.Acad Med.2006;81(5):432435.
References
  1. Whitcomb WF,Nelson JR.The role of hospitalists in medical education.Am J Med.1999;107(4):305309.
  2. Wachter RM,Katz P,Showstack J,Bindman AB,Goldman L.Reorganizing an academic medical service: impact on cost, quality, patient satisfaction, and education.JAMA.1998;279:15601565.
  3. Huddleston JM,Long KH,Naessens JM, et al.,Hospitalist‐Orthopedic Team Trial Investigators. Medical and surgical comanagement after elective hip and knee arthroplasty: a randomized, controlled trial.Ann Intern Med.2004;141(1):2838.
  4. Auerbach AD,Wachter RM,Katz P,Showstack J,Baron RB,Goldman L.Implementation of a voluntary hospitalist service at a community teaching hospital: improved efficiency and patient outcomes.Ann Intern Med.2002;137:859865.
  5. Lindenauer PK,Rothberg MB,Pekow PS,Kenwood C,Benjamin EM,Auerbach AD.Outcomes of care by hospitalists, general internists, and family physicians.N Engl J Med.2007;357(25):25892600.
  6. Southern WN,Berger MA,Bellin EY,Hailpern SM,Arnsten JH.Hospitalist care and length of stay in patients requiring complex discharge planning and close clinical monitoring.Arch Intern Med.2007;167(17):18691874.
  7. Everett G,Uddin N,Rudloff B.Comparison of hospital costs and length of stay for community internists, hospitalists, and academicians.J Gen Int Med.2007;22(5):662667.
  8. Meltzer D,Manning WG,Morrison J, et al.Effects of physician experience on cost and outcomes on an academic general medicine service: results of a trial of hospitalists.Ann Intern Med.2002;37:866875.
  9. Abenhain HA,Kahn SR,Raffoul J,Becker MR.Program description: a hospitalist‐run, medical short‐stay unit in a teaching hospital.CMAJ.2000;163(11):14771480.
  10. Myers JS,Bellini LM,Rohrbach J,Shofter FS,Hollander JE.Improving resource utilization in a teaching hospital: development of a nonteaching service for chest pain admissions.Acad Med.2006;81(5):432435.
Issue
Journal of Hospital Medicine - 5(9)
Issue
Journal of Hospital Medicine - 5(9)
Page Number
E2-E5
Page Number
E2-E5
Article Type
Display Headline
Implementation of a hospitalist‐run observation unit and impact on length of stay (LOS): A brief report
Display Headline
Implementation of a hospitalist‐run observation unit and impact on length of stay (LOS): A brief report
Legacy Keywords
asthma, chest pain, clinical, outcomes measurement
Legacy Keywords
asthma, chest pain, clinical, outcomes measurement
Sections
Article Source
Copyright © 2010 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
South Texas Veterans' Health Care System, University of Texas Health Science Center at San Antonio, Department of Medicine, Division of Hospital Medicine, 7703 Floyd Curl Drive, Room 5.070R Dental, San Antonio, TX 78229‐3900
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media

Geriatric Train‐The‐Trainer Program

Article Type
Changed
Sun, 05/28/2017 - 20:03
Display Headline
Advancing geriatrics education: An efficient faculty development program for academic hospitalists increases geriatric teaching

Nearly half of the hospital beds in the United States are occupied by the elderly,1 whose numbers are increasing.2 The odds of a hospitalized Medicare patient being cared for by a hospitalist are increasing by nearly 30% per year.3 Hospitalists require competence in geriatrics to serve their patients and to teach trainees. Train‐the‐Trainer (TTT) programs both educate health care providers and provide educational materials, information, and skills for teaching others.4 This model has been successfully used in geriatrics to impact knowledge, attitudes, and self‐efficacy among health care workers.46

A prominent example of a geriatrics TTT program is the University of Chicago Curriculum for the Hospitalized Aging Medical Patient (CHAMP),7 which requires 48 hours of instruction over 12 sessions. To create a less time‐intensive learning format for busy hospitalists, the University of Chicago developed Mini‐CHAMP, a streamlined 2‐day workshop with web‐based components for hospitalist clinicians, but not necessarily hospitalist educators.7

We created The Donald W. Reynolds Program for Advancing Geriatrics Education (PAGE) at the University of California, San Francisco (UCSF), in light of the time intensity of CHAMP, to integrate geriatric TTT sessions within preexisting hospitalist faculty meetings. This model is consistent with current practices in faculty development.8 This paper describes the evaluation of the PAGE Model, which sought answers to 3 research questions: (1) Does PAGE increase faculty confidence in teaching geriatrics?, (2) Does PAGE increase the frequency of hospitalist teaching geriatrics topics?, and (3) Does PAGE increase residents' practice of geriatrics skills?

Methods

The PAGE Model

The PAGE Model comprises 10 hour‐long monthly seminars held at UCSF from January through December 2008 to teach specific geriatrics principles and clinical skills relevant to providing competent care to a hospitalized older adult. The aims of the PAGE are to:

  • Give hospitalist physicians knowledge and skills to teach geriatric topics to trainees in a time‐limited environment

  • Provide exportable teaching modules on geriatric topics for inpatient teaching

  • Increase teaching about geriatrics received by internal medicine residents

  • Increase resident use of 15 specific geriatric skills

  • Create a collaborative environment between the Geriatrics and Hospital Medicine Divisions at UCSF

 

The PAGE Development Group, which included 2 hospitalists, 2 geriatricians, and an analyst funded by the Donald W. Reynolds Foundation, reviewed American Geriatrics Society core competencies,9 national guidelines and mandates,10, 11 and existing published geriatric curricula.7, 1214 In late 2007, an email‐based needs assessment listing 38 possible topics, drawn from the resources above, was emailed to the 31 hospitalists at UCSF. Each hospitalist identified, in no particular order, 5 topics considered most useful to improve his/her geriatric teaching skills, with write‐in space for additional topic suggestions. The needs assessment also queried what format of teaching tools would be most useful and efficient, such as PowerPoint slides or pocket cards, and interest in session coteaching.

The topics most commonly selected by the respondents (n = 14, response rate 45%) included: home/community resources (64%), delirium/dementia (57%), minimizing medication problems (50%), using prognostic indices to make decisions (43%), and general approach to older inpatients (43%). The Development Group identified less popular topics (falls, pressure ulcers, indwelling catheters/emncontinence) that were gaining significant national attention.15 Finally, a topic suggested by many hospitalists, pain management, was added. Each topic session was mapped to 1 or more of the 15 geriatrics skills in the CHAMP model7 for residents to acquire. The requested and selected topics were then modified to create distinct sessions grouped around a theme, shown in Table 1. For example home and community resources was addressed in the session on Framework on Transitions in Care.

PAGE Faculty Development Seminar Topics
TopicsGeriatric Skills Addressed for Hospitalized Older Patients
  • Abbreviations: DNR, do not resuscitate; WHO, world health organization.

1. Approach to the vulnerable older patient; assessing function; goals of careConduct functional status assessmentMobilize early to prevent deconditioning
2. Minimizing medication problemsReduce polypharmacy and use of high risk/low benefit drugs
3. Framework for transitions in care (including home and community resources)Develop a safe and appropriate discharge plan, involving communication with other team members, family members and primary care physicians
4. Using prognostics to guide treatment decisionsGive bad news
 Document advance directives and DNR orders
 Discuss hospice care
5. Falls & immobilityIdentify risk factors of hospital falls, including conventional and unconventional types of restraints
6. DeliriumAssess risk and prevent delirium
7. Dementia & depressionConduct cognitive assessmentScreen for depression
 Routinely assess pain at bedside in persons with dementia
8. Pain assessment in the elderlyRoutinely assess pain at bedside in persons with dementia
 Manage pain using the WHO 3‐step ladder and opiate conversion table and manage side effects of opiates
9. Foley catheters and incontinenceDetermine appropriateness for urinary catheter use, discontinuing when inappropriate
10. Pressure ulcers and wound careRoutinely perform a complete skin exam

Most respondents (86%) wanted teaching materials in a format suitable for attending rounds; 64% preferred teaching cases, 29% PowerPoint presentations, and 29% quality improvement resources. The Development Group, with approval of the Chief of Hospital Medicine, planned 10, 1‐hour monthly sessions during weekly hospitalist meetings to optimize participation. Nine hospitalists agreed to lead sessions with geriatricians; 1 session was co‐led by a hospitalist and urologist.

The Development Group encouraged session leaders to create case‐based PowerPoint teaching modules that could be used during attending rounds, highlighting teaching triggers or teachable moments that modify or reinforce skills.1618 A Development Group hospitalist/geriatrician team cotaught the first session, which modeled the structure and style recommended. A teaching team typically met at least once to define goals and outline their teaching hour; most met repeatedly to refine their presentations. An example of a 1 PAGE session can be found online.19

Evaluation

Evaluation involved data from hospitalist faculty trainees, hospitalist and geriatrician session leaders, and internal medicine residents. The institutional review board approved this study. Self‐report rating scales were used for data collection, which were reviewed by experts in medical education at UCSF and piloted on nonparticipant faculty, or had been previously used by the CHAMP study.7

Hospitalist Trainees' Program Perceptions and Self‐Efficacy

Hospitalist trainees (n = 36) completed paper questionnaires after each session to assess perceived likelihood to use the teaching tools that were presented (1: not at all likely, 5: highly likely), whether they would recommend the program to colleagues (1: do not recommend, 5: highly recommend), and the utility of the PAGE program (Was this experience useful? and Prior to the sessions, did you think it would be useful? 1: definitely not, 5: definitely yes). Change in trainees' perceived self‐efficacy20 to teach geriatrics skills was assessed at the end of the PAGE program, using a posttest and retrospective pretest format with a 12‐items (1: low, 5: high) that was used in the CHAMP study.7 This format was used to avoid response shift bias, or the program‐produced change in a participant's understanding of the construct being measured.21

Faculty Session Leaders' Program Perceptions

After PAGE completion, all faculty session leaders (n = 15) completed an online questionnaire assessing teaching satisfaction (Likert‐type 5‐point scales), experience with coteaching, and years of faculty teaching experience.

Medical Residents

To assess change in hospitalists' teaching about geriatrics and residents' practice of geriatric clinical skills, residents (n = 56; post‐graduate year (PGY)1 = 29, PGY2 = 27) who would not complete residency before the end of PAGE received an online questionnaire, modified from the CHAMP study,7 prior to and after the completion of PAGE. Respondents received monetary gift cards as incentives. Residents gave separate ratings for their inpatient teaching attendings who were hospitalists (80% of inpatient ward attendings) and nonhospitalists (20%, mostly generalists) regarding frequency over the past year of being taught each of 15 geriatric clinical skills. A 3‐point scale was used: (1) never, (2) once, and (3) more than once. Residents also reported the frequency of practicing those skills themselves, using a questionnaire from the CHAMP study,7 with a scale of (1) never to (5) always.

Analysis

Descriptive statistics were computed for all measures. Scale means were constructed from all individual items for the retrospective pretest and posttest measures. Wilcoxon matched‐pairs signed ranks‐tests were used to compare teaching differences between hospitalist and other attendings. For the unmatched pre‐post data on frequency of teaching, Wilcoxon‐Mann‐Whitney tests were used to determine significant differences in instruction, conducting separate tests for hospitalists and nonhospitalist attendings. Effect size22 was calculated using Cohen's d23 to determine the magnitude of increase in self‐efficacy to teach geriatrics; an effect size exceeding 0.8 is considered large. Statistics were performed using PASW Statistics 17.0 (SPSS Inc., Chicago, IL, USA).

Results

The hospitalist group grew from 31 to 36 members in June of 2008. On average, 14 hospitalists (M = 14.40, standard deviation [SD] = 2.41, range 1119) attended each session, with all hospitalists (n = 36) attending 1 session (M = 3.83, SD = 2.35, range 19). At each session, an average of 72% completed a post‐session evaluation form. Overall, faculty were likely to use the PAGE teaching tools (M = 4.61, SD = 0.53) and would recommend PAGE to other hospitalists (M = 4.63, SD = 0.51).

Thirteen hospitalist trainees of 36 (36%) completed a post‐PAGE online questionnaire. Respondents taught on faculty for an average of 5 years (mean (M) = 5.08, SD = 3.52). Faculty perceived self‐efficacy at teaching residents about geriatrics improved significantly with a large effect size (pretest M = 3.05, SD = .60; posttest M = 3.96, SD = .36, d = 1.52; P < 0.001). Session attendance was positively correlated with the increase in geriatrics teaching self‐efficacy (r = .62, P < 0.05), while teaching experience was not (r = 0.05, P = 0.88). Hospitalist trainees found the PAGE model more useful after participating (M = 4.62, SD = 0.65), than they had expected (M = 3.92, SD = 0.76; P < 0.05).

All session leaders (n = 15) completed the questionnaire after PAGE (9 hospitalists, 5 geriatricians, 1 urologist). Two‐thirds had 5 years on faculty; eight had no prior experience as a faculty development trainer. Over 80% indicated that they found their coteaching experience, enjoyable, useful and collaborative. Only 1 participant did not commit to interdisciplinary teaching again. Most hospitalist session leaders reported that coteaching with a geriatrician enhanced their knowledge; they were more likely to consult a geriatrician regarding patients. All but 2 session leaders felt that the model fostered a collaborative environment between their 2 divisions.

Of the 56 residents, 41% (16 PGY1, 7 PGY2) completed a pretest; 43% (15 PGY1, 9 PGY2) completed a posttest. Residents reported receiving inpatient teaching on geriatrics skills significantly more frequently from hospitalists vs. nonhospitalist attendings both before PAGE (hospitalists M = 2.18, SD = 0.37; nonhospitalists M = 2.00, SD = 0.53, P < 0.05), and after (hospitalists M = 2.39, SD = 0.46; nonhospitalists M = 2.05, SD = 0.57, P < 0.05; see Fig. 1). Although hospitalists taught more frequently about geriatrics than nonhospitalists before PAGE, our findings suggest that they increased their teaching by a greater magnitude than nonhospitalists (P < 0.01, P > 0.05, respectively). Residents reported increased geriatric skill practice after PAGE with a medium effect size (pretest M = 2.92, SD = 0.55, posttest M = 3.28, SD = 0.66, P = 0.052, d = 0.66). There was greater mean reported practice for all skills with the exception of hospice care, which already was being performed between often and very often before PAGE. The largest increases in skill practice were (descending order, most increased first): assessing polypharmacy, performing skin exams, prognostication, performing functional assessments and examining Foley catheter use.

Figure 1
Frequency of geriatrics teaching by faculty before and after PAGE reported by medical residents.

Discussion

Our aging population and a shortage of geriatricians necessitates new, feasible models for geriatric training. Similar to the CHAMP model,7 PAGE had a favorable impact on faculty perceived behavioral change; after the PAGE sessions, faculty reported significantly greater self‐efficacy of teaching geriatrics. However, this study also examined the impact of the PAGE Model on 2 groups not previously reported in the literature: faculty session leaders and medicine residents.

To our knowledge, this is the first study about a hospitalist TTT program codeveloped with nonhospitalists aimed at teaching geriatrics skills to residents, though smaller scale programs for medical students exist.24 We believe codevelopment was important in our model for many reasons. First, using hospitalist peers and local geriatricians likely increased trust in the educational curricula and allowed for strong communication channels between instructors.25, 26 Second, coteaching allowed for hospitalist mentorship. Hospitalists acknowledged their coleaders as mentors and several hospitalists subsequently engaged in new geriatric projects. Third, coteaching was felt to enhance patient care and increase geriatrician consultations. Coteaching may have applicability to other hospitalist faculty development such as intensive care and palliative care, and hospitalist programs may benefit from creating faculty development programs internally with their colleagues, rather than using online resources.

Another important finding of this study is that training hospitalists to teach about geriatrics seems to result in an increase in both the geriatric teaching that residents receive and residents' practice of geriatric skills. This outcome has not been previously demonstrated with geriatric TTT activities.27 This trickle‐down effect to residents likely results from both the increased teaching efficacy of hospitalists after the PAGE Model and the exportable nature of the teaching tools.

Several continuing medical education best practices were used which we believe contributed to the success of PAGE. First, we conducted a needs assessment, which improves knowledge outcomes.28, 29 Second, sessions included cases, lectures, and discussions. Use of multiple educational techniques yields greater knowledge and behavioral change as compared to a single method, such as lecture alone.24, 25, 30, 31 Finally, sessions were sequenced over a year, rather than clustered in short, intensive activity. Sequenced, or learn‐work‐learn opportunities allow education to be translated to practice and reinforced.8, 27, 30, 32

We believe that the PAGE Model is transportable to other hospitalist programs due to its cost and flexible nature. In economically‐lean times, hospitalist divisions can create a program similar to the PAGE Model essentially at no cost, except for donated faculty preparation time. In contrast, CHAMP was expensive, costing nearly $72,000 for 12 faculty to participate in the 48‐hour curriculum,7, 33 and volunteering physicians were compensated for their time. Though Mini‐CHAMP is a streamlined 2‐day workshop that offers free online lectures and slide sets, there may be some benefit to producing a faculty development program internally, as we stated above, and PAGE included additional topics (urinary catheters and decubitus ulcers/wound care) not covered in mini‐CHAMP.

There were several limitations to this study. First, some outcomes of the PAGE Model were assessed by retrospective self‐report, which may allow for recall bias. Although self‐report may or may not correlate with actual behavior,34 faculty and resident perspectives of their teaching and learning experiences are themselves important. Furthermore, a retrospective presurvey allows for content of an educational program or intervention to be explained prior to a survey, so that participants first assess their new level of understanding or skill on the post test, then reflectively assess the level of understanding or skill they had prior to the workshop. This avoids response shift bias and can improve internal validity.21, 35

Second, the small numbers of session leaders, hospitalist trainees, and residents restricted statistical power to detect small effects. The fact that we found significant improvements enhances the likelihood that the differences observed were not due to chance.

Third, the low response rates from the hospitalist trainee post‐intervention questionnaire and the residents' questionnaires may affect the validity of our results. For the resident survey, the subjects were not matched, and we cannot state that an individual's geriatric skill practice changed due to PAGE, though the results suggest the residency program as a whole improved the frequency of geriatric skill practice.

Finally, the residents were required to report the frequency of teaching on and practice of geriatric skills practice over the prior year and accuracy of recall may be an issue. However, frequencies were queried both pre and post intervention and favorable change was noted. Furthermore, because the high end of the 3‐point teaching scale was limited to more than once, the true amount of teaching may have been underestimated if more than once actually represented high frequencies.

Future studies are needed to replicate these findings at other institutions to confirm generalizability. It would be beneficial to measure patient outcomes to determine whether increased teaching and skill practice benefits patients using measures such as reduction in catheter related urinary tract infections, falls, and inadequate pain management. Further investigations of cotaught faculty development programs between hospitalists and other specialists help emphasize why internally created TTT programs are of greater value than online resources.

Conclusions

This time‐sensitive adaptation of a hospitalist geriatric TTT program was successfully implemented at an academic medical center and suggests improved hospitalist faculty self‐efficacy at teaching geriatric skills, increased frequency of inpatient geriatric teaching by hospitalists and increased resident geriatric skill practice. Confidence to care for geriatric patients and a strong skill set to assess risks and manage them appropriately will equip hospitalists and trainees to provide care that reduces geriatric patients' in‐hospital morbidity and costs of care. As hospitalists increasingly care for older adults, the need for time‐efficient methods of teaching geriatrics will continue to grow. The PAGE Model, and other new models of geriatric training for hospitalists, demonstrates that we are beginning to address this urgent need.

Acknowledgements

The authors thank Joan Abrams, MA, MPA, and Patricia O'Sullivan, EdD, whose work was key to the success of this program and this manuscript. They also thank the Donald W. Reynolds Foundation for support of this project.

References
  1. Defrancis CJ,Hall MJ.2005 National Hospital Discharge Survey.Adv Data.2007;385:119.
  2. He W,Sengupta M,Velko VA,DeBarros KA. In:U.S. Census Bureau, Current Population Reports, 65+ in the United States: 2005,Washington, D.C.:U.S. Government Printing Office;2005:23209.
  3. Kuo Y,Sharma G,Freeman JL,Goodwin JS.Growth in the care of older patients by hospitalists in the United States.N Engl J Med.2009;360(11):11021112.
  4. Connell CM,Holmes SB,Voelkl JE,Bakalar H.Providing dementia outreach education to rural communities: lessons learned from a train‐the‐trainer program.J Appl Gerontol.2002;21:294313.
  5. Langer N.Gerontologizing health care: a train‐the‐trainer program for nurses.Gerontol Geriatr Educ.1999;19:4756.
  6. Coogle CL,Osgood NJ,Parham IA.A statewide model detection and prevention program for geriatric alcoholism and alcohol abuse: increased knowledge among service providers.Community Ment Health J.2000;36:137148.
  7. Podrazik PM,Levine S,Smith S, et al.The curriculum for the hospitalized aging medical patient program: a collaborative faculty development program for hospitalists, general internists, and geriatricians.J Hosp Med.2008;3(5):384393.
  8. Webster‐Wright A.Reframing professional development through understanding authentic professional learning.Rev Educ Res.2009;79:702739.
  9. The Education Committee Writing Group of the American Geriatrics Society.Core competencies for the care of older patients: recommendations of the American Geriatrics Society.Acad Med.2000;75:252255.
  10. Besdine R,Boult C,Brangman S, et al.American Geriatrics Society Task Force on the future of geriatric medicine.J Am Geriatr Soc.2005;53 (6 Suppl):S245S256.
  11. Nadzam, Deborah. Preventing patient falls. Joint Commission Resources. Available at: http://www.jcrinc.com/Preventing‐Patient‐Falls. Accessed April2010.
  12. Counsell SR,Sullivan GM.Curricular recommendations for resident training in nursing home care. A collaborative effort of the Society of General Internal Medicine Task Force on Geriatric Medicine, the Society of Teachers of Family Medicine Geriatrics Task Force, the American Medical Directors Association, and the American Geriatrics Society Education Committee.J Am Geriatr Soc.1994;42:12001201.
  13. Counsell SR,Kennedy RD,Szwabo P,Wadsworth NS,Wohlgemuth C.Curriculum recommendations for resident training in geriatrics interdisciplinary team care.J Am Geriatr Soc.1999;47:11451148.
  14. Bragg EJ,Warshaw GA.ACGME requirements for geriatrics medicine curricula in medical specialties: Progress made and progress needed.Acad Med.2005;80:279285.
  15. CMS Office of Public Affairs. CMS Improves Patient Safety for Medicare and Medicaid by Addressing Never Events, August 04, 2008. Available at: http://www.cms.gov/apps/media/press/factsheet.asp?Counter=322434(5):337343.
  16. Leist JC,Kristofco RE.The changing paradigm for continuing medical education: impact of information on the teachable moment.Bull Med Libr Assoc.1990;78(2):173179.
  17. Wagner PS,Ash KL.Creating the teachable moment.J Nurs Educ.1998;37(6):278280.
  18. Society of Hospital Medicine, BOOSTing Care Transitions Resource Room. Mazotti L, Johnston CB. Faculty development: Teaching triggers for transitional care. “A train‐the‐trainer model.” Available at: http://www.hospitalmedicine.org/ResourceRoomRedesign/RR_CareTransitions/PDFs/Mazotti_UCSF_Transitions.PPT. Accessed April2010.
  19. Bandura A.Self‐efficacy: The Exercise of Control.New York:W.H. Freeman and Company;1997.
  20. Howard GS.Internal invalidity in pretest‐posttest self‐report evaluations and a re‐evaluation of retrospective pretests.Applied Psychological Measurement.1979;3:123.
  21. Hojat M,Xu G.A visitor's guide to effect sizes.Adv Health Sci Educ Theory Pract.2004;9:241249.
  22. Cohen J.Statistical Power Analyses for the Behavioral Sciences.2nd ed.Hillsdale, NJ:Lawrence Erlbaum Associates;1988.
  23. Lang VJ,Clark NS,Medina‐Walpole A,McCann R.Hazards of hospitalization: Hospitalists and geriatricians educating medical students about delirium and falls in geriatric patients.Gerontol Geriatr Educ.2008;28(4):94104.
  24. Thomas DC,Johnson B,Dunn K, et al.Continuing medical education, continuing professional development, and knowledge translation: Improving care of older patients by practicing physicians.J Am Geriatr Soc.2006:54(10):16101618.
  25. Levine SA,Brett B,Robinson BE, et al.Practicing physician education in geriatrics: Lessons learned from a train‐the‐trainer model.J Am Geriatr Soc.2007:55(8):12811286.
  26. Hauer KE,Landefeld CS.CHAMP trains champions: hospitalist‐educators develop new ways to teach care for older patients.J Hosp Med.2008;3(5):357360.
  27. Davis D,O'Brien MA,Freemantle N,Wolf FM,Mazmanian P,Taylor‐Vaisey A.Impact of formal continuing medical education: Do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes?JAMA.1999;282(9):867874.
  28. Grant J,Stanton F.Association for the Study of Medical Education Booklet: The effectiveness of continuing professional development.Edinburgh, Scotland:Association for the Study of Medical Education;2000.
  29. Marinopoulos SS,Dorman T,Ratanawongsa N, et al.Effectiveness of continuing medical education.Evid Rep Technol Assess (Full Rep).2007;149:169.
  30. Forsetlund L,Bjorndal A,Rashidan A, et al.Continuing education meetings and workshops: effects on professional practice and health care outcomes.Cochrane Database Syst Rev.2009;(2):CD003030.
  31. Mazmanian PE,Davis DA.Continuing medical education and the physician as learner: guide to the evidence.JAMA.2002;288(9):10571060.
  32. Landefeld CS.Care of hospitalized older patients: opportunities for hospital‐based physicians.J Hosp Med.2006;1:4247.
  33. Hartman SL,Nelson MS.What we say and what we do: self‐reported teaching behavior versus performances in written simulations among medical school faculty.Acad Med.1992;67(8):522527.
  34. Goedhart H,Hoogstraten J.The retrospective pretest and the role of pretest information in evaluation studies.Psychol Rep.1992;70:699704.
Article PDF
Issue
Journal of Hospital Medicine - 5(9)
Page Number
541-546
Legacy Keywords
continuing medical education (CME), education, geriatric patient, hospitalist as educators, resident
Sections
Article PDF
Article PDF

Nearly half of the hospital beds in the United States are occupied by the elderly,1 whose numbers are increasing.2 The odds of a hospitalized Medicare patient being cared for by a hospitalist are increasing by nearly 30% per year.3 Hospitalists require competence in geriatrics to serve their patients and to teach trainees. Train‐the‐Trainer (TTT) programs both educate health care providers and provide educational materials, information, and skills for teaching others.4 This model has been successfully used in geriatrics to impact knowledge, attitudes, and self‐efficacy among health care workers.46

A prominent example of a geriatrics TTT program is the University of Chicago Curriculum for the Hospitalized Aging Medical Patient (CHAMP),7 which requires 48 hours of instruction over 12 sessions. To create a less time‐intensive learning format for busy hospitalists, the University of Chicago developed Mini‐CHAMP, a streamlined 2‐day workshop with web‐based components for hospitalist clinicians, but not necessarily hospitalist educators.7

We created The Donald W. Reynolds Program for Advancing Geriatrics Education (PAGE) at the University of California, San Francisco (UCSF), in light of the time intensity of CHAMP, to integrate geriatric TTT sessions within preexisting hospitalist faculty meetings. This model is consistent with current practices in faculty development.8 This paper describes the evaluation of the PAGE Model, which sought answers to 3 research questions: (1) Does PAGE increase faculty confidence in teaching geriatrics?, (2) Does PAGE increase the frequency of hospitalist teaching geriatrics topics?, and (3) Does PAGE increase residents' practice of geriatrics skills?

Methods

The PAGE Model

The PAGE Model comprises 10 hour‐long monthly seminars held at UCSF from January through December 2008 to teach specific geriatrics principles and clinical skills relevant to providing competent care to a hospitalized older adult. The aims of the PAGE are to:

  • Give hospitalist physicians knowledge and skills to teach geriatric topics to trainees in a time‐limited environment

  • Provide exportable teaching modules on geriatric topics for inpatient teaching

  • Increase teaching about geriatrics received by internal medicine residents

  • Increase resident use of 15 specific geriatric skills

  • Create a collaborative environment between the Geriatrics and Hospital Medicine Divisions at UCSF

 

The PAGE Development Group, which included 2 hospitalists, 2 geriatricians, and an analyst funded by the Donald W. Reynolds Foundation, reviewed American Geriatrics Society core competencies,9 national guidelines and mandates,10, 11 and existing published geriatric curricula.7, 1214 In late 2007, an email‐based needs assessment listing 38 possible topics, drawn from the resources above, was emailed to the 31 hospitalists at UCSF. Each hospitalist identified, in no particular order, 5 topics considered most useful to improve his/her geriatric teaching skills, with write‐in space for additional topic suggestions. The needs assessment also queried what format of teaching tools would be most useful and efficient, such as PowerPoint slides or pocket cards, and interest in session coteaching.

The topics most commonly selected by the respondents (n = 14, response rate 45%) included: home/community resources (64%), delirium/dementia (57%), minimizing medication problems (50%), using prognostic indices to make decisions (43%), and general approach to older inpatients (43%). The Development Group identified less popular topics (falls, pressure ulcers, indwelling catheters/emncontinence) that were gaining significant national attention.15 Finally, a topic suggested by many hospitalists, pain management, was added. Each topic session was mapped to 1 or more of the 15 geriatrics skills in the CHAMP model7 for residents to acquire. The requested and selected topics were then modified to create distinct sessions grouped around a theme, shown in Table 1. For example home and community resources was addressed in the session on Framework on Transitions in Care.

PAGE Faculty Development Seminar Topics
TopicsGeriatric Skills Addressed for Hospitalized Older Patients
  • Abbreviations: DNR, do not resuscitate; WHO, world health organization.

1. Approach to the vulnerable older patient; assessing function; goals of careConduct functional status assessmentMobilize early to prevent deconditioning
2. Minimizing medication problemsReduce polypharmacy and use of high risk/low benefit drugs
3. Framework for transitions in care (including home and community resources)Develop a safe and appropriate discharge plan, involving communication with other team members, family members and primary care physicians
4. Using prognostics to guide treatment decisionsGive bad news
 Document advance directives and DNR orders
 Discuss hospice care
5. Falls & immobilityIdentify risk factors of hospital falls, including conventional and unconventional types of restraints
6. DeliriumAssess risk and prevent delirium
7. Dementia & depressionConduct cognitive assessmentScreen for depression
 Routinely assess pain at bedside in persons with dementia
8. Pain assessment in the elderlyRoutinely assess pain at bedside in persons with dementia
 Manage pain using the WHO 3‐step ladder and opiate conversion table and manage side effects of opiates
9. Foley catheters and incontinenceDetermine appropriateness for urinary catheter use, discontinuing when inappropriate
10. Pressure ulcers and wound careRoutinely perform a complete skin exam

Most respondents (86%) wanted teaching materials in a format suitable for attending rounds; 64% preferred teaching cases, 29% PowerPoint presentations, and 29% quality improvement resources. The Development Group, with approval of the Chief of Hospital Medicine, planned 10, 1‐hour monthly sessions during weekly hospitalist meetings to optimize participation. Nine hospitalists agreed to lead sessions with geriatricians; 1 session was co‐led by a hospitalist and urologist.

The Development Group encouraged session leaders to create case‐based PowerPoint teaching modules that could be used during attending rounds, highlighting teaching triggers or teachable moments that modify or reinforce skills.1618 A Development Group hospitalist/geriatrician team cotaught the first session, which modeled the structure and style recommended. A teaching team typically met at least once to define goals and outline their teaching hour; most met repeatedly to refine their presentations. An example of a 1 PAGE session can be found online.19

Evaluation

Evaluation involved data from hospitalist faculty trainees, hospitalist and geriatrician session leaders, and internal medicine residents. The institutional review board approved this study. Self‐report rating scales were used for data collection, which were reviewed by experts in medical education at UCSF and piloted on nonparticipant faculty, or had been previously used by the CHAMP study.7

Hospitalist Trainees' Program Perceptions and Self‐Efficacy

Hospitalist trainees (n = 36) completed paper questionnaires after each session to assess perceived likelihood to use the teaching tools that were presented (1: not at all likely, 5: highly likely), whether they would recommend the program to colleagues (1: do not recommend, 5: highly recommend), and the utility of the PAGE program (Was this experience useful? and Prior to the sessions, did you think it would be useful? 1: definitely not, 5: definitely yes). Change in trainees' perceived self‐efficacy20 to teach geriatrics skills was assessed at the end of the PAGE program, using a posttest and retrospective pretest format with a 12‐items (1: low, 5: high) that was used in the CHAMP study.7 This format was used to avoid response shift bias, or the program‐produced change in a participant's understanding of the construct being measured.21

Faculty Session Leaders' Program Perceptions

After PAGE completion, all faculty session leaders (n = 15) completed an online questionnaire assessing teaching satisfaction (Likert‐type 5‐point scales), experience with coteaching, and years of faculty teaching experience.

Medical Residents

To assess change in hospitalists' teaching about geriatrics and residents' practice of geriatric clinical skills, residents (n = 56; post‐graduate year (PGY)1 = 29, PGY2 = 27) who would not complete residency before the end of PAGE received an online questionnaire, modified from the CHAMP study,7 prior to and after the completion of PAGE. Respondents received monetary gift cards as incentives. Residents gave separate ratings for their inpatient teaching attendings who were hospitalists (80% of inpatient ward attendings) and nonhospitalists (20%, mostly generalists) regarding frequency over the past year of being taught each of 15 geriatric clinical skills. A 3‐point scale was used: (1) never, (2) once, and (3) more than once. Residents also reported the frequency of practicing those skills themselves, using a questionnaire from the CHAMP study,7 with a scale of (1) never to (5) always.

Analysis

Descriptive statistics were computed for all measures. Scale means were constructed from all individual items for the retrospective pretest and posttest measures. Wilcoxon matched‐pairs signed ranks‐tests were used to compare teaching differences between hospitalist and other attendings. For the unmatched pre‐post data on frequency of teaching, Wilcoxon‐Mann‐Whitney tests were used to determine significant differences in instruction, conducting separate tests for hospitalists and nonhospitalist attendings. Effect size22 was calculated using Cohen's d23 to determine the magnitude of increase in self‐efficacy to teach geriatrics; an effect size exceeding 0.8 is considered large. Statistics were performed using PASW Statistics 17.0 (SPSS Inc., Chicago, IL, USA).

Results

The hospitalist group grew from 31 to 36 members in June of 2008. On average, 14 hospitalists (M = 14.40, standard deviation [SD] = 2.41, range 1119) attended each session, with all hospitalists (n = 36) attending 1 session (M = 3.83, SD = 2.35, range 19). At each session, an average of 72% completed a post‐session evaluation form. Overall, faculty were likely to use the PAGE teaching tools (M = 4.61, SD = 0.53) and would recommend PAGE to other hospitalists (M = 4.63, SD = 0.51).

Thirteen hospitalist trainees of 36 (36%) completed a post‐PAGE online questionnaire. Respondents taught on faculty for an average of 5 years (mean (M) = 5.08, SD = 3.52). Faculty perceived self‐efficacy at teaching residents about geriatrics improved significantly with a large effect size (pretest M = 3.05, SD = .60; posttest M = 3.96, SD = .36, d = 1.52; P < 0.001). Session attendance was positively correlated with the increase in geriatrics teaching self‐efficacy (r = .62, P < 0.05), while teaching experience was not (r = 0.05, P = 0.88). Hospitalist trainees found the PAGE model more useful after participating (M = 4.62, SD = 0.65), than they had expected (M = 3.92, SD = 0.76; P < 0.05).

All session leaders (n = 15) completed the questionnaire after PAGE (9 hospitalists, 5 geriatricians, 1 urologist). Two‐thirds had 5 years on faculty; eight had no prior experience as a faculty development trainer. Over 80% indicated that they found their coteaching experience, enjoyable, useful and collaborative. Only 1 participant did not commit to interdisciplinary teaching again. Most hospitalist session leaders reported that coteaching with a geriatrician enhanced their knowledge; they were more likely to consult a geriatrician regarding patients. All but 2 session leaders felt that the model fostered a collaborative environment between their 2 divisions.

Of the 56 residents, 41% (16 PGY1, 7 PGY2) completed a pretest; 43% (15 PGY1, 9 PGY2) completed a posttest. Residents reported receiving inpatient teaching on geriatrics skills significantly more frequently from hospitalists vs. nonhospitalist attendings both before PAGE (hospitalists M = 2.18, SD = 0.37; nonhospitalists M = 2.00, SD = 0.53, P < 0.05), and after (hospitalists M = 2.39, SD = 0.46; nonhospitalists M = 2.05, SD = 0.57, P < 0.05; see Fig. 1). Although hospitalists taught more frequently about geriatrics than nonhospitalists before PAGE, our findings suggest that they increased their teaching by a greater magnitude than nonhospitalists (P < 0.01, P > 0.05, respectively). Residents reported increased geriatric skill practice after PAGE with a medium effect size (pretest M = 2.92, SD = 0.55, posttest M = 3.28, SD = 0.66, P = 0.052, d = 0.66). There was greater mean reported practice for all skills with the exception of hospice care, which already was being performed between often and very often before PAGE. The largest increases in skill practice were (descending order, most increased first): assessing polypharmacy, performing skin exams, prognostication, performing functional assessments and examining Foley catheter use.

Figure 1
Frequency of geriatrics teaching by faculty before and after PAGE reported by medical residents.

Discussion

Our aging population and a shortage of geriatricians necessitates new, feasible models for geriatric training. Similar to the CHAMP model,7 PAGE had a favorable impact on faculty perceived behavioral change; after the PAGE sessions, faculty reported significantly greater self‐efficacy of teaching geriatrics. However, this study also examined the impact of the PAGE Model on 2 groups not previously reported in the literature: faculty session leaders and medicine residents.

To our knowledge, this is the first study about a hospitalist TTT program codeveloped with nonhospitalists aimed at teaching geriatrics skills to residents, though smaller scale programs for medical students exist.24 We believe codevelopment was important in our model for many reasons. First, using hospitalist peers and local geriatricians likely increased trust in the educational curricula and allowed for strong communication channels between instructors.25, 26 Second, coteaching allowed for hospitalist mentorship. Hospitalists acknowledged their coleaders as mentors and several hospitalists subsequently engaged in new geriatric projects. Third, coteaching was felt to enhance patient care and increase geriatrician consultations. Coteaching may have applicability to other hospitalist faculty development such as intensive care and palliative care, and hospitalist programs may benefit from creating faculty development programs internally with their colleagues, rather than using online resources.

Another important finding of this study is that training hospitalists to teach about geriatrics seems to result in an increase in both the geriatric teaching that residents receive and residents' practice of geriatric skills. This outcome has not been previously demonstrated with geriatric TTT activities.27 This trickle‐down effect to residents likely results from both the increased teaching efficacy of hospitalists after the PAGE Model and the exportable nature of the teaching tools.

Several continuing medical education best practices were used which we believe contributed to the success of PAGE. First, we conducted a needs assessment, which improves knowledge outcomes.28, 29 Second, sessions included cases, lectures, and discussions. Use of multiple educational techniques yields greater knowledge and behavioral change as compared to a single method, such as lecture alone.24, 25, 30, 31 Finally, sessions were sequenced over a year, rather than clustered in short, intensive activity. Sequenced, or learn‐work‐learn opportunities allow education to be translated to practice and reinforced.8, 27, 30, 32

We believe that the PAGE Model is transportable to other hospitalist programs due to its cost and flexible nature. In economically‐lean times, hospitalist divisions can create a program similar to the PAGE Model essentially at no cost, except for donated faculty preparation time. In contrast, CHAMP was expensive, costing nearly $72,000 for 12 faculty to participate in the 48‐hour curriculum,7, 33 and volunteering physicians were compensated for their time. Though Mini‐CHAMP is a streamlined 2‐day workshop that offers free online lectures and slide sets, there may be some benefit to producing a faculty development program internally, as we stated above, and PAGE included additional topics (urinary catheters and decubitus ulcers/wound care) not covered in mini‐CHAMP.

There were several limitations to this study. First, some outcomes of the PAGE Model were assessed by retrospective self‐report, which may allow for recall bias. Although self‐report may or may not correlate with actual behavior,34 faculty and resident perspectives of their teaching and learning experiences are themselves important. Furthermore, a retrospective presurvey allows for content of an educational program or intervention to be explained prior to a survey, so that participants first assess their new level of understanding or skill on the post test, then reflectively assess the level of understanding or skill they had prior to the workshop. This avoids response shift bias and can improve internal validity.21, 35

Second, the small numbers of session leaders, hospitalist trainees, and residents restricted statistical power to detect small effects. The fact that we found significant improvements enhances the likelihood that the differences observed were not due to chance.

Third, the low response rates from the hospitalist trainee post‐intervention questionnaire and the residents' questionnaires may affect the validity of our results. For the resident survey, the subjects were not matched, and we cannot state that an individual's geriatric skill practice changed due to PAGE, though the results suggest the residency program as a whole improved the frequency of geriatric skill practice.

Finally, the residents were required to report the frequency of teaching on and practice of geriatric skills practice over the prior year and accuracy of recall may be an issue. However, frequencies were queried both pre and post intervention and favorable change was noted. Furthermore, because the high end of the 3‐point teaching scale was limited to more than once, the true amount of teaching may have been underestimated if more than once actually represented high frequencies.

Future studies are needed to replicate these findings at other institutions to confirm generalizability. It would be beneficial to measure patient outcomes to determine whether increased teaching and skill practice benefits patients using measures such as reduction in catheter related urinary tract infections, falls, and inadequate pain management. Further investigations of cotaught faculty development programs between hospitalists and other specialists help emphasize why internally created TTT programs are of greater value than online resources.

Conclusions

This time‐sensitive adaptation of a hospitalist geriatric TTT program was successfully implemented at an academic medical center and suggests improved hospitalist faculty self‐efficacy at teaching geriatric skills, increased frequency of inpatient geriatric teaching by hospitalists and increased resident geriatric skill practice. Confidence to care for geriatric patients and a strong skill set to assess risks and manage them appropriately will equip hospitalists and trainees to provide care that reduces geriatric patients' in‐hospital morbidity and costs of care. As hospitalists increasingly care for older adults, the need for time‐efficient methods of teaching geriatrics will continue to grow. The PAGE Model, and other new models of geriatric training for hospitalists, demonstrates that we are beginning to address this urgent need.

Acknowledgements

The authors thank Joan Abrams, MA, MPA, and Patricia O'Sullivan, EdD, whose work was key to the success of this program and this manuscript. They also thank the Donald W. Reynolds Foundation for support of this project.

Nearly half of the hospital beds in the United States are occupied by the elderly,1 whose numbers are increasing.2 The odds of a hospitalized Medicare patient being cared for by a hospitalist are increasing by nearly 30% per year.3 Hospitalists require competence in geriatrics to serve their patients and to teach trainees. Train‐the‐Trainer (TTT) programs both educate health care providers and provide educational materials, information, and skills for teaching others.4 This model has been successfully used in geriatrics to impact knowledge, attitudes, and self‐efficacy among health care workers.46

A prominent example of a geriatrics TTT program is the University of Chicago Curriculum for the Hospitalized Aging Medical Patient (CHAMP),7 which requires 48 hours of instruction over 12 sessions. To create a less time‐intensive learning format for busy hospitalists, the University of Chicago developed Mini‐CHAMP, a streamlined 2‐day workshop with web‐based components for hospitalist clinicians, but not necessarily hospitalist educators.7

We created The Donald W. Reynolds Program for Advancing Geriatrics Education (PAGE) at the University of California, San Francisco (UCSF), in light of the time intensity of CHAMP, to integrate geriatric TTT sessions within preexisting hospitalist faculty meetings. This model is consistent with current practices in faculty development.8 This paper describes the evaluation of the PAGE Model, which sought answers to 3 research questions: (1) Does PAGE increase faculty confidence in teaching geriatrics?, (2) Does PAGE increase the frequency of hospitalist teaching geriatrics topics?, and (3) Does PAGE increase residents' practice of geriatrics skills?

Methods

The PAGE Model

The PAGE Model comprises 10 hour‐long monthly seminars held at UCSF from January through December 2008 to teach specific geriatrics principles and clinical skills relevant to providing competent care to a hospitalized older adult. The aims of the PAGE are to:

  • Give hospitalist physicians knowledge and skills to teach geriatric topics to trainees in a time‐limited environment

  • Provide exportable teaching modules on geriatric topics for inpatient teaching

  • Increase teaching about geriatrics received by internal medicine residents

  • Increase resident use of 15 specific geriatric skills

  • Create a collaborative environment between the Geriatrics and Hospital Medicine Divisions at UCSF

 

The PAGE Development Group, which included 2 hospitalists, 2 geriatricians, and an analyst funded by the Donald W. Reynolds Foundation, reviewed American Geriatrics Society core competencies,9 national guidelines and mandates,10, 11 and existing published geriatric curricula.7, 1214 In late 2007, an email‐based needs assessment listing 38 possible topics, drawn from the resources above, was emailed to the 31 hospitalists at UCSF. Each hospitalist identified, in no particular order, 5 topics considered most useful to improve his/her geriatric teaching skills, with write‐in space for additional topic suggestions. The needs assessment also queried what format of teaching tools would be most useful and efficient, such as PowerPoint slides or pocket cards, and interest in session coteaching.

The topics most commonly selected by the respondents (n = 14, response rate 45%) included: home/community resources (64%), delirium/dementia (57%), minimizing medication problems (50%), using prognostic indices to make decisions (43%), and general approach to older inpatients (43%). The Development Group identified less popular topics (falls, pressure ulcers, indwelling catheters/emncontinence) that were gaining significant national attention.15 Finally, a topic suggested by many hospitalists, pain management, was added. Each topic session was mapped to 1 or more of the 15 geriatrics skills in the CHAMP model7 for residents to acquire. The requested and selected topics were then modified to create distinct sessions grouped around a theme, shown in Table 1. For example home and community resources was addressed in the session on Framework on Transitions in Care.

PAGE Faculty Development Seminar Topics
TopicsGeriatric Skills Addressed for Hospitalized Older Patients
  • Abbreviations: DNR, do not resuscitate; WHO, world health organization.

1. Approach to the vulnerable older patient; assessing function; goals of careConduct functional status assessmentMobilize early to prevent deconditioning
2. Minimizing medication problemsReduce polypharmacy and use of high risk/low benefit drugs
3. Framework for transitions in care (including home and community resources)Develop a safe and appropriate discharge plan, involving communication with other team members, family members and primary care physicians
4. Using prognostics to guide treatment decisionsGive bad news
 Document advance directives and DNR orders
 Discuss hospice care
5. Falls & immobilityIdentify risk factors of hospital falls, including conventional and unconventional types of restraints
6. DeliriumAssess risk and prevent delirium
7. Dementia & depressionConduct cognitive assessmentScreen for depression
 Routinely assess pain at bedside in persons with dementia
8. Pain assessment in the elderlyRoutinely assess pain at bedside in persons with dementia
 Manage pain using the WHO 3‐step ladder and opiate conversion table and manage side effects of opiates
9. Foley catheters and incontinenceDetermine appropriateness for urinary catheter use, discontinuing when inappropriate
10. Pressure ulcers and wound careRoutinely perform a complete skin exam

Most respondents (86%) wanted teaching materials in a format suitable for attending rounds; 64% preferred teaching cases, 29% PowerPoint presentations, and 29% quality improvement resources. The Development Group, with approval of the Chief of Hospital Medicine, planned 10, 1‐hour monthly sessions during weekly hospitalist meetings to optimize participation. Nine hospitalists agreed to lead sessions with geriatricians; 1 session was co‐led by a hospitalist and urologist.

The Development Group encouraged session leaders to create case‐based PowerPoint teaching modules that could be used during attending rounds, highlighting teaching triggers or teachable moments that modify or reinforce skills.1618 A Development Group hospitalist/geriatrician team cotaught the first session, which modeled the structure and style recommended. A teaching team typically met at least once to define goals and outline their teaching hour; most met repeatedly to refine their presentations. An example of a 1 PAGE session can be found online.19

Evaluation

Evaluation involved data from hospitalist faculty trainees, hospitalist and geriatrician session leaders, and internal medicine residents. The institutional review board approved this study. Self‐report rating scales were used for data collection, which were reviewed by experts in medical education at UCSF and piloted on nonparticipant faculty, or had been previously used by the CHAMP study.7

Hospitalist Trainees' Program Perceptions and Self‐Efficacy

Hospitalist trainees (n = 36) completed paper questionnaires after each session to assess perceived likelihood to use the teaching tools that were presented (1: not at all likely, 5: highly likely), whether they would recommend the program to colleagues (1: do not recommend, 5: highly recommend), and the utility of the PAGE program (Was this experience useful? and Prior to the sessions, did you think it would be useful? 1: definitely not, 5: definitely yes). Change in trainees' perceived self‐efficacy20 to teach geriatrics skills was assessed at the end of the PAGE program, using a posttest and retrospective pretest format with a 12‐items (1: low, 5: high) that was used in the CHAMP study.7 This format was used to avoid response shift bias, or the program‐produced change in a participant's understanding of the construct being measured.21

Faculty Session Leaders' Program Perceptions

After PAGE completion, all faculty session leaders (n = 15) completed an online questionnaire assessing teaching satisfaction (Likert‐type 5‐point scales), experience with coteaching, and years of faculty teaching experience.

Medical Residents

To assess change in hospitalists' teaching about geriatrics and residents' practice of geriatric clinical skills, residents (n = 56; post‐graduate year (PGY)1 = 29, PGY2 = 27) who would not complete residency before the end of PAGE received an online questionnaire, modified from the CHAMP study,7 prior to and after the completion of PAGE. Respondents received monetary gift cards as incentives. Residents gave separate ratings for their inpatient teaching attendings who were hospitalists (80% of inpatient ward attendings) and nonhospitalists (20%, mostly generalists) regarding frequency over the past year of being taught each of 15 geriatric clinical skills. A 3‐point scale was used: (1) never, (2) once, and (3) more than once. Residents also reported the frequency of practicing those skills themselves, using a questionnaire from the CHAMP study,7 with a scale of (1) never to (5) always.

Analysis

Descriptive statistics were computed for all measures. Scale means were constructed from all individual items for the retrospective pretest and posttest measures. Wilcoxon matched‐pairs signed ranks‐tests were used to compare teaching differences between hospitalist and other attendings. For the unmatched pre‐post data on frequency of teaching, Wilcoxon‐Mann‐Whitney tests were used to determine significant differences in instruction, conducting separate tests for hospitalists and nonhospitalist attendings. Effect size22 was calculated using Cohen's d23 to determine the magnitude of increase in self‐efficacy to teach geriatrics; an effect size exceeding 0.8 is considered large. Statistics were performed using PASW Statistics 17.0 (SPSS Inc., Chicago, IL, USA).

Results

The hospitalist group grew from 31 to 36 members in June of 2008. On average, 14 hospitalists (M = 14.40, standard deviation [SD] = 2.41, range 1119) attended each session, with all hospitalists (n = 36) attending 1 session (M = 3.83, SD = 2.35, range 19). At each session, an average of 72% completed a post‐session evaluation form. Overall, faculty were likely to use the PAGE teaching tools (M = 4.61, SD = 0.53) and would recommend PAGE to other hospitalists (M = 4.63, SD = 0.51).

Thirteen hospitalist trainees of 36 (36%) completed a post‐PAGE online questionnaire. Respondents taught on faculty for an average of 5 years (mean (M) = 5.08, SD = 3.52). Faculty perceived self‐efficacy at teaching residents about geriatrics improved significantly with a large effect size (pretest M = 3.05, SD = .60; posttest M = 3.96, SD = .36, d = 1.52; P < 0.001). Session attendance was positively correlated with the increase in geriatrics teaching self‐efficacy (r = .62, P < 0.05), while teaching experience was not (r = 0.05, P = 0.88). Hospitalist trainees found the PAGE model more useful after participating (M = 4.62, SD = 0.65), than they had expected (M = 3.92, SD = 0.76; P < 0.05).

All session leaders (n = 15) completed the questionnaire after PAGE (9 hospitalists, 5 geriatricians, 1 urologist). Two‐thirds had 5 years on faculty; eight had no prior experience as a faculty development trainer. Over 80% indicated that they found their coteaching experience, enjoyable, useful and collaborative. Only 1 participant did not commit to interdisciplinary teaching again. Most hospitalist session leaders reported that coteaching with a geriatrician enhanced their knowledge; they were more likely to consult a geriatrician regarding patients. All but 2 session leaders felt that the model fostered a collaborative environment between their 2 divisions.

Of the 56 residents, 41% (16 PGY1, 7 PGY2) completed a pretest; 43% (15 PGY1, 9 PGY2) completed a posttest. Residents reported receiving inpatient teaching on geriatrics skills significantly more frequently from hospitalists vs. nonhospitalist attendings both before PAGE (hospitalists M = 2.18, SD = 0.37; nonhospitalists M = 2.00, SD = 0.53, P < 0.05), and after (hospitalists M = 2.39, SD = 0.46; nonhospitalists M = 2.05, SD = 0.57, P < 0.05; see Fig. 1). Although hospitalists taught more frequently about geriatrics than nonhospitalists before PAGE, our findings suggest that they increased their teaching by a greater magnitude than nonhospitalists (P < 0.01, P > 0.05, respectively). Residents reported increased geriatric skill practice after PAGE with a medium effect size (pretest M = 2.92, SD = 0.55, posttest M = 3.28, SD = 0.66, P = 0.052, d = 0.66). There was greater mean reported practice for all skills with the exception of hospice care, which already was being performed between often and very often before PAGE. The largest increases in skill practice were (descending order, most increased first): assessing polypharmacy, performing skin exams, prognostication, performing functional assessments and examining Foley catheter use.

Figure 1
Frequency of geriatrics teaching by faculty before and after PAGE reported by medical residents.

Discussion

Our aging population and a shortage of geriatricians necessitates new, feasible models for geriatric training. Similar to the CHAMP model,7 PAGE had a favorable impact on faculty perceived behavioral change; after the PAGE sessions, faculty reported significantly greater self‐efficacy of teaching geriatrics. However, this study also examined the impact of the PAGE Model on 2 groups not previously reported in the literature: faculty session leaders and medicine residents.

To our knowledge, this is the first study about a hospitalist TTT program codeveloped with nonhospitalists aimed at teaching geriatrics skills to residents, though smaller scale programs for medical students exist.24 We believe codevelopment was important in our model for many reasons. First, using hospitalist peers and local geriatricians likely increased trust in the educational curricula and allowed for strong communication channels between instructors.25, 26 Second, coteaching allowed for hospitalist mentorship. Hospitalists acknowledged their coleaders as mentors and several hospitalists subsequently engaged in new geriatric projects. Third, coteaching was felt to enhance patient care and increase geriatrician consultations. Coteaching may have applicability to other hospitalist faculty development such as intensive care and palliative care, and hospitalist programs may benefit from creating faculty development programs internally with their colleagues, rather than using online resources.

Another important finding of this study is that training hospitalists to teach about geriatrics seems to result in an increase in both the geriatric teaching that residents receive and residents' practice of geriatric skills. This outcome has not been previously demonstrated with geriatric TTT activities.27 This trickle‐down effect to residents likely results from both the increased teaching efficacy of hospitalists after the PAGE Model and the exportable nature of the teaching tools.

Several continuing medical education best practices were used which we believe contributed to the success of PAGE. First, we conducted a needs assessment, which improves knowledge outcomes.28, 29 Second, sessions included cases, lectures, and discussions. Use of multiple educational techniques yields greater knowledge and behavioral change as compared to a single method, such as lecture alone.24, 25, 30, 31 Finally, sessions were sequenced over a year, rather than clustered in short, intensive activity. Sequenced, or learn‐work‐learn opportunities allow education to be translated to practice and reinforced.8, 27, 30, 32

We believe that the PAGE Model is transportable to other hospitalist programs due to its cost and flexible nature. In economically‐lean times, hospitalist divisions can create a program similar to the PAGE Model essentially at no cost, except for donated faculty preparation time. In contrast, CHAMP was expensive, costing nearly $72,000 for 12 faculty to participate in the 48‐hour curriculum,7, 33 and volunteering physicians were compensated for their time. Though Mini‐CHAMP is a streamlined 2‐day workshop that offers free online lectures and slide sets, there may be some benefit to producing a faculty development program internally, as we stated above, and PAGE included additional topics (urinary catheters and decubitus ulcers/wound care) not covered in mini‐CHAMP.

There were several limitations to this study. First, some outcomes of the PAGE Model were assessed by retrospective self‐report, which may allow for recall bias. Although self‐report may or may not correlate with actual behavior,34 faculty and resident perspectives of their teaching and learning experiences are themselves important. Furthermore, a retrospective presurvey allows for content of an educational program or intervention to be explained prior to a survey, so that participants first assess their new level of understanding or skill on the post test, then reflectively assess the level of understanding or skill they had prior to the workshop. This avoids response shift bias and can improve internal validity.21, 35

Second, the small numbers of session leaders, hospitalist trainees, and residents restricted statistical power to detect small effects. The fact that we found significant improvements enhances the likelihood that the differences observed were not due to chance.

Third, the low response rates from the hospitalist trainee post‐intervention questionnaire and the residents' questionnaires may affect the validity of our results. For the resident survey, the subjects were not matched, and we cannot state that an individual's geriatric skill practice changed due to PAGE, though the results suggest the residency program as a whole improved the frequency of geriatric skill practice.

Finally, the residents were required to report the frequency of teaching on and practice of geriatric skills practice over the prior year and accuracy of recall may be an issue. However, frequencies were queried both pre and post intervention and favorable change was noted. Furthermore, because the high end of the 3‐point teaching scale was limited to more than once, the true amount of teaching may have been underestimated if more than once actually represented high frequencies.

Future studies are needed to replicate these findings at other institutions to confirm generalizability. It would be beneficial to measure patient outcomes to determine whether increased teaching and skill practice benefits patients using measures such as reduction in catheter related urinary tract infections, falls, and inadequate pain management. Further investigations of cotaught faculty development programs between hospitalists and other specialists help emphasize why internally created TTT programs are of greater value than online resources.

Conclusions

This time‐sensitive adaptation of a hospitalist geriatric TTT program was successfully implemented at an academic medical center and suggests improved hospitalist faculty self‐efficacy at teaching geriatric skills, increased frequency of inpatient geriatric teaching by hospitalists and increased resident geriatric skill practice. Confidence to care for geriatric patients and a strong skill set to assess risks and manage them appropriately will equip hospitalists and trainees to provide care that reduces geriatric patients' in‐hospital morbidity and costs of care. As hospitalists increasingly care for older adults, the need for time‐efficient methods of teaching geriatrics will continue to grow. The PAGE Model, and other new models of geriatric training for hospitalists, demonstrates that we are beginning to address this urgent need.

Acknowledgements

The authors thank Joan Abrams, MA, MPA, and Patricia O'Sullivan, EdD, whose work was key to the success of this program and this manuscript. They also thank the Donald W. Reynolds Foundation for support of this project.

References
  1. Defrancis CJ,Hall MJ.2005 National Hospital Discharge Survey.Adv Data.2007;385:119.
  2. He W,Sengupta M,Velko VA,DeBarros KA. In:U.S. Census Bureau, Current Population Reports, 65+ in the United States: 2005,Washington, D.C.:U.S. Government Printing Office;2005:23209.
  3. Kuo Y,Sharma G,Freeman JL,Goodwin JS.Growth in the care of older patients by hospitalists in the United States.N Engl J Med.2009;360(11):11021112.
  4. Connell CM,Holmes SB,Voelkl JE,Bakalar H.Providing dementia outreach education to rural communities: lessons learned from a train‐the‐trainer program.J Appl Gerontol.2002;21:294313.
  5. Langer N.Gerontologizing health care: a train‐the‐trainer program for nurses.Gerontol Geriatr Educ.1999;19:4756.
  6. Coogle CL,Osgood NJ,Parham IA.A statewide model detection and prevention program for geriatric alcoholism and alcohol abuse: increased knowledge among service providers.Community Ment Health J.2000;36:137148.
  7. Podrazik PM,Levine S,Smith S, et al.The curriculum for the hospitalized aging medical patient program: a collaborative faculty development program for hospitalists, general internists, and geriatricians.J Hosp Med.2008;3(5):384393.
  8. Webster‐Wright A.Reframing professional development through understanding authentic professional learning.Rev Educ Res.2009;79:702739.
  9. The Education Committee Writing Group of the American Geriatrics Society.Core competencies for the care of older patients: recommendations of the American Geriatrics Society.Acad Med.2000;75:252255.
  10. Besdine R,Boult C,Brangman S, et al.American Geriatrics Society Task Force on the future of geriatric medicine.J Am Geriatr Soc.2005;53 (6 Suppl):S245S256.
  11. Nadzam, Deborah. Preventing patient falls. Joint Commission Resources. Available at: http://www.jcrinc.com/Preventing‐Patient‐Falls. Accessed April2010.
  12. Counsell SR,Sullivan GM.Curricular recommendations for resident training in nursing home care. A collaborative effort of the Society of General Internal Medicine Task Force on Geriatric Medicine, the Society of Teachers of Family Medicine Geriatrics Task Force, the American Medical Directors Association, and the American Geriatrics Society Education Committee.J Am Geriatr Soc.1994;42:12001201.
  13. Counsell SR,Kennedy RD,Szwabo P,Wadsworth NS,Wohlgemuth C.Curriculum recommendations for resident training in geriatrics interdisciplinary team care.J Am Geriatr Soc.1999;47:11451148.
  14. Bragg EJ,Warshaw GA.ACGME requirements for geriatrics medicine curricula in medical specialties: Progress made and progress needed.Acad Med.2005;80:279285.
  15. CMS Office of Public Affairs. CMS Improves Patient Safety for Medicare and Medicaid by Addressing Never Events, August 04, 2008. Available at: http://www.cms.gov/apps/media/press/factsheet.asp?Counter=322434(5):337343.
  16. Leist JC,Kristofco RE.The changing paradigm for continuing medical education: impact of information on the teachable moment.Bull Med Libr Assoc.1990;78(2):173179.
  17. Wagner PS,Ash KL.Creating the teachable moment.J Nurs Educ.1998;37(6):278280.
  18. Society of Hospital Medicine, BOOSTing Care Transitions Resource Room. Mazotti L, Johnston CB. Faculty development: Teaching triggers for transitional care. “A train‐the‐trainer model.” Available at: http://www.hospitalmedicine.org/ResourceRoomRedesign/RR_CareTransitions/PDFs/Mazotti_UCSF_Transitions.PPT. Accessed April2010.
  19. Bandura A.Self‐efficacy: The Exercise of Control.New York:W.H. Freeman and Company;1997.
  20. Howard GS.Internal invalidity in pretest‐posttest self‐report evaluations and a re‐evaluation of retrospective pretests.Applied Psychological Measurement.1979;3:123.
  21. Hojat M,Xu G.A visitor's guide to effect sizes.Adv Health Sci Educ Theory Pract.2004;9:241249.
  22. Cohen J.Statistical Power Analyses for the Behavioral Sciences.2nd ed.Hillsdale, NJ:Lawrence Erlbaum Associates;1988.
  23. Lang VJ,Clark NS,Medina‐Walpole A,McCann R.Hazards of hospitalization: Hospitalists and geriatricians educating medical students about delirium and falls in geriatric patients.Gerontol Geriatr Educ.2008;28(4):94104.
  24. Thomas DC,Johnson B,Dunn K, et al.Continuing medical education, continuing professional development, and knowledge translation: Improving care of older patients by practicing physicians.J Am Geriatr Soc.2006:54(10):16101618.
  25. Levine SA,Brett B,Robinson BE, et al.Practicing physician education in geriatrics: Lessons learned from a train‐the‐trainer model.J Am Geriatr Soc.2007:55(8):12811286.
  26. Hauer KE,Landefeld CS.CHAMP trains champions: hospitalist‐educators develop new ways to teach care for older patients.J Hosp Med.2008;3(5):357360.
  27. Davis D,O'Brien MA,Freemantle N,Wolf FM,Mazmanian P,Taylor‐Vaisey A.Impact of formal continuing medical education: Do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes?JAMA.1999;282(9):867874.
  28. Grant J,Stanton F.Association for the Study of Medical Education Booklet: The effectiveness of continuing professional development.Edinburgh, Scotland:Association for the Study of Medical Education;2000.
  29. Marinopoulos SS,Dorman T,Ratanawongsa N, et al.Effectiveness of continuing medical education.Evid Rep Technol Assess (Full Rep).2007;149:169.
  30. Forsetlund L,Bjorndal A,Rashidan A, et al.Continuing education meetings and workshops: effects on professional practice and health care outcomes.Cochrane Database Syst Rev.2009;(2):CD003030.
  31. Mazmanian PE,Davis DA.Continuing medical education and the physician as learner: guide to the evidence.JAMA.2002;288(9):10571060.
  32. Landefeld CS.Care of hospitalized older patients: opportunities for hospital‐based physicians.J Hosp Med.2006;1:4247.
  33. Hartman SL,Nelson MS.What we say and what we do: self‐reported teaching behavior versus performances in written simulations among medical school faculty.Acad Med.1992;67(8):522527.
  34. Goedhart H,Hoogstraten J.The retrospective pretest and the role of pretest information in evaluation studies.Psychol Rep.1992;70:699704.
References
  1. Defrancis CJ,Hall MJ.2005 National Hospital Discharge Survey.Adv Data.2007;385:119.
  2. He W,Sengupta M,Velko VA,DeBarros KA. In:U.S. Census Bureau, Current Population Reports, 65+ in the United States: 2005,Washington, D.C.:U.S. Government Printing Office;2005:23209.
  3. Kuo Y,Sharma G,Freeman JL,Goodwin JS.Growth in the care of older patients by hospitalists in the United States.N Engl J Med.2009;360(11):11021112.
  4. Connell CM,Holmes SB,Voelkl JE,Bakalar H.Providing dementia outreach education to rural communities: lessons learned from a train‐the‐trainer program.J Appl Gerontol.2002;21:294313.
  5. Langer N.Gerontologizing health care: a train‐the‐trainer program for nurses.Gerontol Geriatr Educ.1999;19:4756.
  6. Coogle CL,Osgood NJ,Parham IA.A statewide model detection and prevention program for geriatric alcoholism and alcohol abuse: increased knowledge among service providers.Community Ment Health J.2000;36:137148.
  7. Podrazik PM,Levine S,Smith S, et al.The curriculum for the hospitalized aging medical patient program: a collaborative faculty development program for hospitalists, general internists, and geriatricians.J Hosp Med.2008;3(5):384393.
  8. Webster‐Wright A.Reframing professional development through understanding authentic professional learning.Rev Educ Res.2009;79:702739.
  9. The Education Committee Writing Group of the American Geriatrics Society.Core competencies for the care of older patients: recommendations of the American Geriatrics Society.Acad Med.2000;75:252255.
  10. Besdine R,Boult C,Brangman S, et al.American Geriatrics Society Task Force on the future of geriatric medicine.J Am Geriatr Soc.2005;53 (6 Suppl):S245S256.
  11. Nadzam, Deborah. Preventing patient falls. Joint Commission Resources. Available at: http://www.jcrinc.com/Preventing‐Patient‐Falls. Accessed April2010.
  12. Counsell SR,Sullivan GM.Curricular recommendations for resident training in nursing home care. A collaborative effort of the Society of General Internal Medicine Task Force on Geriatric Medicine, the Society of Teachers of Family Medicine Geriatrics Task Force, the American Medical Directors Association, and the American Geriatrics Society Education Committee.J Am Geriatr Soc.1994;42:12001201.
  13. Counsell SR,Kennedy RD,Szwabo P,Wadsworth NS,Wohlgemuth C.Curriculum recommendations for resident training in geriatrics interdisciplinary team care.J Am Geriatr Soc.1999;47:11451148.
  14. Bragg EJ,Warshaw GA.ACGME requirements for geriatrics medicine curricula in medical specialties: Progress made and progress needed.Acad Med.2005;80:279285.
  15. CMS Office of Public Affairs. CMS Improves Patient Safety for Medicare and Medicaid by Addressing Never Events, August 04, 2008. Available at: http://www.cms.gov/apps/media/press/factsheet.asp?Counter=322434(5):337343.
  16. Leist JC,Kristofco RE.The changing paradigm for continuing medical education: impact of information on the teachable moment.Bull Med Libr Assoc.1990;78(2):173179.
  17. Wagner PS,Ash KL.Creating the teachable moment.J Nurs Educ.1998;37(6):278280.
  18. Society of Hospital Medicine, BOOSTing Care Transitions Resource Room. Mazotti L, Johnston CB. Faculty development: Teaching triggers for transitional care. “A train‐the‐trainer model.” Available at: http://www.hospitalmedicine.org/ResourceRoomRedesign/RR_CareTransitions/PDFs/Mazotti_UCSF_Transitions.PPT. Accessed April2010.
  19. Bandura A.Self‐efficacy: The Exercise of Control.New York:W.H. Freeman and Company;1997.
  20. Howard GS.Internal invalidity in pretest‐posttest self‐report evaluations and a re‐evaluation of retrospective pretests.Applied Psychological Measurement.1979;3:123.
  21. Hojat M,Xu G.A visitor's guide to effect sizes.Adv Health Sci Educ Theory Pract.2004;9:241249.
  22. Cohen J.Statistical Power Analyses for the Behavioral Sciences.2nd ed.Hillsdale, NJ:Lawrence Erlbaum Associates;1988.
  23. Lang VJ,Clark NS,Medina‐Walpole A,McCann R.Hazards of hospitalization: Hospitalists and geriatricians educating medical students about delirium and falls in geriatric patients.Gerontol Geriatr Educ.2008;28(4):94104.
  24. Thomas DC,Johnson B,Dunn K, et al.Continuing medical education, continuing professional development, and knowledge translation: Improving care of older patients by practicing physicians.J Am Geriatr Soc.2006:54(10):16101618.
  25. Levine SA,Brett B,Robinson BE, et al.Practicing physician education in geriatrics: Lessons learned from a train‐the‐trainer model.J Am Geriatr Soc.2007:55(8):12811286.
  26. Hauer KE,Landefeld CS.CHAMP trains champions: hospitalist‐educators develop new ways to teach care for older patients.J Hosp Med.2008;3(5):357360.
  27. Davis D,O'Brien MA,Freemantle N,Wolf FM,Mazmanian P,Taylor‐Vaisey A.Impact of formal continuing medical education: Do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes?JAMA.1999;282(9):867874.
  28. Grant J,Stanton F.Association for the Study of Medical Education Booklet: The effectiveness of continuing professional development.Edinburgh, Scotland:Association for the Study of Medical Education;2000.
  29. Marinopoulos SS,Dorman T,Ratanawongsa N, et al.Effectiveness of continuing medical education.Evid Rep Technol Assess (Full Rep).2007;149:169.
  30. Forsetlund L,Bjorndal A,Rashidan A, et al.Continuing education meetings and workshops: effects on professional practice and health care outcomes.Cochrane Database Syst Rev.2009;(2):CD003030.
  31. Mazmanian PE,Davis DA.Continuing medical education and the physician as learner: guide to the evidence.JAMA.2002;288(9):10571060.
  32. Landefeld CS.Care of hospitalized older patients: opportunities for hospital‐based physicians.J Hosp Med.2006;1:4247.
  33. Hartman SL,Nelson MS.What we say and what we do: self‐reported teaching behavior versus performances in written simulations among medical school faculty.Acad Med.1992;67(8):522527.
  34. Goedhart H,Hoogstraten J.The retrospective pretest and the role of pretest information in evaluation studies.Psychol Rep.1992;70:699704.
Issue
Journal of Hospital Medicine - 5(9)
Issue
Journal of Hospital Medicine - 5(9)
Page Number
541-546
Page Number
541-546
Article Type
Display Headline
Advancing geriatrics education: An efficient faculty development program for academic hospitalists increases geriatric teaching
Display Headline
Advancing geriatrics education: An efficient faculty development program for academic hospitalists increases geriatric teaching
Legacy Keywords
continuing medical education (CME), education, geriatric patient, hospitalist as educators, resident
Legacy Keywords
continuing medical education (CME), education, geriatric patient, hospitalist as educators, resident
Sections
Article Source

Copyright © 2010 Society of Hospital Medicine

Disallow All Ads
Correspondence Location
Assistant Clinical Professor of Medicine, University of California, San Francisco, 533 Parnassus Ave, RoomU112; Box 0131, San Francisco, CA 94143‐0131
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Article PDF Media

Cognitive Errors in Medical Injury

Article Type
Changed
Thu, 05/25/2017 - 21:30
Display Headline
Cognitive error as the most frequent contributory factor in cases of medical injury: A study on verdict's judgment among closed claims in Japan

Promotion of safer healthcare by patient organizations has led to an expansion of studies aimed at understanding medical errors to minimize injury through systemic improvement. These efforts have focused on identifying patient‐related factors, reducing technology failures, and improving communication.1 In contrast, factors related to cognitive errors by healthcare providers have received relatively little attention, although such errors may be an important source of preventable harm.1, 2

Limited information is available on the types and prevalence of cognitive factors in cases of medical injury, although cognitive factors may be a major risk for medical injury. If these factors were confirmed to be important factors for medical injury, better educational strategies may be needed to reduce cognitive errors among physicians and to enhance quality improvement and patient safety. Better understanding of these cognitive factors may also help to implement educational programs aimed at the improvement of cognitive performance in medical schools or teaching hospital.35

Closed‐claim files for cases of medical injury contain valuable information for investigation of the factors involved in medical errors.3 In Japan, court claims were tried and closed orders were issued by judges without a jury system until 2009. Under this system, representatives for defense and plaintiffs can present medical experts. Courts can also appoint experts independent of either party. Court opinions in Japan are considered as neutral judgments for conflicts between plaintiffs and defendants. Usually there are 3 judges who are required to be involved with each judgment in Japanese courts.

Closed‐claim files in cases of medical injury contain information about the types and prevalence of cognitive factors suggested to be causally related to the injuries by verdicts in district courts. Thus, by analyzing these files, an unbiased description of the characteristics and epidemiology of cognitive factors can be obtained for cases of medical injury, with minimization of potentially biased claims indicated by both parties; ie, plaintiffs vs. hospitals. Therefore, in this study, by using information from closed claims files at district courts in Tokyo and Osaka, Japan, we aimed to determine the important cognitive factors associated with cases of medical injury from such factors as judgment, vigilance, memory, technical competence, or knowledge. Since we anticipated that cognitive factors would dominate among the causative factors, we also explored the association of these factors with cases in which a judgment of paid compensation was made.

Methods

Study Sample

The authors acknowledge that the methodologies are based on those from the Malpractice Insurers' Medical Errors Prevention Study.6 A claim was defined as a written demand for compensation for cases of medical injury, based on a similar approach in previous studies.7, 8 Reviews were performed for closed‐claim files for cases of medical injury involving physicians from 2001 to 2005. These files were published by the Division of the Tokyo‐Osaka Medical Malpractice Lawsuits, organized by district courts in Tokyo and Osaka. The files included all closed‐claim cases of medical injury involving physicians from 2001 to 2005 at district courts in Tokyo and Osaka. The locations of delivery of care were inpatients in this study. All patients in Japan were insured during the study period.

Data Collection

Reviews were conducted by 3 board‐certified Japanese physician‐investigators specializing in internal medicine (1 chief investigator and 2 coinvestigators). The chief investigator trained the coinvestigators in 1‐day sessions with regard to the content of claims files, data collection, and the confidentiality procedure. Reviews were first performed by 1 coinvestigator and then confirmed by the chief investigator.

Data were collected for patient demographics and characteristics of adverse events, including types, locations, clinical areas, and specialties involved in the claims. Classification of specialties was based on that of Singh et al.3 Types of adverse events included minor injury for cases with complete recovery within a year, significant injury for those with complete recovery requiring more than a year, major injury for those with incomplete recovery (any physical sequelae) after more than a year, and death. Clinical areas consisted of surgery, obstetrics, missed diagnosis, delayed diagnosis, medication, and fall. Data for litigation outcomes and the amounts of paid compensation in Japanese Yen (JY) were also collected for claims that received verdicts supporting the plaintiffs.

All factors identified in the verdicts as causally related to the medical injury were recorded for data analysis. Classification of these factors was based on that of Singh et al.3 Cognitive factors were drawn from a list of categories of physicians' tasks provided by the Occupational Information Network. This network is a database of occupational requirements and worker attributes and it describes occupations in terms of the skills and knowledge required, how the work is performed, and typical work settings. The list of cognitive factor categories of physicians' tasks included judgment, vigilance, memory, technical competence, or knowledge. Accordingly, the cognitive factor category list was considered to capture the work of clinicians across the entire range of specialties.3

An example concerning failure of judgment would be that a rapid respiratory rate in initial vital signs was missed or ignored in a patient who complained of upper abdominal pain, was sent home with a diagnosis of gastritis, and eventually died at home; and an autopsy diagnosis of myocardial infarction with congestive heart failure was later confirmed. A vigilance error example would be that, in an electronic ordering system, typing an incorrect medication that has the similar commercial name of a correct medication. An example of failure of memory as a cognitive error would be that a physician forgot a result of laboratory data (positive sputum cytology of lung cancer), and so the physician did not explain it to the patient and did not perform an appropriate subsequent treatment referral. A technical incompetence example would be an operative or procedural injury due to technical problems of physicians. An example of a knowledge error would be that a contraindicated drug combination was prescribed such as the use of both selective serotonin reuptake inhibitor and monoamine oxidase inhibitor.

For systemic factors, a teamwork problem (poor teamwork) was used to describe disruptive team behavior, based on the concept of teamwork described by the Agency for Healthcare Research and Quality and the British Medical Association.9, 10 Cases with teamwork problems were defined as those in which the original reviewer had judged that 1 or more of the following contributory factors played a role in the error: communication breakdowns, supervision problems, handoff problems, failures to establish clear lines of responsibility, and conflict among clinical staff. Technology failure indicated an error of commission or omission by devices, tools, or machines.

The Japanese courts analyze medical records but they do not open the records to the public and so we could not analyze the medical records of the cases in our study. Thus, we did not judge whether the adverse outcome could have been attributed to medical errors, while we analyzed the claims files and followed the conclusions reached by the end of the claims.

Statistical Analysis

Data are given as proportions for categorical variables and means or medians for continuous variables. Cognitive factors associated with cases receiving adjudication of a compensation payment by district courts (litigation outcomes) were analyzed using a logistic regression model including 5 types of cognitive errors. Analyses were conducted with the Stata SE 10.0 statistical software package (College Station, TX). All P values are 2‐sided and P < 0.05 was considered to be statistically significant. The study was approved by the ethics review board at the institution of the chief investigator.

Results

In a total of 274 closed cases of medical injury, the mean age of the patients was 49 years old and 45% were women (Table 1). The reviews performed by the coinvestigators were all confirmed by the chief investigator without discordance of the reviews between the coinvestigators and the chief investigator. The claims involved death of patients in 45% of cases; injuries that caused significant or major disability in 10% and 24%, respectively (a total of 34%); and minor adverse outcomes of medical care in 21% (57 cases). Closing verdicts supporting the plaintiffs (patients or family) by the district courts were given in 103 claims (38%), with compensation at a median of 8,000,000 JY (100 JY = $1 US in 2005). The compensation ranged from 20,000 JY to 222,710,251 JY. The highest compensation was ordered to be paid to a 36‐year‐old woman with an obstetrics‐related major injury and the court indicated the injury was causally related to the following 3 cognitive factors: error in judgment, failure of vigilance, and lack of technical competence.

Characteristics of Claims (n = 274)
Characteristicn (%)
  • NOTE: Demographic of patients, severity of adverse outcome, and involved clinical areas are provided in this table.

  • Abbreviation: SD, standard deviation.

Demographic of patients 
Women121 (45)
Men153 (55)
Age, mean SD, year49 22
Adverse outcome 
Minor57 (21)
Significant28 (10)
Major67 (24)
Death122 (45)
Operative36
Delayed diagnosis35
Medication26
Missed diagnosis16
Obstetrics8
Clinical area 
Operative120 (44)
Delayed diagnosis54 (20)
Medication50 (18)
Missed diagnosis28 (10)
Obstetrics19 (7)
Fall3 (1)

Operative injury was the most frequent reason for claims, followed by delayed diagnosis, medication error, and missed diagnosis. General surgery, orthopedics, internal medicine, and obstetrics/gynecology were the most frequently involved specialties, comprising 30% of all cases (Table 2). The verdicts suggested cognitive factors were the most prevalent factors associated with cases of medical injury: 73% of the injuries were judged to be the result of an error in judgment (Table 3), followed by failure of vigilance (65%), lack of technical competence (34%), and lack of knowledge (31%). Verdicts indicated systemic factors in only a few cases, including poor teamwork in 4% and technology failure in 2%. Patient‐related factors were suggested in 32% of the claims.

Specialty Involved in Claims
SpecialtyCases, n (%)
General surgery27 (10)
Orthopedic surgery27 (10)
Internal medicine27 (10)
Obstetrics‐gynecology26 (9)
Neurosurgery19 (7)
Ear, nose, and throat18 (7)
Plastic surgery15 (5)
Psychiatry14 (5)
Cardiology13 (5)
Dental care13 (5)
Ophthalmology12 (4)
Hematology or oncology10 (4)
Adult primary care9 (3)
Pediatrics8 (3)
Urology8 (3)
Cardiothoracic surgery8 (3)
Neurology5 (2)
Anesthesiology4 (1)
Physical medicine or rehabilitation3 (1)
Emergency medicine2 (1)
Infectious disease2 (1)
Dermatology2 (1)
Radiology1 (<1)
Vascular surgery1 (<1)
Contributory Factors to Medical Injury Suggested in Verdicts
Contributory Factorn (%)
  • NOTE: This table shows frequency and percentage of contributory factors to medical injury suggested in verdicts.

Cognitive factors 
Error in judgment199 (73)
Failure of vigilance177 (65)
Lack of technical competence94 (34)
Lack of knowledge86 (31)
Failure of memory5 (2)
System factors 
Poor teamwork11 (4)
Technology failure5 (2)
Patient‐related factors87 (32)

In a multivariable‐adjusted logistic regression analysis of cognitive factors with a potential association with the claims with paid compensation (Table 4), only error in judgment showed a significant association (odds ratio, 1.9; 95% confidence interval [CI], 1.01‐3.40). The other four cognitive factors in the model were not associated with these claims. The odds ratio for failure of memory was high (2.8), but this factor was identified by the courts in only 5 cases and was not significantly associated with claims with paid compensation.

Cognitive Factors for Cases With Paid Compensation
Cognitive FactorCases With No Compensation (n = 171), n (%)Cases With Paid Compensation (n = 103), n (%)Odds Ratio (95% CI)*
  • Abbreviation: CI, confidence interval.

  • For paid compensation.

  • P < 0.05

Error in judgment117 (68)82 (80)1.9 (1.03.4)
Failure of vigilance111 (65)66 (64)1.0 (0.61.7)
Failure of memory2 (1)3 (3)2.8 (0.518)
Lack of technical competence58 (34)36 (35)1.1 (0.61.8)
Lack of knowledge52 (30)34 (33)1.0 (0.61.7)

Discussion

In this study of closed claims files, we identified 2 important cognitive factors involved in cases of medical injury. Error in judgment was the most common factor, comprising about 70% of all claims, and was significantly associated with cases with paid compensation for medical injury. The second cognitive factor was failure of vigilance, which was found in 65% of the claims. Other cognitive factors, such as lack of technical competence and knowledge or failure of memory, as well as systemic factors (poor teamwork and technology failure) were less frequently found to be causally related to cases with medical injury in the verdicts examined in the study.

Reasons for the low frequency of systemic factors involved in cases of medical injury in our study are unclear. This may be the cultural characteristics such as greater emphasis to working in teams and following rules of an organization in Japan. Another possibility is that plaintiffs might have tended to generate lawsuits in cases with suspected higher frequency of individual physicians' factors in Japan. Moreover, among cognitive factors, lack of technical competence and knowledge or failure of memory was also less frequently related to cases with medical injury in our study compared to those of the previous studies.3, 11

The study design of analyzing closed claims files of cases of medical injury is noteworthy for its methodology of error assessment and provides valuable information on errors related to medical injury.3, 7 Moreover, the system of court verdicts in Japan based on decisions by a professional judge allows elimination of potential bias from stakeholders (plaintiffs vs. hospitals) involved in cases of medical injury. Thus, probable causes related to adverse events can be determined from a neutral position. Previous studies of medical error have focused on medical record reviews, surveys, and interviews;12, 13 our study corroborates and extends the findings in these studies that cognitive errors are the most frequent source of medical injury.

Error in judgment is commonly made in the course of decision making in multiple clinical areas. This type of error is referred to recently as cognitive dispositions to respond,14 which is different from bias or heuristics, since not all heuristics are biased and not all errors in judgments come from bias. There is a well‐established value of heuristics in medical diagnosis. Moreover, the properties of this type of error are likely to be distinct from those associated with performance of procedures (lack of technical competence), such as operative injury, which are directly visible and can be prevented through rapid dissemination of information on safety procedures among a medical team. However, the consequences of error in judgment are important for patients, family, and healthcare providers, and these errors are also largely preventable by implementation of educational programs.15

Possible solutions for improving clinical judgment skills may be derived from recent education theory. The theory provides a means for minimizing errors in judgment through the process of meta‐cognition, in which cognitive forcing strategies can be developed through thinking that involves active control over the process of one's own thinking.14, 15 For example, reflective practice has been suggested to be an important instrument for improving clinical judgment and may particularly improve diagnoses in situations of uncertainty and uniqueness, thereby reducing diagnostic errors.16 The capability of critical reflection in real‐time practice (reflection‐in‐action) and on our own practice (reflection‐on‐action) appears to be a key requirement for developing and maintaining medical expertise.17, 18 For instance, case‐based discussion with clinician educators can be an opportunity for enhancing critical thinking skills of medical trainees.

Based on a context‐based approach that focuses on the nature of the clinical problem, potential systemic solutions have recently been proposed for reducing errors in judgment.1 These solutions utilize advanced technology, including symptom‐oriented diagnostic decision support, internet search engines for information on possible diagnoses, and automated reminders in electronic health records.1, 19 Previous studies have shown that long work hours and sleep deprivation can decrease cognitive function, leading to failure of vigilance and increased medical errors,20 and several systemic solutions provide models for avoidance of failure of vigilance. For instance, eliminating extended work shifts and reducing the number of work hours per week was shown to reduce serious medical errors through increased sleep and decreased failure of vigilance during night work in an intensive care unit.21, 22 Taking a brief nap during work hours has also been associated with decreased medical errors in a recent study conducted in Japan.23 Despite the well‐known importance of factors of physicians' workloads, our study did not analyze these factors and thus further studies are needed to confirm their importance in Japanese medical practice.

There were also 32% of patient‐related factors suggested as contributory factors to medical injury in verdicts of the closed claims. This finding may be also important in planning educational intervention strategies to reduce medical errors. Although our data did not include the relative frequency of components related to these factors, major components of patient‐related factors may include age, severity of illnesses, comorbidity, functional status, or mental status. Educational intervention programs may help healthcare providers to evaluate patients with these risk factors and to implement preventive strategies to avoid incidents among these patients.

General surgery, orthopedic surgery, internal medicine, and obstetrics‐gynecology were the most frequently involved specialties in our study. The reasons why these specialties were highly involved in the claims are unclear and our study could not analyze these issues. However, these specialties may be related to patients with greater clinical severity and thus they may have subsequently higher risk for receiving claims. Further, physicians in these specialties may be at higher risk for having various errors because of the complexity of care for patients.

Our study has several limitations. First, the closed claims are more likely to represent cases with severe injury.3 Therefore, it is unclear if we can generalize our findings beyond cases with severe injury.3 Second, certain contributory factors may not have been suggested by the verdicts, even though they played a role. Among these potential factors, poor teamwork and communication issues are unlikely to be identified as causative in verdicts, unless the allegation of the plaintiffs documented these issues. Moreover, the Japanese courts did not open the medical records to the public and so we could not analyze the medical records of the cases. Third, we only evaluated closed verdicts given by professional judges of district courts, who are unlikely to be medical experts. However, the closed verdicts underwent an extensive process involving testimony from medical professionals and academic societies. Fourth, we, as investigators, had few members with surgical backgrounds in this study so we might have underestimated issues related to technical competence among the claims. Finally, although a small percentage of closed‐ claim cases involving team performance were identified in our study, the plaintiffs might have indicated this point to the court claims, since it might have been difficult to describe this issue as a reason for requesting compensations from defendants. Thus, despite a low proportion of team performance involvement in the verdicts, we still believe that poor team performance is a factor related to most medical injuries.

In summary, causal factors obtained from closed claims files suggest the importance of cognitive factors in cases of medical injury. Among the cognitive factors, error in judgment and failure of vigilance were the most frequent. These findings may help leaders of medical schools and hospitals to allocate more resources for research into strategies to improve cognitive performance and thereby ensure patient safety. Further research is needed to better understand the cognitive mechanisms involved in medical errors and to translate this into educational strategies.

References
  1. Newman‐Toker DE,Pronovost PJ.Diagnostic errors‐the next frontier for patient safety.JAMA.2009;301(10):10601062.
  2. Graber ML,Franklin N,Gordon R.Diagnostic error in internal medicine.Arch Intern Med.2005;165(13):14931499.
  3. Singh H,Thomas E,Petersen L,Studdert D.Medical errors involving trainees: a study of closed malpractice claims from 5 insurers.Arch Intern Med.2007;167(19):20302036.
  4. Singh H,Petersen LA,Thomas EJ.Understanding diagnostic errors in medicine: a lesson from aviation.Qual Saf Health Care.2006;15(3):159164.
  5. Croskerry P.The importance of cognitive errors in diagnosis and strategies to minimize them.Acad Med.2003;78(8):775780.
  6. Studdert DM,Mello MM,Gawande AA, et al.Claims, errors, and compensation payments in medical malpractice litigation.N Engl J Med.2006;354(19):20242033.
  7. Studdert DM,Thomas EJ,Burstin HR,Zbar BI,Orav EJ,Brennan TA.Negligent care and malpractice claiming behavior in Utah and Colorado.Med Care.2000;38(3):250260.
  8. Thomas EJ,Studdert DM,Burstin HR, et al.Incidence and types of adverse events and negligent care in Utah and Colorado.Med Care.2000;38(3):261271.
  9. Baker DP,Gustafson S,Beaubien J,Salas E,Barach P.Medical Teamwork and Patient Safety: The Evidence‐Based Relation.Rockville, MD:Agency for Healthcare Research and Quality;2005 [updated April 2005]; Available at: http://www.ahrq.gov/qual/medteam. Accessed June 2010.
  10. Glover C,Bogle I.Team working in Primary Health Care. Realising Shared Aims in Patient Care.London, UK:Royal Pharmaceutical Society and British Medical Association.2005.
  11. Smits M,Groenewegen PP,Timmermans DR,van der Wal G,Wagner C.The nature and causes of unintended events reported at ten emergency departments.BMC Emerg Med.2009;9:16.
  12. Kohn LT,Corrigan J,Donaldson MS.To Err Is Human: Building a Safer Health System.Washington, USA:National Academy Press;2000.
  13. Gawande AA,Zinner MJ,Studdert DM,Brennan TA.Analysis of errors reported by surgeons at three teaching hospitals.Surgery.2003;133(6):614621.
  14. Croskerry P.Achieving quality in clinical decision making: cognitive strategies and detection of bias.Acad Emerg Med.2002;9(11):11841204.
  15. Croskerry P.Cognitive forcing strategies in clinical decision making.Ann Emerg Med.2003;41(1):110120.
  16. Mamede S,Schmidt HG,Penaforte JC.Effects of reflective practice on the accuracy of medical diagnoses.Med Educ.2008;42(5):468475.
  17. Schön DA.The Reflective Practitioner: How Professionals Think in Action.New York, NY:Basic Books;1983.
  18. Mamede S,Schmidt HG,Rikers R.Diagnostic errors and reflective practice in medicine.J Eval Clin Pract.2007;13(1):138145.
  19. Tokuda Y,Aoki M,Kandpal SB,Tierney LM.Caught in the web: e‐diagnosis.J Hosp Med.2009;4(4):262266.
  20. Ayas NT,Barger LK,Cade BE, et al.Extended work duration and the risk of self‐reported percutaneous injuries in interns.JAMA.2006;296(9):10551062.
  21. Landrigan CP,Rothschild JM,Cronin JW, et al.Effect of reducing interns' work hours on serious medical errors in intensive care units.N Engl J Med.2004;351(18):18381848.
  22. Lockley SW,Cronin JW,Evans EE, et al.Effect of reducing interns' weekly work hours on sleep and attentional failures.N Engl J Med.2004;351(18):18291837.
  23. Horinouchi H,Tokuda Y,Nishimura N, et al.Influence of Residents' Workload, Mental State and Job Satisfaction on Procedural Error: a prospective daily questionnaire‐based study.General Medicine.2008;9(2):5764.
Article PDF
Issue
Journal of Hospital Medicine - 6(3)
Page Number
109-114
Legacy Keywords
cognition, error in judgment, failure of vigilance, medical injury
Sections
Article PDF
Article PDF

Promotion of safer healthcare by patient organizations has led to an expansion of studies aimed at understanding medical errors to minimize injury through systemic improvement. These efforts have focused on identifying patient‐related factors, reducing technology failures, and improving communication.1 In contrast, factors related to cognitive errors by healthcare providers have received relatively little attention, although such errors may be an important source of preventable harm.1, 2

Limited information is available on the types and prevalence of cognitive factors in cases of medical injury, although cognitive factors may be a major risk for medical injury. If these factors were confirmed to be important factors for medical injury, better educational strategies may be needed to reduce cognitive errors among physicians and to enhance quality improvement and patient safety. Better understanding of these cognitive factors may also help to implement educational programs aimed at the improvement of cognitive performance in medical schools or teaching hospital.35

Closed‐claim files for cases of medical injury contain valuable information for investigation of the factors involved in medical errors.3 In Japan, court claims were tried and closed orders were issued by judges without a jury system until 2009. Under this system, representatives for defense and plaintiffs can present medical experts. Courts can also appoint experts independent of either party. Court opinions in Japan are considered as neutral judgments for conflicts between plaintiffs and defendants. Usually there are 3 judges who are required to be involved with each judgment in Japanese courts.

Closed‐claim files in cases of medical injury contain information about the types and prevalence of cognitive factors suggested to be causally related to the injuries by verdicts in district courts. Thus, by analyzing these files, an unbiased description of the characteristics and epidemiology of cognitive factors can be obtained for cases of medical injury, with minimization of potentially biased claims indicated by both parties; ie, plaintiffs vs. hospitals. Therefore, in this study, by using information from closed claims files at district courts in Tokyo and Osaka, Japan, we aimed to determine the important cognitive factors associated with cases of medical injury from such factors as judgment, vigilance, memory, technical competence, or knowledge. Since we anticipated that cognitive factors would dominate among the causative factors, we also explored the association of these factors with cases in which a judgment of paid compensation was made.

Methods

Study Sample

The authors acknowledge that the methodologies are based on those from the Malpractice Insurers' Medical Errors Prevention Study.6 A claim was defined as a written demand for compensation for cases of medical injury, based on a similar approach in previous studies.7, 8 Reviews were performed for closed‐claim files for cases of medical injury involving physicians from 2001 to 2005. These files were published by the Division of the Tokyo‐Osaka Medical Malpractice Lawsuits, organized by district courts in Tokyo and Osaka. The files included all closed‐claim cases of medical injury involving physicians from 2001 to 2005 at district courts in Tokyo and Osaka. The locations of delivery of care were inpatients in this study. All patients in Japan were insured during the study period.

Data Collection

Reviews were conducted by 3 board‐certified Japanese physician‐investigators specializing in internal medicine (1 chief investigator and 2 coinvestigators). The chief investigator trained the coinvestigators in 1‐day sessions with regard to the content of claims files, data collection, and the confidentiality procedure. Reviews were first performed by 1 coinvestigator and then confirmed by the chief investigator.

Data were collected for patient demographics and characteristics of adverse events, including types, locations, clinical areas, and specialties involved in the claims. Classification of specialties was based on that of Singh et al.3 Types of adverse events included minor injury for cases with complete recovery within a year, significant injury for those with complete recovery requiring more than a year, major injury for those with incomplete recovery (any physical sequelae) after more than a year, and death. Clinical areas consisted of surgery, obstetrics, missed diagnosis, delayed diagnosis, medication, and fall. Data for litigation outcomes and the amounts of paid compensation in Japanese Yen (JY) were also collected for claims that received verdicts supporting the plaintiffs.

All factors identified in the verdicts as causally related to the medical injury were recorded for data analysis. Classification of these factors was based on that of Singh et al.3 Cognitive factors were drawn from a list of categories of physicians' tasks provided by the Occupational Information Network. This network is a database of occupational requirements and worker attributes and it describes occupations in terms of the skills and knowledge required, how the work is performed, and typical work settings. The list of cognitive factor categories of physicians' tasks included judgment, vigilance, memory, technical competence, or knowledge. Accordingly, the cognitive factor category list was considered to capture the work of clinicians across the entire range of specialties.3

An example concerning failure of judgment would be that a rapid respiratory rate in initial vital signs was missed or ignored in a patient who complained of upper abdominal pain, was sent home with a diagnosis of gastritis, and eventually died at home; and an autopsy diagnosis of myocardial infarction with congestive heart failure was later confirmed. A vigilance error example would be that, in an electronic ordering system, typing an incorrect medication that has the similar commercial name of a correct medication. An example of failure of memory as a cognitive error would be that a physician forgot a result of laboratory data (positive sputum cytology of lung cancer), and so the physician did not explain it to the patient and did not perform an appropriate subsequent treatment referral. A technical incompetence example would be an operative or procedural injury due to technical problems of physicians. An example of a knowledge error would be that a contraindicated drug combination was prescribed such as the use of both selective serotonin reuptake inhibitor and monoamine oxidase inhibitor.

For systemic factors, a teamwork problem (poor teamwork) was used to describe disruptive team behavior, based on the concept of teamwork described by the Agency for Healthcare Research and Quality and the British Medical Association.9, 10 Cases with teamwork problems were defined as those in which the original reviewer had judged that 1 or more of the following contributory factors played a role in the error: communication breakdowns, supervision problems, handoff problems, failures to establish clear lines of responsibility, and conflict among clinical staff. Technology failure indicated an error of commission or omission by devices, tools, or machines.

The Japanese courts analyze medical records but they do not open the records to the public and so we could not analyze the medical records of the cases in our study. Thus, we did not judge whether the adverse outcome could have been attributed to medical errors, while we analyzed the claims files and followed the conclusions reached by the end of the claims.

Statistical Analysis

Data are given as proportions for categorical variables and means or medians for continuous variables. Cognitive factors associated with cases receiving adjudication of a compensation payment by district courts (litigation outcomes) were analyzed using a logistic regression model including 5 types of cognitive errors. Analyses were conducted with the Stata SE 10.0 statistical software package (College Station, TX). All P values are 2‐sided and P < 0.05 was considered to be statistically significant. The study was approved by the ethics review board at the institution of the chief investigator.

Results

In a total of 274 closed cases of medical injury, the mean age of the patients was 49 years old and 45% were women (Table 1). The reviews performed by the coinvestigators were all confirmed by the chief investigator without discordance of the reviews between the coinvestigators and the chief investigator. The claims involved death of patients in 45% of cases; injuries that caused significant or major disability in 10% and 24%, respectively (a total of 34%); and minor adverse outcomes of medical care in 21% (57 cases). Closing verdicts supporting the plaintiffs (patients or family) by the district courts were given in 103 claims (38%), with compensation at a median of 8,000,000 JY (100 JY = $1 US in 2005). The compensation ranged from 20,000 JY to 222,710,251 JY. The highest compensation was ordered to be paid to a 36‐year‐old woman with an obstetrics‐related major injury and the court indicated the injury was causally related to the following 3 cognitive factors: error in judgment, failure of vigilance, and lack of technical competence.

Characteristics of Claims (n = 274)
Characteristicn (%)
  • NOTE: Demographic of patients, severity of adverse outcome, and involved clinical areas are provided in this table.

  • Abbreviation: SD, standard deviation.

Demographic of patients 
Women121 (45)
Men153 (55)
Age, mean SD, year49 22
Adverse outcome 
Minor57 (21)
Significant28 (10)
Major67 (24)
Death122 (45)
Operative36
Delayed diagnosis35
Medication26
Missed diagnosis16
Obstetrics8
Clinical area 
Operative120 (44)
Delayed diagnosis54 (20)
Medication50 (18)
Missed diagnosis28 (10)
Obstetrics19 (7)
Fall3 (1)

Operative injury was the most frequent reason for claims, followed by delayed diagnosis, medication error, and missed diagnosis. General surgery, orthopedics, internal medicine, and obstetrics/gynecology were the most frequently involved specialties, comprising 30% of all cases (Table 2). The verdicts suggested cognitive factors were the most prevalent factors associated with cases of medical injury: 73% of the injuries were judged to be the result of an error in judgment (Table 3), followed by failure of vigilance (65%), lack of technical competence (34%), and lack of knowledge (31%). Verdicts indicated systemic factors in only a few cases, including poor teamwork in 4% and technology failure in 2%. Patient‐related factors were suggested in 32% of the claims.

Specialty Involved in Claims
SpecialtyCases, n (%)
General surgery27 (10)
Orthopedic surgery27 (10)
Internal medicine27 (10)
Obstetrics‐gynecology26 (9)
Neurosurgery19 (7)
Ear, nose, and throat18 (7)
Plastic surgery15 (5)
Psychiatry14 (5)
Cardiology13 (5)
Dental care13 (5)
Ophthalmology12 (4)
Hematology or oncology10 (4)
Adult primary care9 (3)
Pediatrics8 (3)
Urology8 (3)
Cardiothoracic surgery8 (3)
Neurology5 (2)
Anesthesiology4 (1)
Physical medicine or rehabilitation3 (1)
Emergency medicine2 (1)
Infectious disease2 (1)
Dermatology2 (1)
Radiology1 (<1)
Vascular surgery1 (<1)
Contributory Factors to Medical Injury Suggested in Verdicts
Contributory Factorn (%)
  • NOTE: This table shows frequency and percentage of contributory factors to medical injury suggested in verdicts.

Cognitive factors 
Error in judgment199 (73)
Failure of vigilance177 (65)
Lack of technical competence94 (34)
Lack of knowledge86 (31)
Failure of memory5 (2)
System factors 
Poor teamwork11 (4)
Technology failure5 (2)
Patient‐related factors87 (32)

In a multivariable‐adjusted logistic regression analysis of cognitive factors with a potential association with the claims with paid compensation (Table 4), only error in judgment showed a significant association (odds ratio, 1.9; 95% confidence interval [CI], 1.01‐3.40). The other four cognitive factors in the model were not associated with these claims. The odds ratio for failure of memory was high (2.8), but this factor was identified by the courts in only 5 cases and was not significantly associated with claims with paid compensation.

Cognitive Factors for Cases With Paid Compensation
Cognitive FactorCases With No Compensation (n = 171), n (%)Cases With Paid Compensation (n = 103), n (%)Odds Ratio (95% CI)*
  • Abbreviation: CI, confidence interval.

  • For paid compensation.

  • P < 0.05

Error in judgment117 (68)82 (80)1.9 (1.03.4)
Failure of vigilance111 (65)66 (64)1.0 (0.61.7)
Failure of memory2 (1)3 (3)2.8 (0.518)
Lack of technical competence58 (34)36 (35)1.1 (0.61.8)
Lack of knowledge52 (30)34 (33)1.0 (0.61.7)

Discussion

In this study of closed claims files, we identified 2 important cognitive factors involved in cases of medical injury. Error in judgment was the most common factor, comprising about 70% of all claims, and was significantly associated with cases with paid compensation for medical injury. The second cognitive factor was failure of vigilance, which was found in 65% of the claims. Other cognitive factors, such as lack of technical competence and knowledge or failure of memory, as well as systemic factors (poor teamwork and technology failure) were less frequently found to be causally related to cases with medical injury in the verdicts examined in the study.

Reasons for the low frequency of systemic factors involved in cases of medical injury in our study are unclear. This may be the cultural characteristics such as greater emphasis to working in teams and following rules of an organization in Japan. Another possibility is that plaintiffs might have tended to generate lawsuits in cases with suspected higher frequency of individual physicians' factors in Japan. Moreover, among cognitive factors, lack of technical competence and knowledge or failure of memory was also less frequently related to cases with medical injury in our study compared to those of the previous studies.3, 11

The study design of analyzing closed claims files of cases of medical injury is noteworthy for its methodology of error assessment and provides valuable information on errors related to medical injury.3, 7 Moreover, the system of court verdicts in Japan based on decisions by a professional judge allows elimination of potential bias from stakeholders (plaintiffs vs. hospitals) involved in cases of medical injury. Thus, probable causes related to adverse events can be determined from a neutral position. Previous studies of medical error have focused on medical record reviews, surveys, and interviews;12, 13 our study corroborates and extends the findings in these studies that cognitive errors are the most frequent source of medical injury.

Error in judgment is commonly made in the course of decision making in multiple clinical areas. This type of error is referred to recently as cognitive dispositions to respond,14 which is different from bias or heuristics, since not all heuristics are biased and not all errors in judgments come from bias. There is a well‐established value of heuristics in medical diagnosis. Moreover, the properties of this type of error are likely to be distinct from those associated with performance of procedures (lack of technical competence), such as operative injury, which are directly visible and can be prevented through rapid dissemination of information on safety procedures among a medical team. However, the consequences of error in judgment are important for patients, family, and healthcare providers, and these errors are also largely preventable by implementation of educational programs.15

Possible solutions for improving clinical judgment skills may be derived from recent education theory. The theory provides a means for minimizing errors in judgment through the process of meta‐cognition, in which cognitive forcing strategies can be developed through thinking that involves active control over the process of one's own thinking.14, 15 For example, reflective practice has been suggested to be an important instrument for improving clinical judgment and may particularly improve diagnoses in situations of uncertainty and uniqueness, thereby reducing diagnostic errors.16 The capability of critical reflection in real‐time practice (reflection‐in‐action) and on our own practice (reflection‐on‐action) appears to be a key requirement for developing and maintaining medical expertise.17, 18 For instance, case‐based discussion with clinician educators can be an opportunity for enhancing critical thinking skills of medical trainees.

Based on a context‐based approach that focuses on the nature of the clinical problem, potential systemic solutions have recently been proposed for reducing errors in judgment.1 These solutions utilize advanced technology, including symptom‐oriented diagnostic decision support, internet search engines for information on possible diagnoses, and automated reminders in electronic health records.1, 19 Previous studies have shown that long work hours and sleep deprivation can decrease cognitive function, leading to failure of vigilance and increased medical errors,20 and several systemic solutions provide models for avoidance of failure of vigilance. For instance, eliminating extended work shifts and reducing the number of work hours per week was shown to reduce serious medical errors through increased sleep and decreased failure of vigilance during night work in an intensive care unit.21, 22 Taking a brief nap during work hours has also been associated with decreased medical errors in a recent study conducted in Japan.23 Despite the well‐known importance of factors of physicians' workloads, our study did not analyze these factors and thus further studies are needed to confirm their importance in Japanese medical practice.

There were also 32% of patient‐related factors suggested as contributory factors to medical injury in verdicts of the closed claims. This finding may be also important in planning educational intervention strategies to reduce medical errors. Although our data did not include the relative frequency of components related to these factors, major components of patient‐related factors may include age, severity of illnesses, comorbidity, functional status, or mental status. Educational intervention programs may help healthcare providers to evaluate patients with these risk factors and to implement preventive strategies to avoid incidents among these patients.

General surgery, orthopedic surgery, internal medicine, and obstetrics‐gynecology were the most frequently involved specialties in our study. The reasons why these specialties were highly involved in the claims are unclear and our study could not analyze these issues. However, these specialties may be related to patients with greater clinical severity and thus they may have subsequently higher risk for receiving claims. Further, physicians in these specialties may be at higher risk for having various errors because of the complexity of care for patients.

Our study has several limitations. First, the closed claims are more likely to represent cases with severe injury.3 Therefore, it is unclear if we can generalize our findings beyond cases with severe injury.3 Second, certain contributory factors may not have been suggested by the verdicts, even though they played a role. Among these potential factors, poor teamwork and communication issues are unlikely to be identified as causative in verdicts, unless the allegation of the plaintiffs documented these issues. Moreover, the Japanese courts did not open the medical records to the public and so we could not analyze the medical records of the cases. Third, we only evaluated closed verdicts given by professional judges of district courts, who are unlikely to be medical experts. However, the closed verdicts underwent an extensive process involving testimony from medical professionals and academic societies. Fourth, we, as investigators, had few members with surgical backgrounds in this study so we might have underestimated issues related to technical competence among the claims. Finally, although a small percentage of closed‐ claim cases involving team performance were identified in our study, the plaintiffs might have indicated this point to the court claims, since it might have been difficult to describe this issue as a reason for requesting compensations from defendants. Thus, despite a low proportion of team performance involvement in the verdicts, we still believe that poor team performance is a factor related to most medical injuries.

In summary, causal factors obtained from closed claims files suggest the importance of cognitive factors in cases of medical injury. Among the cognitive factors, error in judgment and failure of vigilance were the most frequent. These findings may help leaders of medical schools and hospitals to allocate more resources for research into strategies to improve cognitive performance and thereby ensure patient safety. Further research is needed to better understand the cognitive mechanisms involved in medical errors and to translate this into educational strategies.

Promotion of safer healthcare by patient organizations has led to an expansion of studies aimed at understanding medical errors to minimize injury through systemic improvement. These efforts have focused on identifying patient‐related factors, reducing technology failures, and improving communication.1 In contrast, factors related to cognitive errors by healthcare providers have received relatively little attention, although such errors may be an important source of preventable harm.1, 2

Limited information is available on the types and prevalence of cognitive factors in cases of medical injury, although cognitive factors may be a major risk for medical injury. If these factors were confirmed to be important factors for medical injury, better educational strategies may be needed to reduce cognitive errors among physicians and to enhance quality improvement and patient safety. Better understanding of these cognitive factors may also help to implement educational programs aimed at the improvement of cognitive performance in medical schools or teaching hospital.35

Closed‐claim files for cases of medical injury contain valuable information for investigation of the factors involved in medical errors.3 In Japan, court claims were tried and closed orders were issued by judges without a jury system until 2009. Under this system, representatives for defense and plaintiffs can present medical experts. Courts can also appoint experts independent of either party. Court opinions in Japan are considered as neutral judgments for conflicts between plaintiffs and defendants. Usually there are 3 judges who are required to be involved with each judgment in Japanese courts.

Closed‐claim files in cases of medical injury contain information about the types and prevalence of cognitive factors suggested to be causally related to the injuries by verdicts in district courts. Thus, by analyzing these files, an unbiased description of the characteristics and epidemiology of cognitive factors can be obtained for cases of medical injury, with minimization of potentially biased claims indicated by both parties; ie, plaintiffs vs. hospitals. Therefore, in this study, by using information from closed claims files at district courts in Tokyo and Osaka, Japan, we aimed to determine the important cognitive factors associated with cases of medical injury from such factors as judgment, vigilance, memory, technical competence, or knowledge. Since we anticipated that cognitive factors would dominate among the causative factors, we also explored the association of these factors with cases in which a judgment of paid compensation was made.

Methods

Study Sample

The authors acknowledge that the methodologies are based on those from the Malpractice Insurers' Medical Errors Prevention Study.6 A claim was defined as a written demand for compensation for cases of medical injury, based on a similar approach in previous studies.7, 8 Reviews were performed for closed‐claim files for cases of medical injury involving physicians from 2001 to 2005. These files were published by the Division of the Tokyo‐Osaka Medical Malpractice Lawsuits, organized by district courts in Tokyo and Osaka. The files included all closed‐claim cases of medical injury involving physicians from 2001 to 2005 at district courts in Tokyo and Osaka. The locations of delivery of care were inpatients in this study. All patients in Japan were insured during the study period.

Data Collection

Reviews were conducted by 3 board‐certified Japanese physician‐investigators specializing in internal medicine (1 chief investigator and 2 coinvestigators). The chief investigator trained the coinvestigators in 1‐day sessions with regard to the content of claims files, data collection, and the confidentiality procedure. Reviews were first performed by 1 coinvestigator and then confirmed by the chief investigator.

Data were collected for patient demographics and characteristics of adverse events, including types, locations, clinical areas, and specialties involved in the claims. Classification of specialties was based on that of Singh et al.3 Types of adverse events included minor injury for cases with complete recovery within a year, significant injury for those with complete recovery requiring more than a year, major injury for those with incomplete recovery (any physical sequelae) after more than a year, and death. Clinical areas consisted of surgery, obstetrics, missed diagnosis, delayed diagnosis, medication, and fall. Data for litigation outcomes and the amounts of paid compensation in Japanese Yen (JY) were also collected for claims that received verdicts supporting the plaintiffs.

All factors identified in the verdicts as causally related to the medical injury were recorded for data analysis. Classification of these factors was based on that of Singh et al.3 Cognitive factors were drawn from a list of categories of physicians' tasks provided by the Occupational Information Network. This network is a database of occupational requirements and worker attributes and it describes occupations in terms of the skills and knowledge required, how the work is performed, and typical work settings. The list of cognitive factor categories of physicians' tasks included judgment, vigilance, memory, technical competence, or knowledge. Accordingly, the cognitive factor category list was considered to capture the work of clinicians across the entire range of specialties.3

An example concerning failure of judgment would be that a rapid respiratory rate in initial vital signs was missed or ignored in a patient who complained of upper abdominal pain, was sent home with a diagnosis of gastritis, and eventually died at home; and an autopsy diagnosis of myocardial infarction with congestive heart failure was later confirmed. A vigilance error example would be that, in an electronic ordering system, typing an incorrect medication that has the similar commercial name of a correct medication. An example of failure of memory as a cognitive error would be that a physician forgot a result of laboratory data (positive sputum cytology of lung cancer), and so the physician did not explain it to the patient and did not perform an appropriate subsequent treatment referral. A technical incompetence example would be an operative or procedural injury due to technical problems of physicians. An example of a knowledge error would be that a contraindicated drug combination was prescribed such as the use of both selective serotonin reuptake inhibitor and monoamine oxidase inhibitor.

For systemic factors, a teamwork problem (poor teamwork) was used to describe disruptive team behavior, based on the concept of teamwork described by the Agency for Healthcare Research and Quality and the British Medical Association.9, 10 Cases with teamwork problems were defined as those in which the original reviewer had judged that 1 or more of the following contributory factors played a role in the error: communication breakdowns, supervision problems, handoff problems, failures to establish clear lines of responsibility, and conflict among clinical staff. Technology failure indicated an error of commission or omission by devices, tools, or machines.

The Japanese courts analyze medical records but they do not open the records to the public and so we could not analyze the medical records of the cases in our study. Thus, we did not judge whether the adverse outcome could have been attributed to medical errors, while we analyzed the claims files and followed the conclusions reached by the end of the claims.

Statistical Analysis

Data are given as proportions for categorical variables and means or medians for continuous variables. Cognitive factors associated with cases receiving adjudication of a compensation payment by district courts (litigation outcomes) were analyzed using a logistic regression model including 5 types of cognitive errors. Analyses were conducted with the Stata SE 10.0 statistical software package (College Station, TX). All P values are 2‐sided and P < 0.05 was considered to be statistically significant. The study was approved by the ethics review board at the institution of the chief investigator.

Results

In a total of 274 closed cases of medical injury, the mean age of the patients was 49 years old and 45% were women (Table 1). The reviews performed by the coinvestigators were all confirmed by the chief investigator without discordance of the reviews between the coinvestigators and the chief investigator. The claims involved death of patients in 45% of cases; injuries that caused significant or major disability in 10% and 24%, respectively (a total of 34%); and minor adverse outcomes of medical care in 21% (57 cases). Closing verdicts supporting the plaintiffs (patients or family) by the district courts were given in 103 claims (38%), with compensation at a median of 8,000,000 JY (100 JY = $1 US in 2005). The compensation ranged from 20,000 JY to 222,710,251 JY. The highest compensation was ordered to be paid to a 36‐year‐old woman with an obstetrics‐related major injury and the court indicated the injury was causally related to the following 3 cognitive factors: error in judgment, failure of vigilance, and lack of technical competence.

Characteristics of Claims (n = 274)
Characteristicn (%)
  • NOTE: Demographic of patients, severity of adverse outcome, and involved clinical areas are provided in this table.

  • Abbreviation: SD, standard deviation.

Demographic of patients 
Women121 (45)
Men153 (55)
Age, mean SD, year49 22
Adverse outcome 
Minor57 (21)
Significant28 (10)
Major67 (24)
Death122 (45)
Operative36
Delayed diagnosis35
Medication26
Missed diagnosis16
Obstetrics8
Clinical area 
Operative120 (44)
Delayed diagnosis54 (20)
Medication50 (18)
Missed diagnosis28 (10)
Obstetrics19 (7)
Fall3 (1)

Operative injury was the most frequent reason for claims, followed by delayed diagnosis, medication error, and missed diagnosis. General surgery, orthopedics, internal medicine, and obstetrics/gynecology were the most frequently involved specialties, comprising 30% of all cases (Table 2). The verdicts suggested cognitive factors were the most prevalent factors associated with cases of medical injury: 73% of the injuries were judged to be the result of an error in judgment (Table 3), followed by failure of vigilance (65%), lack of technical competence (34%), and lack of knowledge (31%). Verdicts indicated systemic factors in only a few cases, including poor teamwork in 4% and technology failure in 2%. Patient‐related factors were suggested in 32% of the claims.

Specialty Involved in Claims
SpecialtyCases, n (%)
General surgery27 (10)
Orthopedic surgery27 (10)
Internal medicine27 (10)
Obstetrics‐gynecology26 (9)
Neurosurgery19 (7)
Ear, nose, and throat18 (7)
Plastic surgery15 (5)
Psychiatry14 (5)
Cardiology13 (5)
Dental care13 (5)
Ophthalmology12 (4)
Hematology or oncology10 (4)
Adult primary care9 (3)
Pediatrics8 (3)
Urology8 (3)
Cardiothoracic surgery8 (3)
Neurology5 (2)
Anesthesiology4 (1)
Physical medicine or rehabilitation3 (1)
Emergency medicine2 (1)
Infectious disease2 (1)
Dermatology2 (1)
Radiology1 (<1)
Vascular surgery1 (<1)
Contributory Factors to Medical Injury Suggested in Verdicts
Contributory Factorn (%)
  • NOTE: This table shows frequency and percentage of contributory factors to medical injury suggested in verdicts.

Cognitive factors 
Error in judgment199 (73)
Failure of vigilance177 (65)
Lack of technical competence94 (34)
Lack of knowledge86 (31)
Failure of memory5 (2)
System factors 
Poor teamwork11 (4)
Technology failure5 (2)
Patient‐related factors87 (32)

In a multivariable‐adjusted logistic regression analysis of cognitive factors with a potential association with the claims with paid compensation (Table 4), only error in judgment showed a significant association (odds ratio, 1.9; 95% confidence interval [CI], 1.01‐3.40). The other four cognitive factors in the model were not associated with these claims. The odds ratio for failure of memory was high (2.8), but this factor was identified by the courts in only 5 cases and was not significantly associated with claims with paid compensation.

Cognitive Factors for Cases With Paid Compensation
Cognitive FactorCases With No Compensation (n = 171), n (%)Cases With Paid Compensation (n = 103), n (%)Odds Ratio (95% CI)*
  • Abbreviation: CI, confidence interval.

  • For paid compensation.

  • P < 0.05

Error in judgment117 (68)82 (80)1.9 (1.03.4)
Failure of vigilance111 (65)66 (64)1.0 (0.61.7)
Failure of memory2 (1)3 (3)2.8 (0.518)
Lack of technical competence58 (34)36 (35)1.1 (0.61.8)
Lack of knowledge52 (30)34 (33)1.0 (0.61.7)

Discussion

In this study of closed claims files, we identified 2 important cognitive factors involved in cases of medical injury. Error in judgment was the most common factor, comprising about 70% of all claims, and was significantly associated with cases with paid compensation for medical injury. The second cognitive factor was failure of vigilance, which was found in 65% of the claims. Other cognitive factors, such as lack of technical competence and knowledge or failure of memory, as well as systemic factors (poor teamwork and technology failure) were less frequently found to be causally related to cases with medical injury in the verdicts examined in the study.

Reasons for the low frequency of systemic factors involved in cases of medical injury in our study are unclear. This may be the cultural characteristics such as greater emphasis to working in teams and following rules of an organization in Japan. Another possibility is that plaintiffs might have tended to generate lawsuits in cases with suspected higher frequency of individual physicians' factors in Japan. Moreover, among cognitive factors, lack of technical competence and knowledge or failure of memory was also less frequently related to cases with medical injury in our study compared to those of the previous studies.3, 11

The study design of analyzing closed claims files of cases of medical injury is noteworthy for its methodology of error assessment and provides valuable information on errors related to medical injury.3, 7 Moreover, the system of court verdicts in Japan based on decisions by a professional judge allows elimination of potential bias from stakeholders (plaintiffs vs. hospitals) involved in cases of medical injury. Thus, probable causes related to adverse events can be determined from a neutral position. Previous studies of medical error have focused on medical record reviews, surveys, and interviews;12, 13 our study corroborates and extends the findings in these studies that cognitive errors are the most frequent source of medical injury.

Error in judgment is commonly made in the course of decision making in multiple clinical areas. This type of error is referred to recently as cognitive dispositions to respond,14 which is different from bias or heuristics, since not all heuristics are biased and not all errors in judgments come from bias. There is a well‐established value of heuristics in medical diagnosis. Moreover, the properties of this type of error are likely to be distinct from those associated with performance of procedures (lack of technical competence), such as operative injury, which are directly visible and can be prevented through rapid dissemination of information on safety procedures among a medical team. However, the consequences of error in judgment are important for patients, family, and healthcare providers, and these errors are also largely preventable by implementation of educational programs.15

Possible solutions for improving clinical judgment skills may be derived from recent education theory. The theory provides a means for minimizing errors in judgment through the process of meta‐cognition, in which cognitive forcing strategies can be developed through thinking that involves active control over the process of one's own thinking.14, 15 For example, reflective practice has been suggested to be an important instrument for improving clinical judgment and may particularly improve diagnoses in situations of uncertainty and uniqueness, thereby reducing diagnostic errors.16 The capability of critical reflection in real‐time practice (reflection‐in‐action) and on our own practice (reflection‐on‐action) appears to be a key requirement for developing and maintaining medical expertise.17, 18 For instance, case‐based discussion with clinician educators can be an opportunity for enhancing critical thinking skills of medical trainees.

Based on a context‐based approach that focuses on the nature of the clinical problem, potential systemic solutions have recently been proposed for reducing errors in judgment.1 These solutions utilize advanced technology, including symptom‐oriented diagnostic decision support, internet search engines for information on possible diagnoses, and automated reminders in electronic health records.1, 19 Previous studies have shown that long work hours and sleep deprivation can decrease cognitive function, leading to failure of vigilance and increased medical errors,20 and several systemic solutions provide models for avoidance of failure of vigilance. For instance, eliminating extended work shifts and reducing the number of work hours per week was shown to reduce serious medical errors through increased sleep and decreased failure of vigilance during night work in an intensive care unit.21, 22 Taking a brief nap during work hours has also been associated with decreased medical errors in a recent study conducted in Japan.23 Despite the well‐known importance of factors of physicians' workloads, our study did not analyze these factors and thus further studies are needed to confirm their importance in Japanese medical practice.

There were also 32% of patient‐related factors suggested as contributory factors to medical injury in verdicts of the closed claims. This finding may be also important in planning educational intervention strategies to reduce medical errors. Although our data did not include the relative frequency of components related to these factors, major components of patient‐related factors may include age, severity of illnesses, comorbidity, functional status, or mental status. Educational intervention programs may help healthcare providers to evaluate patients with these risk factors and to implement preventive strategies to avoid incidents among these patients.

General surgery, orthopedic surgery, internal medicine, and obstetrics‐gynecology were the most frequently involved specialties in our study. The reasons why these specialties were highly involved in the claims are unclear and our study could not analyze these issues. However, these specialties may be related to patients with greater clinical severity and thus they may have subsequently higher risk for receiving claims. Further, physicians in these specialties may be at higher risk for having various errors because of the complexity of care for patients.

Our study has several limitations. First, the closed claims are more likely to represent cases with severe injury.3 Therefore, it is unclear if we can generalize our findings beyond cases with severe injury.3 Second, certain contributory factors may not have been suggested by the verdicts, even though they played a role. Among these potential factors, poor teamwork and communication issues are unlikely to be identified as causative in verdicts, unless the allegation of the plaintiffs documented these issues. Moreover, the Japanese courts did not open the medical records to the public and so we could not analyze the medical records of the cases. Third, we only evaluated closed verdicts given by professional judges of district courts, who are unlikely to be medical experts. However, the closed verdicts underwent an extensive process involving testimony from medical professionals and academic societies. Fourth, we, as investigators, had few members with surgical backgrounds in this study so we might have underestimated issues related to technical competence among the claims. Finally, although a small percentage of closed‐ claim cases involving team performance were identified in our study, the plaintiffs might have indicated this point to the court claims, since it might have been difficult to describe this issue as a reason for requesting compensations from defendants. Thus, despite a low proportion of team performance involvement in the verdicts, we still believe that poor team performance is a factor related to most medical injuries.

In summary, causal factors obtained from closed claims files suggest the importance of cognitive factors in cases of medical injury. Among the cognitive factors, error in judgment and failure of vigilance were the most frequent. These findings may help leaders of medical schools and hospitals to allocate more resources for research into strategies to improve cognitive performance and thereby ensure patient safety. Further research is needed to better understand the cognitive mechanisms involved in medical errors and to translate this into educational strategies.

References
  1. Newman‐Toker DE,Pronovost PJ.Diagnostic errors‐the next frontier for patient safety.JAMA.2009;301(10):10601062.
  2. Graber ML,Franklin N,Gordon R.Diagnostic error in internal medicine.Arch Intern Med.2005;165(13):14931499.
  3. Singh H,Thomas E,Petersen L,Studdert D.Medical errors involving trainees: a study of closed malpractice claims from 5 insurers.Arch Intern Med.2007;167(19):20302036.
  4. Singh H,Petersen LA,Thomas EJ.Understanding diagnostic errors in medicine: a lesson from aviation.Qual Saf Health Care.2006;15(3):159164.
  5. Croskerry P.The importance of cognitive errors in diagnosis and strategies to minimize them.Acad Med.2003;78(8):775780.
  6. Studdert DM,Mello MM,Gawande AA, et al.Claims, errors, and compensation payments in medical malpractice litigation.N Engl J Med.2006;354(19):20242033.
  7. Studdert DM,Thomas EJ,Burstin HR,Zbar BI,Orav EJ,Brennan TA.Negligent care and malpractice claiming behavior in Utah and Colorado.Med Care.2000;38(3):250260.
  8. Thomas EJ,Studdert DM,Burstin HR, et al.Incidence and types of adverse events and negligent care in Utah and Colorado.Med Care.2000;38(3):261271.
  9. Baker DP,Gustafson S,Beaubien J,Salas E,Barach P.Medical Teamwork and Patient Safety: The Evidence‐Based Relation.Rockville, MD:Agency for Healthcare Research and Quality;2005 [updated April 2005]; Available at: http://www.ahrq.gov/qual/medteam. Accessed June 2010.
  10. Glover C,Bogle I.Team working in Primary Health Care. Realising Shared Aims in Patient Care.London, UK:Royal Pharmaceutical Society and British Medical Association.2005.
  11. Smits M,Groenewegen PP,Timmermans DR,van der Wal G,Wagner C.The nature and causes of unintended events reported at ten emergency departments.BMC Emerg Med.2009;9:16.
  12. Kohn LT,Corrigan J,Donaldson MS.To Err Is Human: Building a Safer Health System.Washington, USA:National Academy Press;2000.
  13. Gawande AA,Zinner MJ,Studdert DM,Brennan TA.Analysis of errors reported by surgeons at three teaching hospitals.Surgery.2003;133(6):614621.
  14. Croskerry P.Achieving quality in clinical decision making: cognitive strategies and detection of bias.Acad Emerg Med.2002;9(11):11841204.
  15. Croskerry P.Cognitive forcing strategies in clinical decision making.Ann Emerg Med.2003;41(1):110120.
  16. Mamede S,Schmidt HG,Penaforte JC.Effects of reflective practice on the accuracy of medical diagnoses.Med Educ.2008;42(5):468475.
  17. Schön DA.The Reflective Practitioner: How Professionals Think in Action.New York, NY:Basic Books;1983.
  18. Mamede S,Schmidt HG,Rikers R.Diagnostic errors and reflective practice in medicine.J Eval Clin Pract.2007;13(1):138145.
  19. Tokuda Y,Aoki M,Kandpal SB,Tierney LM.Caught in the web: e‐diagnosis.J Hosp Med.2009;4(4):262266.
  20. Ayas NT,Barger LK,Cade BE, et al.Extended work duration and the risk of self‐reported percutaneous injuries in interns.JAMA.2006;296(9):10551062.
  21. Landrigan CP,Rothschild JM,Cronin JW, et al.Effect of reducing interns' work hours on serious medical errors in intensive care units.N Engl J Med.2004;351(18):18381848.
  22. Lockley SW,Cronin JW,Evans EE, et al.Effect of reducing interns' weekly work hours on sleep and attentional failures.N Engl J Med.2004;351(18):18291837.
  23. Horinouchi H,Tokuda Y,Nishimura N, et al.Influence of Residents' Workload, Mental State and Job Satisfaction on Procedural Error: a prospective daily questionnaire‐based study.General Medicine.2008;9(2):5764.
References
  1. Newman‐Toker DE,Pronovost PJ.Diagnostic errors‐the next frontier for patient safety.JAMA.2009;301(10):10601062.
  2. Graber ML,Franklin N,Gordon R.Diagnostic error in internal medicine.Arch Intern Med.2005;165(13):14931499.
  3. Singh H,Thomas E,Petersen L,Studdert D.Medical errors involving trainees: a study of closed malpractice claims from 5 insurers.Arch Intern Med.2007;167(19):20302036.
  4. Singh H,Petersen LA,Thomas EJ.Understanding diagnostic errors in medicine: a lesson from aviation.Qual Saf Health Care.2006;15(3):159164.
  5. Croskerry P.The importance of cognitive errors in diagnosis and strategies to minimize them.Acad Med.2003;78(8):775780.
  6. Studdert DM,Mello MM,Gawande AA, et al.Claims, errors, and compensation payments in medical malpractice litigation.N Engl J Med.2006;354(19):20242033.
  7. Studdert DM,Thomas EJ,Burstin HR,Zbar BI,Orav EJ,Brennan TA.Negligent care and malpractice claiming behavior in Utah and Colorado.Med Care.2000;38(3):250260.
  8. Thomas EJ,Studdert DM,Burstin HR, et al.Incidence and types of adverse events and negligent care in Utah and Colorado.Med Care.2000;38(3):261271.
  9. Baker DP,Gustafson S,Beaubien J,Salas E,Barach P.Medical Teamwork and Patient Safety: The Evidence‐Based Relation.Rockville, MD:Agency for Healthcare Research and Quality;2005 [updated April 2005]; Available at: http://www.ahrq.gov/qual/medteam. Accessed June 2010.
  10. Glover C,Bogle I.Team working in Primary Health Care. Realising Shared Aims in Patient Care.London, UK:Royal Pharmaceutical Society and British Medical Association.2005.
  11. Smits M,Groenewegen PP,Timmermans DR,van der Wal G,Wagner C.The nature and causes of unintended events reported at ten emergency departments.BMC Emerg Med.2009;9:16.
  12. Kohn LT,Corrigan J,Donaldson MS.To Err Is Human: Building a Safer Health System.Washington, USA:National Academy Press;2000.
  13. Gawande AA,Zinner MJ,Studdert DM,Brennan TA.Analysis of errors reported by surgeons at three teaching hospitals.Surgery.2003;133(6):614621.
  14. Croskerry P.Achieving quality in clinical decision making: cognitive strategies and detection of bias.Acad Emerg Med.2002;9(11):11841204.
  15. Croskerry P.Cognitive forcing strategies in clinical decision making.Ann Emerg Med.2003;41(1):110120.
  16. Mamede S,Schmidt HG,Penaforte JC.Effects of reflective practice on the accuracy of medical diagnoses.Med Educ.2008;42(5):468475.
  17. Schön DA.The Reflective Practitioner: How Professionals Think in Action.New York, NY:Basic Books;1983.
  18. Mamede S,Schmidt HG,Rikers R.Diagnostic errors and reflective practice in medicine.J Eval Clin Pract.2007;13(1):138145.
  19. Tokuda Y,Aoki M,Kandpal SB,Tierney LM.Caught in the web: e‐diagnosis.J Hosp Med.2009;4(4):262266.
  20. Ayas NT,Barger LK,Cade BE, et al.Extended work duration and the risk of self‐reported percutaneous injuries in interns.JAMA.2006;296(9):10551062.
  21. Landrigan CP,Rothschild JM,Cronin JW, et al.Effect of reducing interns' work hours on serious medical errors in intensive care units.N Engl J Med.2004;351(18):18381848.
  22. Lockley SW,Cronin JW,Evans EE, et al.Effect of reducing interns' weekly work hours on sleep and attentional failures.N Engl J Med.2004;351(18):18291837.
  23. Horinouchi H,Tokuda Y,Nishimura N, et al.Influence of Residents' Workload, Mental State and Job Satisfaction on Procedural Error: a prospective daily questionnaire‐based study.General Medicine.2008;9(2):5764.
Issue
Journal of Hospital Medicine - 6(3)
Issue
Journal of Hospital Medicine - 6(3)
Page Number
109-114
Page Number
109-114
Article Type
Display Headline
Cognitive error as the most frequent contributory factor in cases of medical injury: A study on verdict's judgment among closed claims in Japan
Display Headline
Cognitive error as the most frequent contributory factor in cases of medical injury: A study on verdict's judgment among closed claims in Japan
Legacy Keywords
cognition, error in judgment, failure of vigilance, medical injury
Legacy Keywords
cognition, error in judgment, failure of vigilance, medical injury
Sections
Article Source

Copyright © 2010 Society of Hospital Medicine

Disallow All Ads
Correspondence Location
Mito Kyodo Hospital, University of Tsukuba, 3‐2‐7 Miya‐machi, Ibaraki, 310‐0015, Japan
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Article PDF Media

GAD Vaccine for Type 1 Diabetes Shows Continued Promise

When to Intervene?
Article Type
Changed
Fri, 01/18/2019 - 11:41
Display Headline
GAD Vaccine for Type 1 Diabetes Shows Continued Promise

KEYSTONE, Colo. – Right now, the Diamyd Medical’s GAD vaccine is in the sweet spot in the developmental pipeline – an interim period of enormous optimism that this novel autoantigen-based immunotherapy will safely prevent many cases of type 1 diabetes.

The results of three phase II studies are in and they look quite promising. Two large phase III clinical trials are well underway in Europe and the United States. The safety experience with the 65-kD isoform of GAD (glutamic acid decarboxylase-65) vaccine has been outstanding. The subcutaneous two-injection series is easy to administer. Acceptance of the vaccine by patients and their families is high. The vaccine targets a serious disease whose incidence is steadily climbing by 3%-5% per year in developed countries. And most patients with recently diagnosed type 1 diabetes possess GAD autoantibodies, so the Diamyd vaccine would be widely applicable.

    Dr. Johnny L. Ludvigsson

All of that was good enough for Johnson and Johnson, which in June inked a huge development and marketing deal for the GAD vaccine with small Swedish biotech company Diamyd Medical. Under the deal, Diamyd receives $45 million upfront, milestone payments of up to $580 million, and tiered royalties after that. The Federal Trade Commission’s antitrust division has already approved the deal.

But during this blissful interlude, one key question remains: Is the Diamyd vaccine effective?

“It’s too early to say if this works. Absolutely too early. We have a phase III trial in Europe with results due next spring. And the TrialNet study [is] going on here in the U.S. So we will know in a year or 2,” Dr. Johnny L. Ludvigsson said at a conference on management of diabetes in youth sponsored by the Children’s Diabetes Foundation at Denver.

Dr. Ludvigsson, professor of pediatrics at the University of Linkoping (Sweden), led the phase III European trial evaluating whether the GAD vaccine preserves beta-cell function and residual insulin secretion in patients with type 1 diabetes diagnosed within 3 months of starting treatment. He also headed a phase II study that caused a favorable buzz within the diabetes research community (N. Engl. J. Med. 2008;359:1909-20) and for which he is now analyzing 5-year follow-up data.

And while the forthcoming phase III trial results will tell the tale as to clinical efficacy, at this time some useful interim observations can be made about the GAD vaccine, according to Dr. Ludvigsson:

The vaccine has demonstrated excellent safety. Experience with the vaccine to date totals 850 patient-years in adults and 350 patient-years in children, with no adverse events reported. This is enormously reassuring because GAD transforms glutamate into GABA, an important neurotransmitter. Lack of GAD in the CNS leads to muscle rigidity and convulsions, while stimulation of CNS GAD results in inhibition of neurotransmission. The absence of any such adverse events indicates the vaccine is working, as designed, to affect only a very small part of the immune system: namely, the activated T cells that have targeted pancreatic beta-cells for destruction, Dr. Ludvigsson said.

The vaccine has demonstrated prolonged immunologic effects. The immunologic response to the Diamyd vaccine lasts surprisingly long – approaching 5 years and still counting. It’s a GAD-specific, cell-mediated, and humoral immune response characterized by increased GAD autoantibodies, a Th2 shift marked by reduction in activated T cells and an increase in regulatory T cells, a sharp and sustained rise in levels of interleukins-2, -5, -10, -13, and -17, and GAD tolerance. “We see this response still after 4 years. The memory is there,” Dr. Ludvigsson observed.

“The earlier we treat, the better the outcome.” That’s why the phase III European trial is restricted to patients diagnosed with type 1 diabetes within the past 3 months. It’s also the impetus for ongoing prevention trials in individuals at very high genetic risk for type 1 diabetes who have GAD autoantibodies but have not developed overt disease.

The vaccine probably won’t work in diabetic patients without GAD autoantibodies. No studies have been carried out in such patients, but Dr. Ludvigsson said it’s his impression that the vaccine is more effective in individuals with higher than lower titers of GAD autoantibodies.

For the future, the GAD vaccine alone probably is not the solution to type 1 diabetes, Dr. Ludvigsson said candidly.

“I believe this opens the door to using different antigens, like in allergy. Allergists don’t use just cat antigen in patients who have cat, dog, and house dust mite allergies. I suppose we may also learn to combine autoantigens, together with possible stimulation of beta-cells in combination with drugs that promote beta-cell regeneration,” he continued.

 

 

Other autoantibodies commonly present in patients with type 1 diabetes, or at high risk for the disease, include insulin autoantibodies, islet cell autoantibodies, and antibodies to the zinc transporter. Combining the GAD vaccine with other major diabetes-specific autoantigens recognized by the immune system could provide synergistic benefits.

  Dr. Jay S. Skyler

The likely necessity for a combined approach addressing multiple pathways was underscored in a separate presentation by Dr. Jay S. Skyler, chairman of the type 1 Diabetes TrialNet, a National Institutes of Health–funded international network of centers conducting clinical trials of diabetes therapies.

The GAD vaccine appears to have the same limitation as the other immunomodulatory therapies evaluated to date in clinical trials, including the B cell–depleting anti-CD20 agent rituximab, and the anti-CD3 biologics teplizumab and otelixizumab: namely, they preserve beta cell function for a while, but the effect is transient. Eventually fasting C-peptide levels start to fall off in parallel to the placebo group. That’s why combination therapy will probably be required in order to cure or prevent Type 1 diabetes, according to Dr. Skyler, a professor of medicine, pediatrics and psychology at the University of Miami.

Ideally, a combination therapy should be multipronged, with three goals: Stop immune destruction, preserve beta-cell mass, and replace or regenerate beta-cells. Such a regimen might start off with a potent anti-inflammatory therapy – perhaps an anti-interleukin-1beta agent or tumor necrosis factor inhibitor – to quell the metabolic stress surrounding the pancreatic islets. This might well need to be given on a continuing basis.

Next would come an immunomodulatory approach; for example, T-cell modulation with an anti-CD3 biologic or B cell depletion with rituximab. This could be followed up with an autoantigen-specific therapy such as the GAD vaccine or oral insulin. “Maybe it needs to be both,” Dr. Skyler continued.

The logical subsequent step would be to try to stimulate immunologic expansion of regulatory T cells, either with granulocyte colony–stimulating factor or by direct infusion of regulatory T cells themselves. This could be combined with beta-cell expansion via exenatide (Byetta) or the investigational HIP2B peptide.

“We could conceivably be doing some of these things even today,” Dr. Skyler said.

Dr. Ludvigsson reported receiving research grant support from Diamyd.

Dr. Skyler has served as a consultant to and/or received research grants from numerous pharmaceutical companies.

Body

Type 1 diabetes (T1D) is an autoimmune disease caused by interplay of genetic and environmental factors. The incidence of childhood T1D has doubled worldwide over the past 20-25 years. Elimination of the environmental agent(s) responsible for this epidemic would be the most efficient approach to primary prevention; however, more work is needed to identify the environmental agents and to develop effective interventions.

Blocking progression from islet autoimmunity to clinical diabetes or secondary prevention has been attempted, so far to no avail, by a number of groups, including large randomized trials: the Diabetes Prevention Trial – Type 1, the European Nicotinamide Diabetes Intervention Trial, and the Type 1 Diabetes Prediction and Prevention Project.

Trials in patients with newly diagnosed T1D aim at tertiary prevention, such as preservation of remaining islet beta-cells to induce and prolong partial remission. Unfortunately, most islets have already been destroyed by the time diabetes is diagnosed and complete reversal of diabetes is highly unlikely. Benefits may include a simpler insulin regimen, lower HbA1c, and reduced risk of hypoglycemia and microvascular complications. The gain may be even greater if the intervention is applied as soon as the patient shows asymptomatic “dysglycemia,” detected by oral glucose tolerance test or A1c, before overt symptoms of diabetes.

While new interventions are often tested first in patients with established diabetes, and, when proven safe, applied to patients with pre-T1D, efficacy after diagnosis of diabetes is not to be a precondition to application in pre-T1D, as there may be a “point of no return” in the destruction of the islets, rendering some interventions effective only at the earlier stages of the process.

Antigen-specific vaccines

Among several approaches to prevention of T1D, “vaccination” using islet autoantigens (intact or altered peptides derived from insulin, GAD65 or other proteins) stands out as potentially inducing long-term tolerance by induction of regulatory T-cells that down-regulate immunity to autoantigens. Until recently, trials of insulin administered parenterally, orally, or intranasally have been unsuccessful. Therefore, the initial results from trials of the Diamyd vaccine, as reviewed here, were greeted with huge interest and excitement. The vaccine includes the whole recombinant human GAD65 (rhGAD65) molecule suspended in alum. The protective effect was most pronounced in patients treated within 3 months of diagnosis, and no serious side effects were observed.

Insulin-related molecules continue to attract great interest in vaccine development. Phase I studies have been completed or are nearing completion for a proinsulin peptide C19-A3, an insulin peptide with incomplete Freund adjuvant, and a plasmid encoding proinsulin.

Combination therapies may enhance efficacy while lowering risk of adverse events if utilizing therapies from different treatment pathways. While more targeted therapies are being employed, immunomodulatory agents are still relatively nonspecific and potentially toxic to some of the trial participants. Some may carry an unacceptable risk of long-term complications. This direction is important; however, multiple scientific and logistic issues remain, for example, the anticipated duration, toxicity, and complexity of immunotherapy.

In the long run, primary prevention will likely be the optimal approach to the prevention of T1D. Once more than one islet autoantibody is present, most individuals progress to diabetes in 5-10 years. The TrialNet consortium (www.diabetestrialnet.org) systematically evaluates therapies in new-onset patients as well as in pre-diabetic subjects, and invites proposals from the research community at large.

Marian Rewers, M.D., Ph.D., is professor of pediatrics and preventive medicine at the Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver.

Author and Disclosure Information

Publications
Topics
Legacy Keywords
Diamyd Medical, GAD vaccine, autoantigen-based immunotherapy, type 1 diabetes, glutamic acid decarboxylase-65,
Author and Disclosure Information

Author and Disclosure Information

Body

Type 1 diabetes (T1D) is an autoimmune disease caused by interplay of genetic and environmental factors. The incidence of childhood T1D has doubled worldwide over the past 20-25 years. Elimination of the environmental agent(s) responsible for this epidemic would be the most efficient approach to primary prevention; however, more work is needed to identify the environmental agents and to develop effective interventions.

Blocking progression from islet autoimmunity to clinical diabetes or secondary prevention has been attempted, so far to no avail, by a number of groups, including large randomized trials: the Diabetes Prevention Trial – Type 1, the European Nicotinamide Diabetes Intervention Trial, and the Type 1 Diabetes Prediction and Prevention Project.

Trials in patients with newly diagnosed T1D aim at tertiary prevention, such as preservation of remaining islet beta-cells to induce and prolong partial remission. Unfortunately, most islets have already been destroyed by the time diabetes is diagnosed and complete reversal of diabetes is highly unlikely. Benefits may include a simpler insulin regimen, lower HbA1c, and reduced risk of hypoglycemia and microvascular complications. The gain may be even greater if the intervention is applied as soon as the patient shows asymptomatic “dysglycemia,” detected by oral glucose tolerance test or A1c, before overt symptoms of diabetes.

While new interventions are often tested first in patients with established diabetes, and, when proven safe, applied to patients with pre-T1D, efficacy after diagnosis of diabetes is not to be a precondition to application in pre-T1D, as there may be a “point of no return” in the destruction of the islets, rendering some interventions effective only at the earlier stages of the process.

Antigen-specific vaccines

Among several approaches to prevention of T1D, “vaccination” using islet autoantigens (intact or altered peptides derived from insulin, GAD65 or other proteins) stands out as potentially inducing long-term tolerance by induction of regulatory T-cells that down-regulate immunity to autoantigens. Until recently, trials of insulin administered parenterally, orally, or intranasally have been unsuccessful. Therefore, the initial results from trials of the Diamyd vaccine, as reviewed here, were greeted with huge interest and excitement. The vaccine includes the whole recombinant human GAD65 (rhGAD65) molecule suspended in alum. The protective effect was most pronounced in patients treated within 3 months of diagnosis, and no serious side effects were observed.

Insulin-related molecules continue to attract great interest in vaccine development. Phase I studies have been completed or are nearing completion for a proinsulin peptide C19-A3, an insulin peptide with incomplete Freund adjuvant, and a plasmid encoding proinsulin.

Combination therapies may enhance efficacy while lowering risk of adverse events if utilizing therapies from different treatment pathways. While more targeted therapies are being employed, immunomodulatory agents are still relatively nonspecific and potentially toxic to some of the trial participants. Some may carry an unacceptable risk of long-term complications. This direction is important; however, multiple scientific and logistic issues remain, for example, the anticipated duration, toxicity, and complexity of immunotherapy.

In the long run, primary prevention will likely be the optimal approach to the prevention of T1D. Once more than one islet autoantibody is present, most individuals progress to diabetes in 5-10 years. The TrialNet consortium (www.diabetestrialnet.org) systematically evaluates therapies in new-onset patients as well as in pre-diabetic subjects, and invites proposals from the research community at large.

Marian Rewers, M.D., Ph.D., is professor of pediatrics and preventive medicine at the Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver.

Body

Type 1 diabetes (T1D) is an autoimmune disease caused by interplay of genetic and environmental factors. The incidence of childhood T1D has doubled worldwide over the past 20-25 years. Elimination of the environmental agent(s) responsible for this epidemic would be the most efficient approach to primary prevention; however, more work is needed to identify the environmental agents and to develop effective interventions.

Blocking progression from islet autoimmunity to clinical diabetes or secondary prevention has been attempted, so far to no avail, by a number of groups, including large randomized trials: the Diabetes Prevention Trial – Type 1, the European Nicotinamide Diabetes Intervention Trial, and the Type 1 Diabetes Prediction and Prevention Project.

Trials in patients with newly diagnosed T1D aim at tertiary prevention, such as preservation of remaining islet beta-cells to induce and prolong partial remission. Unfortunately, most islets have already been destroyed by the time diabetes is diagnosed and complete reversal of diabetes is highly unlikely. Benefits may include a simpler insulin regimen, lower HbA1c, and reduced risk of hypoglycemia and microvascular complications. The gain may be even greater if the intervention is applied as soon as the patient shows asymptomatic “dysglycemia,” detected by oral glucose tolerance test or A1c, before overt symptoms of diabetes.

While new interventions are often tested first in patients with established diabetes, and, when proven safe, applied to patients with pre-T1D, efficacy after diagnosis of diabetes is not to be a precondition to application in pre-T1D, as there may be a “point of no return” in the destruction of the islets, rendering some interventions effective only at the earlier stages of the process.

Antigen-specific vaccines

Among several approaches to prevention of T1D, “vaccination” using islet autoantigens (intact or altered peptides derived from insulin, GAD65 or other proteins) stands out as potentially inducing long-term tolerance by induction of regulatory T-cells that down-regulate immunity to autoantigens. Until recently, trials of insulin administered parenterally, orally, or intranasally have been unsuccessful. Therefore, the initial results from trials of the Diamyd vaccine, as reviewed here, were greeted with huge interest and excitement. The vaccine includes the whole recombinant human GAD65 (rhGAD65) molecule suspended in alum. The protective effect was most pronounced in patients treated within 3 months of diagnosis, and no serious side effects were observed.

Insulin-related molecules continue to attract great interest in vaccine development. Phase I studies have been completed or are nearing completion for a proinsulin peptide C19-A3, an insulin peptide with incomplete Freund adjuvant, and a plasmid encoding proinsulin.

Combination therapies may enhance efficacy while lowering risk of adverse events if utilizing therapies from different treatment pathways. While more targeted therapies are being employed, immunomodulatory agents are still relatively nonspecific and potentially toxic to some of the trial participants. Some may carry an unacceptable risk of long-term complications. This direction is important; however, multiple scientific and logistic issues remain, for example, the anticipated duration, toxicity, and complexity of immunotherapy.

In the long run, primary prevention will likely be the optimal approach to the prevention of T1D. Once more than one islet autoantibody is present, most individuals progress to diabetes in 5-10 years. The TrialNet consortium (www.diabetestrialnet.org) systematically evaluates therapies in new-onset patients as well as in pre-diabetic subjects, and invites proposals from the research community at large.

Marian Rewers, M.D., Ph.D., is professor of pediatrics and preventive medicine at the Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver.

Title
When to Intervene?
When to Intervene?

KEYSTONE, Colo. – Right now, the Diamyd Medical’s GAD vaccine is in the sweet spot in the developmental pipeline – an interim period of enormous optimism that this novel autoantigen-based immunotherapy will safely prevent many cases of type 1 diabetes.

The results of three phase II studies are in and they look quite promising. Two large phase III clinical trials are well underway in Europe and the United States. The safety experience with the 65-kD isoform of GAD (glutamic acid decarboxylase-65) vaccine has been outstanding. The subcutaneous two-injection series is easy to administer. Acceptance of the vaccine by patients and their families is high. The vaccine targets a serious disease whose incidence is steadily climbing by 3%-5% per year in developed countries. And most patients with recently diagnosed type 1 diabetes possess GAD autoantibodies, so the Diamyd vaccine would be widely applicable.

    Dr. Johnny L. Ludvigsson

All of that was good enough for Johnson and Johnson, which in June inked a huge development and marketing deal for the GAD vaccine with small Swedish biotech company Diamyd Medical. Under the deal, Diamyd receives $45 million upfront, milestone payments of up to $580 million, and tiered royalties after that. The Federal Trade Commission’s antitrust division has already approved the deal.

But during this blissful interlude, one key question remains: Is the Diamyd vaccine effective?

“It’s too early to say if this works. Absolutely too early. We have a phase III trial in Europe with results due next spring. And the TrialNet study [is] going on here in the U.S. So we will know in a year or 2,” Dr. Johnny L. Ludvigsson said at a conference on management of diabetes in youth sponsored by the Children’s Diabetes Foundation at Denver.

Dr. Ludvigsson, professor of pediatrics at the University of Linkoping (Sweden), led the phase III European trial evaluating whether the GAD vaccine preserves beta-cell function and residual insulin secretion in patients with type 1 diabetes diagnosed within 3 months of starting treatment. He also headed a phase II study that caused a favorable buzz within the diabetes research community (N. Engl. J. Med. 2008;359:1909-20) and for which he is now analyzing 5-year follow-up data.

And while the forthcoming phase III trial results will tell the tale as to clinical efficacy, at this time some useful interim observations can be made about the GAD vaccine, according to Dr. Ludvigsson:

The vaccine has demonstrated excellent safety. Experience with the vaccine to date totals 850 patient-years in adults and 350 patient-years in children, with no adverse events reported. This is enormously reassuring because GAD transforms glutamate into GABA, an important neurotransmitter. Lack of GAD in the CNS leads to muscle rigidity and convulsions, while stimulation of CNS GAD results in inhibition of neurotransmission. The absence of any such adverse events indicates the vaccine is working, as designed, to affect only a very small part of the immune system: namely, the activated T cells that have targeted pancreatic beta-cells for destruction, Dr. Ludvigsson said.

The vaccine has demonstrated prolonged immunologic effects. The immunologic response to the Diamyd vaccine lasts surprisingly long – approaching 5 years and still counting. It’s a GAD-specific, cell-mediated, and humoral immune response characterized by increased GAD autoantibodies, a Th2 shift marked by reduction in activated T cells and an increase in regulatory T cells, a sharp and sustained rise in levels of interleukins-2, -5, -10, -13, and -17, and GAD tolerance. “We see this response still after 4 years. The memory is there,” Dr. Ludvigsson observed.

“The earlier we treat, the better the outcome.” That’s why the phase III European trial is restricted to patients diagnosed with type 1 diabetes within the past 3 months. It’s also the impetus for ongoing prevention trials in individuals at very high genetic risk for type 1 diabetes who have GAD autoantibodies but have not developed overt disease.

The vaccine probably won’t work in diabetic patients without GAD autoantibodies. No studies have been carried out in such patients, but Dr. Ludvigsson said it’s his impression that the vaccine is more effective in individuals with higher than lower titers of GAD autoantibodies.

For the future, the GAD vaccine alone probably is not the solution to type 1 diabetes, Dr. Ludvigsson said candidly.

“I believe this opens the door to using different antigens, like in allergy. Allergists don’t use just cat antigen in patients who have cat, dog, and house dust mite allergies. I suppose we may also learn to combine autoantigens, together with possible stimulation of beta-cells in combination with drugs that promote beta-cell regeneration,” he continued.

 

 

Other autoantibodies commonly present in patients with type 1 diabetes, or at high risk for the disease, include insulin autoantibodies, islet cell autoantibodies, and antibodies to the zinc transporter. Combining the GAD vaccine with other major diabetes-specific autoantigens recognized by the immune system could provide synergistic benefits.

  Dr. Jay S. Skyler

The likely necessity for a combined approach addressing multiple pathways was underscored in a separate presentation by Dr. Jay S. Skyler, chairman of the type 1 Diabetes TrialNet, a National Institutes of Health–funded international network of centers conducting clinical trials of diabetes therapies.

The GAD vaccine appears to have the same limitation as the other immunomodulatory therapies evaluated to date in clinical trials, including the B cell–depleting anti-CD20 agent rituximab, and the anti-CD3 biologics teplizumab and otelixizumab: namely, they preserve beta cell function for a while, but the effect is transient. Eventually fasting C-peptide levels start to fall off in parallel to the placebo group. That’s why combination therapy will probably be required in order to cure or prevent Type 1 diabetes, according to Dr. Skyler, a professor of medicine, pediatrics and psychology at the University of Miami.

Ideally, a combination therapy should be multipronged, with three goals: Stop immune destruction, preserve beta-cell mass, and replace or regenerate beta-cells. Such a regimen might start off with a potent anti-inflammatory therapy – perhaps an anti-interleukin-1beta agent or tumor necrosis factor inhibitor – to quell the metabolic stress surrounding the pancreatic islets. This might well need to be given on a continuing basis.

Next would come an immunomodulatory approach; for example, T-cell modulation with an anti-CD3 biologic or B cell depletion with rituximab. This could be followed up with an autoantigen-specific therapy such as the GAD vaccine or oral insulin. “Maybe it needs to be both,” Dr. Skyler continued.

The logical subsequent step would be to try to stimulate immunologic expansion of regulatory T cells, either with granulocyte colony–stimulating factor or by direct infusion of regulatory T cells themselves. This could be combined with beta-cell expansion via exenatide (Byetta) or the investigational HIP2B peptide.

“We could conceivably be doing some of these things even today,” Dr. Skyler said.

Dr. Ludvigsson reported receiving research grant support from Diamyd.

Dr. Skyler has served as a consultant to and/or received research grants from numerous pharmaceutical companies.

KEYSTONE, Colo. – Right now, the Diamyd Medical’s GAD vaccine is in the sweet spot in the developmental pipeline – an interim period of enormous optimism that this novel autoantigen-based immunotherapy will safely prevent many cases of type 1 diabetes.

The results of three phase II studies are in and they look quite promising. Two large phase III clinical trials are well underway in Europe and the United States. The safety experience with the 65-kD isoform of GAD (glutamic acid decarboxylase-65) vaccine has been outstanding. The subcutaneous two-injection series is easy to administer. Acceptance of the vaccine by patients and their families is high. The vaccine targets a serious disease whose incidence is steadily climbing by 3%-5% per year in developed countries. And most patients with recently diagnosed type 1 diabetes possess GAD autoantibodies, so the Diamyd vaccine would be widely applicable.

    Dr. Johnny L. Ludvigsson

All of that was good enough for Johnson and Johnson, which in June inked a huge development and marketing deal for the GAD vaccine with small Swedish biotech company Diamyd Medical. Under the deal, Diamyd receives $45 million upfront, milestone payments of up to $580 million, and tiered royalties after that. The Federal Trade Commission’s antitrust division has already approved the deal.

But during this blissful interlude, one key question remains: Is the Diamyd vaccine effective?

“It’s too early to say if this works. Absolutely too early. We have a phase III trial in Europe with results due next spring. And the TrialNet study [is] going on here in the U.S. So we will know in a year or 2,” Dr. Johnny L. Ludvigsson said at a conference on management of diabetes in youth sponsored by the Children’s Diabetes Foundation at Denver.

Dr. Ludvigsson, professor of pediatrics at the University of Linkoping (Sweden), led the phase III European trial evaluating whether the GAD vaccine preserves beta-cell function and residual insulin secretion in patients with type 1 diabetes diagnosed within 3 months of starting treatment. He also headed a phase II study that caused a favorable buzz within the diabetes research community (N. Engl. J. Med. 2008;359:1909-20) and for which he is now analyzing 5-year follow-up data.

And while the forthcoming phase III trial results will tell the tale as to clinical efficacy, at this time some useful interim observations can be made about the GAD vaccine, according to Dr. Ludvigsson:

The vaccine has demonstrated excellent safety. Experience with the vaccine to date totals 850 patient-years in adults and 350 patient-years in children, with no adverse events reported. This is enormously reassuring because GAD transforms glutamate into GABA, an important neurotransmitter. Lack of GAD in the CNS leads to muscle rigidity and convulsions, while stimulation of CNS GAD results in inhibition of neurotransmission. The absence of any such adverse events indicates the vaccine is working, as designed, to affect only a very small part of the immune system: namely, the activated T cells that have targeted pancreatic beta-cells for destruction, Dr. Ludvigsson said.

The vaccine has demonstrated prolonged immunologic effects. The immunologic response to the Diamyd vaccine lasts surprisingly long – approaching 5 years and still counting. It’s a GAD-specific, cell-mediated, and humoral immune response characterized by increased GAD autoantibodies, a Th2 shift marked by reduction in activated T cells and an increase in regulatory T cells, a sharp and sustained rise in levels of interleukins-2, -5, -10, -13, and -17, and GAD tolerance. “We see this response still after 4 years. The memory is there,” Dr. Ludvigsson observed.

“The earlier we treat, the better the outcome.” That’s why the phase III European trial is restricted to patients diagnosed with type 1 diabetes within the past 3 months. It’s also the impetus for ongoing prevention trials in individuals at very high genetic risk for type 1 diabetes who have GAD autoantibodies but have not developed overt disease.

The vaccine probably won’t work in diabetic patients without GAD autoantibodies. No studies have been carried out in such patients, but Dr. Ludvigsson said it’s his impression that the vaccine is more effective in individuals with higher than lower titers of GAD autoantibodies.

For the future, the GAD vaccine alone probably is not the solution to type 1 diabetes, Dr. Ludvigsson said candidly.

“I believe this opens the door to using different antigens, like in allergy. Allergists don’t use just cat antigen in patients who have cat, dog, and house dust mite allergies. I suppose we may also learn to combine autoantigens, together with possible stimulation of beta-cells in combination with drugs that promote beta-cell regeneration,” he continued.

 

 

Other autoantibodies commonly present in patients with type 1 diabetes, or at high risk for the disease, include insulin autoantibodies, islet cell autoantibodies, and antibodies to the zinc transporter. Combining the GAD vaccine with other major diabetes-specific autoantigens recognized by the immune system could provide synergistic benefits.

  Dr. Jay S. Skyler

The likely necessity for a combined approach addressing multiple pathways was underscored in a separate presentation by Dr. Jay S. Skyler, chairman of the type 1 Diabetes TrialNet, a National Institutes of Health–funded international network of centers conducting clinical trials of diabetes therapies.

The GAD vaccine appears to have the same limitation as the other immunomodulatory therapies evaluated to date in clinical trials, including the B cell–depleting anti-CD20 agent rituximab, and the anti-CD3 biologics teplizumab and otelixizumab: namely, they preserve beta cell function for a while, but the effect is transient. Eventually fasting C-peptide levels start to fall off in parallel to the placebo group. That’s why combination therapy will probably be required in order to cure or prevent Type 1 diabetes, according to Dr. Skyler, a professor of medicine, pediatrics and psychology at the University of Miami.

Ideally, a combination therapy should be multipronged, with three goals: Stop immune destruction, preserve beta-cell mass, and replace or regenerate beta-cells. Such a regimen might start off with a potent anti-inflammatory therapy – perhaps an anti-interleukin-1beta agent or tumor necrosis factor inhibitor – to quell the metabolic stress surrounding the pancreatic islets. This might well need to be given on a continuing basis.

Next would come an immunomodulatory approach; for example, T-cell modulation with an anti-CD3 biologic or B cell depletion with rituximab. This could be followed up with an autoantigen-specific therapy such as the GAD vaccine or oral insulin. “Maybe it needs to be both,” Dr. Skyler continued.

The logical subsequent step would be to try to stimulate immunologic expansion of regulatory T cells, either with granulocyte colony–stimulating factor or by direct infusion of regulatory T cells themselves. This could be combined with beta-cell expansion via exenatide (Byetta) or the investigational HIP2B peptide.

“We could conceivably be doing some of these things even today,” Dr. Skyler said.

Dr. Ludvigsson reported receiving research grant support from Diamyd.

Dr. Skyler has served as a consultant to and/or received research grants from numerous pharmaceutical companies.

Publications
Publications
Topics
Article Type
Display Headline
GAD Vaccine for Type 1 Diabetes Shows Continued Promise
Display Headline
GAD Vaccine for Type 1 Diabetes Shows Continued Promise
Legacy Keywords
Diamyd Medical, GAD vaccine, autoantigen-based immunotherapy, type 1 diabetes, glutamic acid decarboxylase-65,
Legacy Keywords
Diamyd Medical, GAD vaccine, autoantigen-based immunotherapy, type 1 diabetes, glutamic acid decarboxylase-65,
Article Source

PURLs Copyright

Inside the Article

GAD Vaccine for Type 1 Diabetes Shows Continued Promise

When to Intervene?
Article Type
Changed
Tue, 01/15/2019 - 09:38
Display Headline
GAD Vaccine for Type 1 Diabetes Shows Continued Promise

KEYSTONE, Colo. – Right now, the Diamyd Medical’s GAD vaccine is in the sweet spot in the developmental pipeline – an interim period of enormous optimism that this novel autoantigen-based immunotherapy will safely prevent many cases of type 1 diabetes.

The results of three phase II studies are in and they look quite promising. Two large phase III clinical trials are well underway in Europe and the United States. The safety experience with the 65-kD isoform of GAD (glutamic acid decarboxylase-65) vaccine has been outstanding. The subcutaneous two-injection series is easy to administer. Acceptance of the vaccine by patients and their families is high. The vaccine targets a serious disease whose incidence is steadily climbing by 3%-5% per year in developed countries. And most patients with recently diagnosed type 1 diabetes possess GAD autoantibodies, so the Diamyd vaccine would be widely applicable.

    Dr. Johnny L. Ludvigsson

All of that was good enough for Johnson and Johnson, which in June inked a huge development and marketing deal for the GAD vaccine with small Swedish biotech company Diamyd Medical. Under the deal, Diamyd receives $45 million upfront, milestone payments of up to $580 million, and tiered royalties after that. The Federal Trade Commission’s antitrust division has already approved the deal.

But during this blissful interlude, one key question remains: Is the Diamyd vaccine effective?

“It’s too early to say if this works. Absolutely too early. We have a phase III trial in Europe with results due next spring. And the TrialNet study [is] going on here in the U.S. So we will know in a year or 2,” Dr. Johnny L. Ludvigsson said at a conference on management of diabetes in youth sponsored by the Children’s Diabetes Foundation at Denver.

Dr. Ludvigsson, professor of pediatrics at the University of Linkoping (Sweden), led the phase III European trial evaluating whether the GAD vaccine preserves beta-cell function and residual insulin secretion in patients with type 1 diabetes diagnosed within 3 months of starting treatment. He also headed a phase II study that caused a favorable buzz within the diabetes research community (N. Engl. J. Med. 2008;359:1909-20) and for which he is now analyzing 5-year follow-up data.

And while the forthcoming phase III trial results will tell the tale as to clinical efficacy, at this time some useful interim observations can be made about the GAD vaccine, according to Dr. Ludvigsson:

The vaccine has demonstrated excellent safety. Experience with the vaccine to date totals 850 patient-years in adults and 350 patient-years in children, with no adverse events reported. This is enormously reassuring because GAD transforms glutamate into GABA, an important neurotransmitter. Lack of GAD in the CNS leads to muscle rigidity and convulsions, while stimulation of CNS GAD results in inhibition of neurotransmission. The absence of any such adverse events indicates the vaccine is working, as designed, to affect only a very small part of the immune system: namely, the activated T cells that have targeted pancreatic beta-cells for destruction, Dr. Ludvigsson said.

The vaccine has demonstrated prolonged immunologic effects. The immunologic response to the Diamyd vaccine lasts surprisingly long – approaching 5 years and still counting. It’s a GAD-specific, cell-mediated, and humoral immune response characterized by increased GAD autoantibodies, a Th2 shift marked by reduction in activated T cells and an increase in regulatory T cells, a sharp and sustained rise in levels of interleukins-2, -5, -10, -13, and -17, and GAD tolerance. “We see this response still after 4 years. The memory is there,” Dr. Ludvigsson observed.

“The earlier we treat, the better the outcome.” That’s why the phase III European trial is restricted to patients diagnosed with type 1 diabetes within the past 3 months. It’s also the impetus for ongoing prevention trials in individuals at very high genetic risk for type 1 diabetes who have GAD autoantibodies but have not developed overt disease.

The vaccine probably won’t work in diabetic patients without GAD autoantibodies. No studies have been carried out in such patients, but Dr. Ludvigsson said it’s his impression that the vaccine is more effective in individuals with higher than lower titers of GAD autoantibodies.

For the future, the GAD vaccine alone probably is not the solution to type 1 diabetes, Dr. Ludvigsson said candidly.

“I believe this opens the door to using different antigens, like in allergy. Allergists don’t use just cat antigen in patients who have cat, dog, and house dust mite allergies. I suppose we may also learn to combine autoantigens, together with possible stimulation of beta-cells in combination with drugs that promote beta-cell regeneration,” he continued.

 

 

Other autoantibodies commonly present in patients with type 1 diabetes, or at high risk for the disease, include insulin autoantibodies, islet cell autoantibodies, and antibodies to the zinc transporter. Combining the GAD vaccine with other major diabetes-specific autoantigens recognized by the immune system could provide synergistic benefits.

  Dr. Jay S. Skyler

The likely necessity for a combined approach addressing multiple pathways was underscored in a separate presentation by Dr. Jay S. Skyler, chairman of the type 1 Diabetes TrialNet, a National Institutes of Health–funded international network of centers conducting clinical trials of diabetes therapies.

The GAD vaccine appears to have the same limitation as the other immunomodulatory therapies evaluated to date in clinical trials, including the B cell–depleting anti-CD20 agent rituximab, and the anti-CD3 biologics teplizumab and otelixizumab: namely, they preserve beta cell function for a while, but the effect is transient. Eventually fasting C-peptide levels start to fall off in parallel to the placebo group. That’s why combination therapy will probably be required in order to cure or prevent Type 1 diabetes, according to Dr. Skyler, a professor of medicine, pediatrics and psychology at the University of Miami.

Ideally, a combination therapy should be multipronged, with three goals: Stop immune destruction, preserve beta-cell mass, and replace or regenerate beta-cells. Such a regimen might start off with a potent anti-inflammatory therapy – perhaps an anti-interleukin-1beta agent or tumor necrosis factor inhibitor – to quell the metabolic stress surrounding the pancreatic islets. This might well need to be given on a continuing basis.

Next would come an immunomodulatory approach; for example, T-cell modulation with an anti-CD3 biologic or B cell depletion with rituximab. This could be followed up with an autoantigen-specific therapy such as the GAD vaccine or oral insulin. “Maybe it needs to be both,” Dr. Skyler continued.

The logical subsequent step would be to try to stimulate immunologic expansion of regulatory T cells, either with granulocyte colony–stimulating factor or by direct infusion of regulatory T cells themselves. This could be combined with beta-cell expansion via exenatide (Byetta) or the investigational HIP2B peptide.

“We could conceivably be doing some of these things even today,” Dr. Skyler said.

Dr. Ludvigsson reported receiving research grant support from Diamyd.

Dr. Skyler has served as a consultant to and/or received research grants from numerous pharmaceutical companies.

Body

Type 1 diabetes (T1D) is an autoimmune disease caused by interplay of genetic and environmental factors. The incidence of childhood T1D has doubled worldwide over the past 20-25 years. Elimination of the environmental agent(s) responsible for this epidemic would be the most efficient approach to primary prevention; however, more work is needed to identify the environmental agents and to develop effective interventions.

Blocking progression from islet autoimmunity to clinical diabetes or secondary prevention has been attempted, so far to no avail, by a number of groups, including large randomized trials: the Diabetes Prevention Trial – Type 1, the European Nicotinamide Diabetes Intervention Trial, and the Type 1 Diabetes Prediction and Prevention Project.

Trials in patients with newly diagnosed T1D aim at tertiary prevention, such as preservation of remaining islet beta-cells to induce and prolong partial remission. Unfortunately, most islets have already been destroyed by the time diabetes is diagnosed and complete reversal of diabetes is highly unlikely. Benefits may include a simpler insulin regimen, lower HbA1c, and reduced risk of hypoglycemia and microvascular complications. The gain may be even greater if the intervention is applied as soon as the patient shows asymptomatic “dysglycemia,” detected by oral glucose tolerance test or A1c, before overt symptoms of diabetes.

While new interventions are often tested first in patients with established diabetes, and, when proven safe, applied to patients with pre-T1D, efficacy after diagnosis of diabetes is not to be a precondition to application in pre-T1D, as there may be a “point of no return” in the destruction of the islets, rendering some interventions effective only at the earlier stages of the process.

Antigen-specific vaccines

Among several approaches to prevention of T1D, “vaccination” using islet autoantigens (intact or altered peptides derived from insulin, GAD65 or other proteins) stands out as potentially inducing long-term tolerance by induction of regulatory T-cells that down-regulate immunity to autoantigens. Until recently, trials of insulin administered parenterally, orally, or intranasally have been unsuccessful. Therefore, the initial results from trials of the Diamyd vaccine, as reviewed here, were greeted with huge interest and excitement. The vaccine includes the whole recombinant human GAD65 (rhGAD65) molecule suspended in alum. The protective effect was most pronounced in patients treated within 3 months of diagnosis, and no serious side effects were observed.

Insulin-related molecules continue to attract great interest in vaccine development. Phase I studies have been completed or are nearing completion for a proinsulin peptide C19-A3, an insulin peptide with incomplete Freund adjuvant, and a plasmid encoding proinsulin.

Combination therapies may enhance efficacy while lowering risk of adverse events if utilizing therapies from different treatment pathways. While more targeted therapies are being employed, immunomodulatory agents are still relatively nonspecific and potentially toxic to some of the trial participants. Some may carry an unacceptable risk of long-term complications. This direction is important; however, multiple scientific and logistic issues remain, for example, the anticipated duration, toxicity, and complexity of immunotherapy.

In the long run, primary prevention will likely be the optimal approach to the prevention of T1D. Once more than one islet autoantibody is present, most individuals progress to diabetes in 5-10 years. The TrialNet consortium (www.diabetestrialnet.org) systematically evaluates therapies in new-onset patients as well as in pre-diabetic subjects, and invites proposals from the research community at large.

Marian Rewers, M.D., Ph.D., is professor of pediatrics and preventive medicine at the Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver.

Author and Disclosure Information

Publications
Topics
Legacy Keywords
Diamyd Medical, GAD vaccine, autoantigen-based immunotherapy, type 1 diabetes, glutamic acid decarboxylase-65,
Author and Disclosure Information

Author and Disclosure Information

Body

Type 1 diabetes (T1D) is an autoimmune disease caused by interplay of genetic and environmental factors. The incidence of childhood T1D has doubled worldwide over the past 20-25 years. Elimination of the environmental agent(s) responsible for this epidemic would be the most efficient approach to primary prevention; however, more work is needed to identify the environmental agents and to develop effective interventions.

Blocking progression from islet autoimmunity to clinical diabetes or secondary prevention has been attempted, so far to no avail, by a number of groups, including large randomized trials: the Diabetes Prevention Trial – Type 1, the European Nicotinamide Diabetes Intervention Trial, and the Type 1 Diabetes Prediction and Prevention Project.

Trials in patients with newly diagnosed T1D aim at tertiary prevention, such as preservation of remaining islet beta-cells to induce and prolong partial remission. Unfortunately, most islets have already been destroyed by the time diabetes is diagnosed and complete reversal of diabetes is highly unlikely. Benefits may include a simpler insulin regimen, lower HbA1c, and reduced risk of hypoglycemia and microvascular complications. The gain may be even greater if the intervention is applied as soon as the patient shows asymptomatic “dysglycemia,” detected by oral glucose tolerance test or A1c, before overt symptoms of diabetes.

While new interventions are often tested first in patients with established diabetes, and, when proven safe, applied to patients with pre-T1D, efficacy after diagnosis of diabetes is not to be a precondition to application in pre-T1D, as there may be a “point of no return” in the destruction of the islets, rendering some interventions effective only at the earlier stages of the process.

Antigen-specific vaccines

Among several approaches to prevention of T1D, “vaccination” using islet autoantigens (intact or altered peptides derived from insulin, GAD65 or other proteins) stands out as potentially inducing long-term tolerance by induction of regulatory T-cells that down-regulate immunity to autoantigens. Until recently, trials of insulin administered parenterally, orally, or intranasally have been unsuccessful. Therefore, the initial results from trials of the Diamyd vaccine, as reviewed here, were greeted with huge interest and excitement. The vaccine includes the whole recombinant human GAD65 (rhGAD65) molecule suspended in alum. The protective effect was most pronounced in patients treated within 3 months of diagnosis, and no serious side effects were observed.

Insulin-related molecules continue to attract great interest in vaccine development. Phase I studies have been completed or are nearing completion for a proinsulin peptide C19-A3, an insulin peptide with incomplete Freund adjuvant, and a plasmid encoding proinsulin.

Combination therapies may enhance efficacy while lowering risk of adverse events if utilizing therapies from different treatment pathways. While more targeted therapies are being employed, immunomodulatory agents are still relatively nonspecific and potentially toxic to some of the trial participants. Some may carry an unacceptable risk of long-term complications. This direction is important; however, multiple scientific and logistic issues remain, for example, the anticipated duration, toxicity, and complexity of immunotherapy.

In the long run, primary prevention will likely be the optimal approach to the prevention of T1D. Once more than one islet autoantibody is present, most individuals progress to diabetes in 5-10 years. The TrialNet consortium (www.diabetestrialnet.org) systematically evaluates therapies in new-onset patients as well as in pre-diabetic subjects, and invites proposals from the research community at large.

Marian Rewers, M.D., Ph.D., is professor of pediatrics and preventive medicine at the Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver.

Body

Type 1 diabetes (T1D) is an autoimmune disease caused by interplay of genetic and environmental factors. The incidence of childhood T1D has doubled worldwide over the past 20-25 years. Elimination of the environmental agent(s) responsible for this epidemic would be the most efficient approach to primary prevention; however, more work is needed to identify the environmental agents and to develop effective interventions.

Blocking progression from islet autoimmunity to clinical diabetes or secondary prevention has been attempted, so far to no avail, by a number of groups, including large randomized trials: the Diabetes Prevention Trial – Type 1, the European Nicotinamide Diabetes Intervention Trial, and the Type 1 Diabetes Prediction and Prevention Project.

Trials in patients with newly diagnosed T1D aim at tertiary prevention, such as preservation of remaining islet beta-cells to induce and prolong partial remission. Unfortunately, most islets have already been destroyed by the time diabetes is diagnosed and complete reversal of diabetes is highly unlikely. Benefits may include a simpler insulin regimen, lower HbA1c, and reduced risk of hypoglycemia and microvascular complications. The gain may be even greater if the intervention is applied as soon as the patient shows asymptomatic “dysglycemia,” detected by oral glucose tolerance test or A1c, before overt symptoms of diabetes.

While new interventions are often tested first in patients with established diabetes, and, when proven safe, applied to patients with pre-T1D, efficacy after diagnosis of diabetes is not to be a precondition to application in pre-T1D, as there may be a “point of no return” in the destruction of the islets, rendering some interventions effective only at the earlier stages of the process.

Antigen-specific vaccines

Among several approaches to prevention of T1D, “vaccination” using islet autoantigens (intact or altered peptides derived from insulin, GAD65 or other proteins) stands out as potentially inducing long-term tolerance by induction of regulatory T-cells that down-regulate immunity to autoantigens. Until recently, trials of insulin administered parenterally, orally, or intranasally have been unsuccessful. Therefore, the initial results from trials of the Diamyd vaccine, as reviewed here, were greeted with huge interest and excitement. The vaccine includes the whole recombinant human GAD65 (rhGAD65) molecule suspended in alum. The protective effect was most pronounced in patients treated within 3 months of diagnosis, and no serious side effects were observed.

Insulin-related molecules continue to attract great interest in vaccine development. Phase I studies have been completed or are nearing completion for a proinsulin peptide C19-A3, an insulin peptide with incomplete Freund adjuvant, and a plasmid encoding proinsulin.

Combination therapies may enhance efficacy while lowering risk of adverse events if utilizing therapies from different treatment pathways. While more targeted therapies are being employed, immunomodulatory agents are still relatively nonspecific and potentially toxic to some of the trial participants. Some may carry an unacceptable risk of long-term complications. This direction is important; however, multiple scientific and logistic issues remain, for example, the anticipated duration, toxicity, and complexity of immunotherapy.

In the long run, primary prevention will likely be the optimal approach to the prevention of T1D. Once more than one islet autoantibody is present, most individuals progress to diabetes in 5-10 years. The TrialNet consortium (www.diabetestrialnet.org) systematically evaluates therapies in new-onset patients as well as in pre-diabetic subjects, and invites proposals from the research community at large.

Marian Rewers, M.D., Ph.D., is professor of pediatrics and preventive medicine at the Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver.

Title
When to Intervene?
When to Intervene?

KEYSTONE, Colo. – Right now, the Diamyd Medical’s GAD vaccine is in the sweet spot in the developmental pipeline – an interim period of enormous optimism that this novel autoantigen-based immunotherapy will safely prevent many cases of type 1 diabetes.

The results of three phase II studies are in and they look quite promising. Two large phase III clinical trials are well underway in Europe and the United States. The safety experience with the 65-kD isoform of GAD (glutamic acid decarboxylase-65) vaccine has been outstanding. The subcutaneous two-injection series is easy to administer. Acceptance of the vaccine by patients and their families is high. The vaccine targets a serious disease whose incidence is steadily climbing by 3%-5% per year in developed countries. And most patients with recently diagnosed type 1 diabetes possess GAD autoantibodies, so the Diamyd vaccine would be widely applicable.

    Dr. Johnny L. Ludvigsson

All of that was good enough for Johnson and Johnson, which in June inked a huge development and marketing deal for the GAD vaccine with small Swedish biotech company Diamyd Medical. Under the deal, Diamyd receives $45 million upfront, milestone payments of up to $580 million, and tiered royalties after that. The Federal Trade Commission’s antitrust division has already approved the deal.

But during this blissful interlude, one key question remains: Is the Diamyd vaccine effective?

“It’s too early to say if this works. Absolutely too early. We have a phase III trial in Europe with results due next spring. And the TrialNet study [is] going on here in the U.S. So we will know in a year or 2,” Dr. Johnny L. Ludvigsson said at a conference on management of diabetes in youth sponsored by the Children’s Diabetes Foundation at Denver.

Dr. Ludvigsson, professor of pediatrics at the University of Linkoping (Sweden), led the phase III European trial evaluating whether the GAD vaccine preserves beta-cell function and residual insulin secretion in patients with type 1 diabetes diagnosed within 3 months of starting treatment. He also headed a phase II study that caused a favorable buzz within the diabetes research community (N. Engl. J. Med. 2008;359:1909-20) and for which he is now analyzing 5-year follow-up data.

And while the forthcoming phase III trial results will tell the tale as to clinical efficacy, at this time some useful interim observations can be made about the GAD vaccine, according to Dr. Ludvigsson:

The vaccine has demonstrated excellent safety. Experience with the vaccine to date totals 850 patient-years in adults and 350 patient-years in children, with no adverse events reported. This is enormously reassuring because GAD transforms glutamate into GABA, an important neurotransmitter. Lack of GAD in the CNS leads to muscle rigidity and convulsions, while stimulation of CNS GAD results in inhibition of neurotransmission. The absence of any such adverse events indicates the vaccine is working, as designed, to affect only a very small part of the immune system: namely, the activated T cells that have targeted pancreatic beta-cells for destruction, Dr. Ludvigsson said.

The vaccine has demonstrated prolonged immunologic effects. The immunologic response to the Diamyd vaccine lasts surprisingly long – approaching 5 years and still counting. It’s a GAD-specific, cell-mediated, and humoral immune response characterized by increased GAD autoantibodies, a Th2 shift marked by reduction in activated T cells and an increase in regulatory T cells, a sharp and sustained rise in levels of interleukins-2, -5, -10, -13, and -17, and GAD tolerance. “We see this response still after 4 years. The memory is there,” Dr. Ludvigsson observed.

“The earlier we treat, the better the outcome.” That’s why the phase III European trial is restricted to patients diagnosed with type 1 diabetes within the past 3 months. It’s also the impetus for ongoing prevention trials in individuals at very high genetic risk for type 1 diabetes who have GAD autoantibodies but have not developed overt disease.

The vaccine probably won’t work in diabetic patients without GAD autoantibodies. No studies have been carried out in such patients, but Dr. Ludvigsson said it’s his impression that the vaccine is more effective in individuals with higher than lower titers of GAD autoantibodies.

For the future, the GAD vaccine alone probably is not the solution to type 1 diabetes, Dr. Ludvigsson said candidly.

“I believe this opens the door to using different antigens, like in allergy. Allergists don’t use just cat antigen in patients who have cat, dog, and house dust mite allergies. I suppose we may also learn to combine autoantigens, together with possible stimulation of beta-cells in combination with drugs that promote beta-cell regeneration,” he continued.

 

 

Other autoantibodies commonly present in patients with type 1 diabetes, or at high risk for the disease, include insulin autoantibodies, islet cell autoantibodies, and antibodies to the zinc transporter. Combining the GAD vaccine with other major diabetes-specific autoantigens recognized by the immune system could provide synergistic benefits.

  Dr. Jay S. Skyler

The likely necessity for a combined approach addressing multiple pathways was underscored in a separate presentation by Dr. Jay S. Skyler, chairman of the type 1 Diabetes TrialNet, a National Institutes of Health–funded international network of centers conducting clinical trials of diabetes therapies.

The GAD vaccine appears to have the same limitation as the other immunomodulatory therapies evaluated to date in clinical trials, including the B cell–depleting anti-CD20 agent rituximab, and the anti-CD3 biologics teplizumab and otelixizumab: namely, they preserve beta cell function for a while, but the effect is transient. Eventually fasting C-peptide levels start to fall off in parallel to the placebo group. That’s why combination therapy will probably be required in order to cure or prevent Type 1 diabetes, according to Dr. Skyler, a professor of medicine, pediatrics and psychology at the University of Miami.

Ideally, a combination therapy should be multipronged, with three goals: Stop immune destruction, preserve beta-cell mass, and replace or regenerate beta-cells. Such a regimen might start off with a potent anti-inflammatory therapy – perhaps an anti-interleukin-1beta agent or tumor necrosis factor inhibitor – to quell the metabolic stress surrounding the pancreatic islets. This might well need to be given on a continuing basis.

Next would come an immunomodulatory approach; for example, T-cell modulation with an anti-CD3 biologic or B cell depletion with rituximab. This could be followed up with an autoantigen-specific therapy such as the GAD vaccine or oral insulin. “Maybe it needs to be both,” Dr. Skyler continued.

The logical subsequent step would be to try to stimulate immunologic expansion of regulatory T cells, either with granulocyte colony–stimulating factor or by direct infusion of regulatory T cells themselves. This could be combined with beta-cell expansion via exenatide (Byetta) or the investigational HIP2B peptide.

“We could conceivably be doing some of these things even today,” Dr. Skyler said.

Dr. Ludvigsson reported receiving research grant support from Diamyd.

Dr. Skyler has served as a consultant to and/or received research grants from numerous pharmaceutical companies.

KEYSTONE, Colo. – Right now, the Diamyd Medical’s GAD vaccine is in the sweet spot in the developmental pipeline – an interim period of enormous optimism that this novel autoantigen-based immunotherapy will safely prevent many cases of type 1 diabetes.

The results of three phase II studies are in and they look quite promising. Two large phase III clinical trials are well underway in Europe and the United States. The safety experience with the 65-kD isoform of GAD (glutamic acid decarboxylase-65) vaccine has been outstanding. The subcutaneous two-injection series is easy to administer. Acceptance of the vaccine by patients and their families is high. The vaccine targets a serious disease whose incidence is steadily climbing by 3%-5% per year in developed countries. And most patients with recently diagnosed type 1 diabetes possess GAD autoantibodies, so the Diamyd vaccine would be widely applicable.

    Dr. Johnny L. Ludvigsson

All of that was good enough for Johnson and Johnson, which in June inked a huge development and marketing deal for the GAD vaccine with small Swedish biotech company Diamyd Medical. Under the deal, Diamyd receives $45 million upfront, milestone payments of up to $580 million, and tiered royalties after that. The Federal Trade Commission’s antitrust division has already approved the deal.

But during this blissful interlude, one key question remains: Is the Diamyd vaccine effective?

“It’s too early to say if this works. Absolutely too early. We have a phase III trial in Europe with results due next spring. And the TrialNet study [is] going on here in the U.S. So we will know in a year or 2,” Dr. Johnny L. Ludvigsson said at a conference on management of diabetes in youth sponsored by the Children’s Diabetes Foundation at Denver.

Dr. Ludvigsson, professor of pediatrics at the University of Linkoping (Sweden), led the phase III European trial evaluating whether the GAD vaccine preserves beta-cell function and residual insulin secretion in patients with type 1 diabetes diagnosed within 3 months of starting treatment. He also headed a phase II study that caused a favorable buzz within the diabetes research community (N. Engl. J. Med. 2008;359:1909-20) and for which he is now analyzing 5-year follow-up data.

And while the forthcoming phase III trial results will tell the tale as to clinical efficacy, at this time some useful interim observations can be made about the GAD vaccine, according to Dr. Ludvigsson:

The vaccine has demonstrated excellent safety. Experience with the vaccine to date totals 850 patient-years in adults and 350 patient-years in children, with no adverse events reported. This is enormously reassuring because GAD transforms glutamate into GABA, an important neurotransmitter. Lack of GAD in the CNS leads to muscle rigidity and convulsions, while stimulation of CNS GAD results in inhibition of neurotransmission. The absence of any such adverse events indicates the vaccine is working, as designed, to affect only a very small part of the immune system: namely, the activated T cells that have targeted pancreatic beta-cells for destruction, Dr. Ludvigsson said.

The vaccine has demonstrated prolonged immunologic effects. The immunologic response to the Diamyd vaccine lasts surprisingly long – approaching 5 years and still counting. It’s a GAD-specific, cell-mediated, and humoral immune response characterized by increased GAD autoantibodies, a Th2 shift marked by reduction in activated T cells and an increase in regulatory T cells, a sharp and sustained rise in levels of interleukins-2, -5, -10, -13, and -17, and GAD tolerance. “We see this response still after 4 years. The memory is there,” Dr. Ludvigsson observed.

“The earlier we treat, the better the outcome.” That’s why the phase III European trial is restricted to patients diagnosed with type 1 diabetes within the past 3 months. It’s also the impetus for ongoing prevention trials in individuals at very high genetic risk for type 1 diabetes who have GAD autoantibodies but have not developed overt disease.

The vaccine probably won’t work in diabetic patients without GAD autoantibodies. No studies have been carried out in such patients, but Dr. Ludvigsson said it’s his impression that the vaccine is more effective in individuals with higher than lower titers of GAD autoantibodies.

For the future, the GAD vaccine alone probably is not the solution to type 1 diabetes, Dr. Ludvigsson said candidly.

“I believe this opens the door to using different antigens, like in allergy. Allergists don’t use just cat antigen in patients who have cat, dog, and house dust mite allergies. I suppose we may also learn to combine autoantigens, together with possible stimulation of beta-cells in combination with drugs that promote beta-cell regeneration,” he continued.

 

 

Other autoantibodies commonly present in patients with type 1 diabetes, or at high risk for the disease, include insulin autoantibodies, islet cell autoantibodies, and antibodies to the zinc transporter. Combining the GAD vaccine with other major diabetes-specific autoantigens recognized by the immune system could provide synergistic benefits.

  Dr. Jay S. Skyler

The likely necessity for a combined approach addressing multiple pathways was underscored in a separate presentation by Dr. Jay S. Skyler, chairman of the type 1 Diabetes TrialNet, a National Institutes of Health–funded international network of centers conducting clinical trials of diabetes therapies.

The GAD vaccine appears to have the same limitation as the other immunomodulatory therapies evaluated to date in clinical trials, including the B cell–depleting anti-CD20 agent rituximab, and the anti-CD3 biologics teplizumab and otelixizumab: namely, they preserve beta cell function for a while, but the effect is transient. Eventually fasting C-peptide levels start to fall off in parallel to the placebo group. That’s why combination therapy will probably be required in order to cure or prevent Type 1 diabetes, according to Dr. Skyler, a professor of medicine, pediatrics and psychology at the University of Miami.

Ideally, a combination therapy should be multipronged, with three goals: Stop immune destruction, preserve beta-cell mass, and replace or regenerate beta-cells. Such a regimen might start off with a potent anti-inflammatory therapy – perhaps an anti-interleukin-1beta agent or tumor necrosis factor inhibitor – to quell the metabolic stress surrounding the pancreatic islets. This might well need to be given on a continuing basis.

Next would come an immunomodulatory approach; for example, T-cell modulation with an anti-CD3 biologic or B cell depletion with rituximab. This could be followed up with an autoantigen-specific therapy such as the GAD vaccine or oral insulin. “Maybe it needs to be both,” Dr. Skyler continued.

The logical subsequent step would be to try to stimulate immunologic expansion of regulatory T cells, either with granulocyte colony–stimulating factor or by direct infusion of regulatory T cells themselves. This could be combined with beta-cell expansion via exenatide (Byetta) or the investigational HIP2B peptide.

“We could conceivably be doing some of these things even today,” Dr. Skyler said.

Dr. Ludvigsson reported receiving research grant support from Diamyd.

Dr. Skyler has served as a consultant to and/or received research grants from numerous pharmaceutical companies.

Publications
Publications
Topics
Article Type
Display Headline
GAD Vaccine for Type 1 Diabetes Shows Continued Promise
Display Headline
GAD Vaccine for Type 1 Diabetes Shows Continued Promise
Legacy Keywords
Diamyd Medical, GAD vaccine, autoantigen-based immunotherapy, type 1 diabetes, glutamic acid decarboxylase-65,
Legacy Keywords
Diamyd Medical, GAD vaccine, autoantigen-based immunotherapy, type 1 diabetes, glutamic acid decarboxylase-65,
Article Source

PURLs Copyright

Inside the Article

Tick, Tock, Tick, Tock

Article Type
Changed
Fri, 09/14/2018 - 12:30
Display Headline
Tick, Tock, Tick, Tock

A new study in this month's Journal of Hospital Medicine that catalogues the daily routine of HM practitioners is a first step in helping streamline the hospitalist’s workflow for efficiency, say several people associated with the report.

The report, “Where Did the Day Go? A Time-Motion Study of Hospitalists,” attempted to capture the amount of time hospitalists spent on various activities, including interacting with electronic health records (EHR) (34.1%), communication with colleagues (25.9%), and direct care (7.4%) (J Hosp Med. 2010;5(6):323-328). But one of the report’s senior authors, as well as the co-author of an accompanying editorial, anticipate that the study will serve as a springboard for future research on how hospitalists can best use their time.

Hospitalists need to “lay the foundation to figure how not to just observe what the doctors are doing, but how, in the future, to what they should be doing,” says Mark Williams, MD, FHM, professor and chief of hospital medicine at Northwestern University's Feinberg School of Medicine in Chicago. “We’ve got to have a good understanding of what we’re doing every day to move forward.”

The research, which furthered a similar Northwestern study completed in 2006 found that 16% of all activities occurred simultaneously, meaning that the surveyed hospitalists spent about 9% of their average 10.3-hour shift multitasking.

“Sadly, we documented that the vast majority [of time] is away from the patient, not with the patient,” Dr. Williams says.

Dr. Williams and Amit Prachand, an administrator in the HM department at Northwestern, hope to see more research done to define the best workflow for a hospitalist. Both agree, though, that dedicated funding will have to be set aside, either by federal agencies or research institutions, to make that happen.

“We need to convince people the money is well spent in focusing on this,” says Prachand, co-author of the editorial “Hospitalists: Lean Leaders for Hospitals.” “I think the hospital is going to be the one with the most to gain by supporting these opportunities.”

Issue
The Hospitalist - 2010(08)
Publications
Sections

A new study in this month's Journal of Hospital Medicine that catalogues the daily routine of HM practitioners is a first step in helping streamline the hospitalist’s workflow for efficiency, say several people associated with the report.

The report, “Where Did the Day Go? A Time-Motion Study of Hospitalists,” attempted to capture the amount of time hospitalists spent on various activities, including interacting with electronic health records (EHR) (34.1%), communication with colleagues (25.9%), and direct care (7.4%) (J Hosp Med. 2010;5(6):323-328). But one of the report’s senior authors, as well as the co-author of an accompanying editorial, anticipate that the study will serve as a springboard for future research on how hospitalists can best use their time.

Hospitalists need to “lay the foundation to figure how not to just observe what the doctors are doing, but how, in the future, to what they should be doing,” says Mark Williams, MD, FHM, professor and chief of hospital medicine at Northwestern University's Feinberg School of Medicine in Chicago. “We’ve got to have a good understanding of what we’re doing every day to move forward.”

The research, which furthered a similar Northwestern study completed in 2006 found that 16% of all activities occurred simultaneously, meaning that the surveyed hospitalists spent about 9% of their average 10.3-hour shift multitasking.

“Sadly, we documented that the vast majority [of time] is away from the patient, not with the patient,” Dr. Williams says.

Dr. Williams and Amit Prachand, an administrator in the HM department at Northwestern, hope to see more research done to define the best workflow for a hospitalist. Both agree, though, that dedicated funding will have to be set aside, either by federal agencies or research institutions, to make that happen.

“We need to convince people the money is well spent in focusing on this,” says Prachand, co-author of the editorial “Hospitalists: Lean Leaders for Hospitals.” “I think the hospital is going to be the one with the most to gain by supporting these opportunities.”

A new study in this month's Journal of Hospital Medicine that catalogues the daily routine of HM practitioners is a first step in helping streamline the hospitalist’s workflow for efficiency, say several people associated with the report.

The report, “Where Did the Day Go? A Time-Motion Study of Hospitalists,” attempted to capture the amount of time hospitalists spent on various activities, including interacting with electronic health records (EHR) (34.1%), communication with colleagues (25.9%), and direct care (7.4%) (J Hosp Med. 2010;5(6):323-328). But one of the report’s senior authors, as well as the co-author of an accompanying editorial, anticipate that the study will serve as a springboard for future research on how hospitalists can best use their time.

Hospitalists need to “lay the foundation to figure how not to just observe what the doctors are doing, but how, in the future, to what they should be doing,” says Mark Williams, MD, FHM, professor and chief of hospital medicine at Northwestern University's Feinberg School of Medicine in Chicago. “We’ve got to have a good understanding of what we’re doing every day to move forward.”

The research, which furthered a similar Northwestern study completed in 2006 found that 16% of all activities occurred simultaneously, meaning that the surveyed hospitalists spent about 9% of their average 10.3-hour shift multitasking.

“Sadly, we documented that the vast majority [of time] is away from the patient, not with the patient,” Dr. Williams says.

Dr. Williams and Amit Prachand, an administrator in the HM department at Northwestern, hope to see more research done to define the best workflow for a hospitalist. Both agree, though, that dedicated funding will have to be set aside, either by federal agencies or research institutions, to make that happen.

“We need to convince people the money is well spent in focusing on this,” says Prachand, co-author of the editorial “Hospitalists: Lean Leaders for Hospitals.” “I think the hospital is going to be the one with the most to gain by supporting these opportunities.”

Issue
The Hospitalist - 2010(08)
Issue
The Hospitalist - 2010(08)
Publications
Publications
Article Type
Display Headline
Tick, Tock, Tick, Tock
Display Headline
Tick, Tock, Tick, Tock
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

In the Literature: Research You Need to Know

Article Type
Changed
Fri, 09/14/2018 - 12:30
Display Headline
In the Literature: Research You Need to Know

Clinical question: Do clinical outcomes differ with the use of dopamine and norepinephrine in the treatment of shock?

Background: Observational trials have suggested higher mortality among patients with shock who are treated with dopamine versus norepinephrine; however, there are limited data from randomized trials.

Study design: Randomized, double-blinded trial.

Setting: Eight ICUs in Europe.

Synopsis: The study enrolled 1,679 consecutive adult patients with shock despite intravenous fluids. Of these, 62.2% were classified as septic shock, 16.7% cardiogenic, and 15.7% hypovolemic. Clinicians titrated the blinded study drug (dopamine or norepinephrine) according to a pre-specified algorithm. If shock persisted despite titration of their study drug to a goal rate, then open-label norepinephrine was added, followed by epinephrine or vasopressin if necessary.

No difference in 28-day mortality between dopamine and norepinephrine (52% versus 48% of patients; odds ratio 1.17 (0.97-1.42); P=0.10) was detected. Patients receiving dopamine experienced more frequent (24% vs. 12%, P<0.001) and more severe arrhythmias (6.1% vs. 1.6%, P< 0.001).

In subgroup analysis, patients in cardiogenic shock had significantly increased 28-day mortality with dopamine (P=0.03).

Study limitations include the use of norepinephrine as an open-label treatment and the inclusion of patients in hypovolemic shock, who are not typically treated with vasopressors.

Bottom line: No mortality difference is detected between dopamine and norepinephrine in patients with shock. Dopamine results in increased rates of mortality in cardiogenic shock and serious arrhythmias in all patients.

Citation: De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.

Reviewed for TH eWire by Robert Chang, MD, Anita Hart, MD, Hae-won Kim, MD, Robert Paretti, MD, Helena Pasieka, MD, and Matt Smitherman, MD, University of Michigan, Ann Arbor

For more physician reviews of HM-related research, visit our website.

Issue
The Hospitalist - 2010(08)
Publications
Sections

Clinical question: Do clinical outcomes differ with the use of dopamine and norepinephrine in the treatment of shock?

Background: Observational trials have suggested higher mortality among patients with shock who are treated with dopamine versus norepinephrine; however, there are limited data from randomized trials.

Study design: Randomized, double-blinded trial.

Setting: Eight ICUs in Europe.

Synopsis: The study enrolled 1,679 consecutive adult patients with shock despite intravenous fluids. Of these, 62.2% were classified as septic shock, 16.7% cardiogenic, and 15.7% hypovolemic. Clinicians titrated the blinded study drug (dopamine or norepinephrine) according to a pre-specified algorithm. If shock persisted despite titration of their study drug to a goal rate, then open-label norepinephrine was added, followed by epinephrine or vasopressin if necessary.

No difference in 28-day mortality between dopamine and norepinephrine (52% versus 48% of patients; odds ratio 1.17 (0.97-1.42); P=0.10) was detected. Patients receiving dopamine experienced more frequent (24% vs. 12%, P<0.001) and more severe arrhythmias (6.1% vs. 1.6%, P< 0.001).

In subgroup analysis, patients in cardiogenic shock had significantly increased 28-day mortality with dopamine (P=0.03).

Study limitations include the use of norepinephrine as an open-label treatment and the inclusion of patients in hypovolemic shock, who are not typically treated with vasopressors.

Bottom line: No mortality difference is detected between dopamine and norepinephrine in patients with shock. Dopamine results in increased rates of mortality in cardiogenic shock and serious arrhythmias in all patients.

Citation: De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.

Reviewed for TH eWire by Robert Chang, MD, Anita Hart, MD, Hae-won Kim, MD, Robert Paretti, MD, Helena Pasieka, MD, and Matt Smitherman, MD, University of Michigan, Ann Arbor

For more physician reviews of HM-related research, visit our website.

Clinical question: Do clinical outcomes differ with the use of dopamine and norepinephrine in the treatment of shock?

Background: Observational trials have suggested higher mortality among patients with shock who are treated with dopamine versus norepinephrine; however, there are limited data from randomized trials.

Study design: Randomized, double-blinded trial.

Setting: Eight ICUs in Europe.

Synopsis: The study enrolled 1,679 consecutive adult patients with shock despite intravenous fluids. Of these, 62.2% were classified as septic shock, 16.7% cardiogenic, and 15.7% hypovolemic. Clinicians titrated the blinded study drug (dopamine or norepinephrine) according to a pre-specified algorithm. If shock persisted despite titration of their study drug to a goal rate, then open-label norepinephrine was added, followed by epinephrine or vasopressin if necessary.

No difference in 28-day mortality between dopamine and norepinephrine (52% versus 48% of patients; odds ratio 1.17 (0.97-1.42); P=0.10) was detected. Patients receiving dopamine experienced more frequent (24% vs. 12%, P<0.001) and more severe arrhythmias (6.1% vs. 1.6%, P< 0.001).

In subgroup analysis, patients in cardiogenic shock had significantly increased 28-day mortality with dopamine (P=0.03).

Study limitations include the use of norepinephrine as an open-label treatment and the inclusion of patients in hypovolemic shock, who are not typically treated with vasopressors.

Bottom line: No mortality difference is detected between dopamine and norepinephrine in patients with shock. Dopamine results in increased rates of mortality in cardiogenic shock and serious arrhythmias in all patients.

Citation: De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.

Reviewed for TH eWire by Robert Chang, MD, Anita Hart, MD, Hae-won Kim, MD, Robert Paretti, MD, Helena Pasieka, MD, and Matt Smitherman, MD, University of Michigan, Ann Arbor

For more physician reviews of HM-related research, visit our website.

Issue
The Hospitalist - 2010(08)
Issue
The Hospitalist - 2010(08)
Publications
Publications
Article Type
Display Headline
In the Literature: Research You Need to Know
Display Headline
In the Literature: Research You Need to Know
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

CDC Recommends Gamma Release Assay (IGRA) for TB

Article Type
Changed
Fri, 09/14/2018 - 12:30
Display Headline
CDC Recommends Gamma Release Assay (IGRA) for TB

New guidelines from the Centers for Disease Control and Prevention (CDC) that recommend interferon-gamma release assay (IGRA) blood tests over the century-old tuberculin skin test (TST) to detect Mycobacterium tuberculosis (TB) could help hospitalist groups save time and money, according to the head of a TB institute.

The guidelines, published in the CDC’s Morbidity & Mortality Weekly Report, recommend providers use IGRAs over TSTs for certain populations, including patients who historically are unlikely to return for a needed second visit to read the TST results and patients who have previously received Bacille Calmette-Guérin (BCG) as a vaccine or as a cancer therapy (MMWR Recomm Rep. 2010;59(RR-5):1-25).

TSTs remain the preferred test for children younger than 5 years old, although some research has suggested that using both tests in youngsters could increase diagnostic sensitivity for that population.

Lee B. Reichman, MD, MPH, FACP, FCCP, of New Jersey Medical School’s Global Tuberculosis Institute in Newark says the improved efficacy of IGRAs should help weed out the false positives associated with the TSTs. That should be a boon for hospitalists looking to boost cost efficiency by focusing care delivery on the most at-risk populations, he adds.

“The hospitalist is busy,” Dr. Reichman says. “So now he doesn’t have to worry about all those people who are turning out to be a false positive.”

Dr. Reichman hopes the new guidelines catch on quickly, particularly because IGRAs must be conducted in laboratory settings that help ensure better predictive results. He fears, however, that adherence to traditional methods like BCG vaccination, which is particularly popular in Europe, might stall widespread IGRA adoption.

“It will take time to get there,” he says. “The TB community is notoriously slow in adapting new technologies.”

Issue
The Hospitalist - 2010(08)
Publications
Sections

New guidelines from the Centers for Disease Control and Prevention (CDC) that recommend interferon-gamma release assay (IGRA) blood tests over the century-old tuberculin skin test (TST) to detect Mycobacterium tuberculosis (TB) could help hospitalist groups save time and money, according to the head of a TB institute.

The guidelines, published in the CDC’s Morbidity & Mortality Weekly Report, recommend providers use IGRAs over TSTs for certain populations, including patients who historically are unlikely to return for a needed second visit to read the TST results and patients who have previously received Bacille Calmette-Guérin (BCG) as a vaccine or as a cancer therapy (MMWR Recomm Rep. 2010;59(RR-5):1-25).

TSTs remain the preferred test for children younger than 5 years old, although some research has suggested that using both tests in youngsters could increase diagnostic sensitivity for that population.

Lee B. Reichman, MD, MPH, FACP, FCCP, of New Jersey Medical School’s Global Tuberculosis Institute in Newark says the improved efficacy of IGRAs should help weed out the false positives associated with the TSTs. That should be a boon for hospitalists looking to boost cost efficiency by focusing care delivery on the most at-risk populations, he adds.

“The hospitalist is busy,” Dr. Reichman says. “So now he doesn’t have to worry about all those people who are turning out to be a false positive.”

Dr. Reichman hopes the new guidelines catch on quickly, particularly because IGRAs must be conducted in laboratory settings that help ensure better predictive results. He fears, however, that adherence to traditional methods like BCG vaccination, which is particularly popular in Europe, might stall widespread IGRA adoption.

“It will take time to get there,” he says. “The TB community is notoriously slow in adapting new technologies.”

New guidelines from the Centers for Disease Control and Prevention (CDC) that recommend interferon-gamma release assay (IGRA) blood tests over the century-old tuberculin skin test (TST) to detect Mycobacterium tuberculosis (TB) could help hospitalist groups save time and money, according to the head of a TB institute.

The guidelines, published in the CDC’s Morbidity & Mortality Weekly Report, recommend providers use IGRAs over TSTs for certain populations, including patients who historically are unlikely to return for a needed second visit to read the TST results and patients who have previously received Bacille Calmette-Guérin (BCG) as a vaccine or as a cancer therapy (MMWR Recomm Rep. 2010;59(RR-5):1-25).

TSTs remain the preferred test for children younger than 5 years old, although some research has suggested that using both tests in youngsters could increase diagnostic sensitivity for that population.

Lee B. Reichman, MD, MPH, FACP, FCCP, of New Jersey Medical School’s Global Tuberculosis Institute in Newark says the improved efficacy of IGRAs should help weed out the false positives associated with the TSTs. That should be a boon for hospitalists looking to boost cost efficiency by focusing care delivery on the most at-risk populations, he adds.

“The hospitalist is busy,” Dr. Reichman says. “So now he doesn’t have to worry about all those people who are turning out to be a false positive.”

Dr. Reichman hopes the new guidelines catch on quickly, particularly because IGRAs must be conducted in laboratory settings that help ensure better predictive results. He fears, however, that adherence to traditional methods like BCG vaccination, which is particularly popular in Europe, might stall widespread IGRA adoption.

“It will take time to get there,” he says. “The TB community is notoriously slow in adapting new technologies.”

Issue
The Hospitalist - 2010(08)
Issue
The Hospitalist - 2010(08)
Publications
Publications
Article Type
Display Headline
CDC Recommends Gamma Release Assay (IGRA) for TB
Display Headline
CDC Recommends Gamma Release Assay (IGRA) for TB
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

What Leads to Lower-Quality Patient Care?

Article Type
Changed
Fri, 09/14/2018 - 12:30
Display Headline
What Leads to Lower-Quality Patient Care?

According to Evan Fieldston, MD, MBA, MSHP, the mismatches between a hospital staff’s workload and its workforce might predict periods of lower-quality care of patients. With a five-year research project in place, Dr. Fieldston is examining the impact of these mismatches on patient care at the Children’s Hospital of Philadelphia (CHOP), where he serves as an assistant professor in pediatrics. He is examining administrative data on approximately 40,500 retrospective cases and conducting more specific prospective validation on approximately 500 cases.

Part of his project is supported by SHM’s Junior Faculty Development Award, a two-year $50,000 grant awarded for the first time in April.

Dr. Fieldston explained to the TH eWire how he’s using the research funds.

Question: What have you done to organize the project?

Answer: I’ve put together an outstanding mentoring and advisory team to guide me through the design of these projects … the analysis and interpretation. I have also secured local support at the hospital and in the department of pediatrics. Now I’m starting to frame out the specifics and the logistics of each of the projects, and I’m preparing the applications for the institutional review board.

Q: How are you spending the grant?

A: The research grant is going to be spent primarily for two research assistants to work on data collection and validation. Frontline observations are important to patient care quality and patient flow work, so I am excited to have the funds to support that work. Other parts of funding are to support biostatistical programming and operations management expertise.

Q: How will you balance your time between research and hospital rounds?

A: Very fortunately, my faculty position here at the University of Pennsylvania and CHOP is primarily for research, so 75% of my time is dedicated to research purposes. As a hospitalist, I attend on the general pediatrics inpatient teaching service for about six to eight weeks a year. … On the weeks that I am on service, it’s a lot more challenging to do research work, but I still try to touch base with the various aspects of the project.

Issue
The Hospitalist - 2010(08)
Publications
Sections

According to Evan Fieldston, MD, MBA, MSHP, the mismatches between a hospital staff’s workload and its workforce might predict periods of lower-quality care of patients. With a five-year research project in place, Dr. Fieldston is examining the impact of these mismatches on patient care at the Children’s Hospital of Philadelphia (CHOP), where he serves as an assistant professor in pediatrics. He is examining administrative data on approximately 40,500 retrospective cases and conducting more specific prospective validation on approximately 500 cases.

Part of his project is supported by SHM’s Junior Faculty Development Award, a two-year $50,000 grant awarded for the first time in April.

Dr. Fieldston explained to the TH eWire how he’s using the research funds.

Question: What have you done to organize the project?

Answer: I’ve put together an outstanding mentoring and advisory team to guide me through the design of these projects … the analysis and interpretation. I have also secured local support at the hospital and in the department of pediatrics. Now I’m starting to frame out the specifics and the logistics of each of the projects, and I’m preparing the applications for the institutional review board.

Q: How are you spending the grant?

A: The research grant is going to be spent primarily for two research assistants to work on data collection and validation. Frontline observations are important to patient care quality and patient flow work, so I am excited to have the funds to support that work. Other parts of funding are to support biostatistical programming and operations management expertise.

Q: How will you balance your time between research and hospital rounds?

A: Very fortunately, my faculty position here at the University of Pennsylvania and CHOP is primarily for research, so 75% of my time is dedicated to research purposes. As a hospitalist, I attend on the general pediatrics inpatient teaching service for about six to eight weeks a year. … On the weeks that I am on service, it’s a lot more challenging to do research work, but I still try to touch base with the various aspects of the project.

According to Evan Fieldston, MD, MBA, MSHP, the mismatches between a hospital staff’s workload and its workforce might predict periods of lower-quality care of patients. With a five-year research project in place, Dr. Fieldston is examining the impact of these mismatches on patient care at the Children’s Hospital of Philadelphia (CHOP), where he serves as an assistant professor in pediatrics. He is examining administrative data on approximately 40,500 retrospective cases and conducting more specific prospective validation on approximately 500 cases.

Part of his project is supported by SHM’s Junior Faculty Development Award, a two-year $50,000 grant awarded for the first time in April.

Dr. Fieldston explained to the TH eWire how he’s using the research funds.

Question: What have you done to organize the project?

Answer: I’ve put together an outstanding mentoring and advisory team to guide me through the design of these projects … the analysis and interpretation. I have also secured local support at the hospital and in the department of pediatrics. Now I’m starting to frame out the specifics and the logistics of each of the projects, and I’m preparing the applications for the institutional review board.

Q: How are you spending the grant?

A: The research grant is going to be spent primarily for two research assistants to work on data collection and validation. Frontline observations are important to patient care quality and patient flow work, so I am excited to have the funds to support that work. Other parts of funding are to support biostatistical programming and operations management expertise.

Q: How will you balance your time between research and hospital rounds?

A: Very fortunately, my faculty position here at the University of Pennsylvania and CHOP is primarily for research, so 75% of my time is dedicated to research purposes. As a hospitalist, I attend on the general pediatrics inpatient teaching service for about six to eight weeks a year. … On the weeks that I am on service, it’s a lot more challenging to do research work, but I still try to touch base with the various aspects of the project.

Issue
The Hospitalist - 2010(08)
Issue
The Hospitalist - 2010(08)
Publications
Publications
Article Type
Display Headline
What Leads to Lower-Quality Patient Care?
Display Headline
What Leads to Lower-Quality Patient Care?
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

Managing Hyponatremia Patients With SIADH

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Managing hyponatremia in patients with syndrome of inappropriate antidiuretic hormone secretion

Why is SIADH Important to Hospitalists?

Disorders of body fluids, and particularly hyponatremia, are among the most commonly encountered problems in clinical medicine, affecting up to 30% of hospitalized patients. In a study of 303,577 laboratory samples collected from 120,137 patients, the prevalence of hyponatremia (serum [Na+] <135 mmol/L) on initial presentation to a healthcare provider was 28.2% among those treated in an acute hospital care setting, 21% among those treated in an ambulatory hospital care setting, and 7.2% in community care centers.1 Numerous other studies have corroborated a high prevalence of hyponatremia in hospitalized patients,2 which reflects the increased vulnerability of this patient population to disruptions of body fluid homeostasis. Recognizing the many possible causes of hyponatremia in hospitalized patients and implementing appropriate treatment strategies therefore are critical steps toward optimizing care and improving outcomes in hospitalized patients with hyponatremia.

In addition to its frequency, hyponatremia is also important because it has been associated with worse clinical outcomes across the entire range of inpatient care, from the general hospital population to those treated in the intensive care unit (ICU). In a study of 4123 patients age 65 years or older who were admitted to a community hospital, 3.5% had clinically significant hyponatremia (serum [Na+] <130 mmol/L) at admission. Compared with nonhyponatremic patients, those with hyponatremia were twice as likely to die during their hospital stay (relative risk [RR], 1.95; P < 0.05).3 In another study of 2188 patients admitted to a medical ICU over a 5‐year period, 13.7% had hyponatremia. The overall rate of in‐hospital mortality among all ICU patients was high at 37.7%. However, severe hyponatremia (serum [Na+] <125 mmol/L) more than doubled the risk of in‐hospital mortality (RR, 2.10; P < 0.001).4 In addition to the general hospital population, in virtually every disease ever studied, the presence of hyponatremia has been found to be an independent risk factor for increased mortality, from congestive heart failure to tuberculosis to liver failure.2

What Causes Hyponatremia in Patients with SIADH?

Hyponatremia can be caused by 1 of 2 potential disruptions in fluid balance: dilution from retained water, or depletion from electrolyte losses in excess of water. Dilutional hyponatremias are associated with either a normal (euvolemic) or an increased (hypervolemic) extracellular fluid (ECF) volume, whereas depletional hyponatremias generally are associated with a decreased ECF volume (hypovolemic). Dilutional hyponatremia can arise from a primary defect in osmoregulation, such as in SIADH, or as a result of ECF volume expansion, as seen in conditions associated with concomitant secondary hyperaldosteronism such as heart failure, hepatic cirrhosis, or nephrotic syndrome. Among some hospitalized patient groups, euvolemic hyponatremia is the most common presentation of abnormally low serum [Na+]. In a study of patients who developed clinically significant postoperative hyponatremia (defined as a serum [Na+] <130 mmol/L) in a large teaching hospital, only 8% were hypovolemic, whereas 42% were euvolemic and 21% were hypervolemic.5

Euvolemic hyponatremia results from an increase in total body water, but with normal or near‐normal total body sodium. As a result, there is an absence of clinical manifestations of ECF volume expansion, such as subcutaneous edema or ascites. It is important to recognize that although SIADH clearly represents a state of volume expansion due to water retention, it rarely causes clinically recognizable hypervolemia since the retained water is distributed across the intracellular fluid (ICF) as well as the ECF, and because volume regulatory processes act to decrease the actual degree of ECF volume expansion.6 Euvolemic hyponatremia can accompany a wide variety of pathological processes, but the most common cause by far is SIADH. Normally, increased plasma osmolality activates osmoreceptors located in the anterior hypothalamus and stimulates the secretion of arginine vasopressin (AVP), also called antidiuretic hormone (ADH), a key neurohormone that regulates fluid homeostasis. In patients with euvolemic hyponatremia due to SIADH, plasma AVP levels are not suppressed despite normal or decreased plasma osmolality.7 This can be a result of ectopic production of AVP by tumors, or stimulation of endogenous pituitary AVP secretion as a result of nonosmotic stimuli that also stimulate vasopressinergic neurons, which include hypovolemia, hypotension, angiotensin II, nausea, hypoxia, hypercarbia, hypoglycemia, stress, and physical activity. Nonsuppressed AVP levels have been documented in the majority of hyponatremic patients, including those with SIADH8 and heart failure.9

SIADH can develop as the result of many different disease processes that disrupt the normal mechanisms that regulate AVP secretion, including pneumonias and other lung infections, thoracic and extrathoracic tumors, a variety of different central nervous system disorders, the postoperative state, human immunodeficiency virus (HIV), and many different drugs (Figure 1). Given the multiplicity of disorders and drugs that can cause disrupted AVP secretion, it is not surprising that hyponatremia is the most common electrolyte abnormality seen in clinical practice.

Figure 1
Etiologies of syndrome of inappropriate antidiuretic hormone secretion.

What Symptoms are Associated With SIADH?

Symptoms of hyponatremia correlate both with the degree of decrease in the serum [Na+] and with the chronicity of the hyponatremia. Acute hyponatremia, defined as <48 hours in duration, is often associated with life‐threatening clinical features such as obtundation, seizures, coma, and respiratory arrest. These symptoms can occur abruptly, sometimes with little warning.10 In the most severe cases, death can occur as a result of cerebral edema with tentorial herniation. Hypoxia secondary to neurogenic pulmonary edema can increase the severity of brain swelling.11

In contrast, chronic hyponatremia is much less symptomatic, and the reason for the profound differences between the symptoms of acute and chronic hyponatremia is now well understood to be due to the process of brain volume regulation.12 It is essential that this process be understood in order to understand the full spectrum of hyponatremic symptoms. As the ECF [Na+] decreases, regardless of whether due to a loss of sodium or a gain of water, there is an obligate movement of water into the brain along osmotic gradients. That water shift causes swelling of the brain, or cerebral edema. If the increased brain water reaches approximately 8% in adults, it exceeds the capacity of the skull to accommodate brain expansion, leading to tentorial herniation and death from respiratory arrest and/or ischemic brain damage. However, if the patient survives the initial hyponatremia, a very strong volume regulatory process follows, consisting of loss of electrolytes and small organic molecules called osmolytes from brain cells into brain ECF, and eventually the peripheral ECF.12, 13 As the solute content of the brain decreases, the water content is allowed to normalize, eventually reaching a state in which brain edema is virtually absent, and as a result symptoms are markedly less than with acute hyponatremia. Although the time required for the brain to acieve a volume‐regulated state varies across patients, this process is completed within 48 hours in experinmental animal studies, and probably follows a similar time course in humans.

Despite this powerful adaptation process, chronic hyponatremia is frequently associated with neurological symptomatology, albeit milder and more subtle in nature. A recent report found a fairly high incidence of symptoms in 223 patients with chronic hyponatremia as a result of thiazide administration: 49% had malaise/lethargy, 47% had dizzy spells, 35% had vomiting, 17% had confusion/obtundation, 17% experienced falls, 6% had headaches, and 0.9% had seizures.14 Although dizziness can potentially be attributed to a diuretic‐induced hypovolemia, symptoms such as confusion, obtundation and seizures are more consistent with hyponatremic symptomatology. Because thiazide‐induced hyponatremia can be readily corrected by stopping the thiazide and/or administering sodium, this represents an ideal situation in which to assess improvement in hyponatremia symptomatology with normalization of the serum [Na+]; in this study, all of these symptoms improved with correction of the hyponatremia. This represents one of the best examples demonstrating reversal of the symptoms associated with chronic hyponatremia by correction of the hyponatremia, because the patients in this study did not in general have severe underlying comorbidities that might complicate interpretation of their symptoms, as is often the case in patients with SIADH.

What Is Required for Making a Diagnosis of SIADH in Hospitalized Patients?

In patients with hypotonic hypoosmolality, ascertainment of their ECF volume status (ie, hypovolemic, euvolemic, or hypervolemic) is an essential first step, as this will segregate patients into different treatment paradigms. For example, in patients who are truly clinically hypovolemic with a decreased ECF volume by clinical parameters, treatment would generally consist of solute repletion with sodium, generally isotonic saline infusion with or without potassium, until the sodium levels normalize. In patients who are hypervolemic, treatment should focus first on the underlying disease rather than addressing the serum [Na+] directly. In patients with clinical euvolemia, the standard diagnostic pathway should be followed to confirm a diagnosis of SIADH as described below.

Assessing ECF volume status can be difficult, even for the most experienced clinicians. Physical signs such as orthostatic decreases in blood pressure and increases in pulse rate, dry mucus membranes, and skin tenting indicate hypovolemic hyponatremia, while signs such as subcutaneous edema, ascites, or anasarca indicate hypervolemic hyponatremia. Patients without any of these findings are generally considered to be euvolemic. However, in any situation these signs are only applicable if there are no other reasons to suspect an altered ECF volume. Along with a complete history and physical examination that includes a careful neurological evaluation, several laboratory tests can help to assess the etiology of the hyponatremia, once serum sodium concentrations have been shown to be below normal ([Na+] <135 mmol/L):

  • Urine osmolality. A urine osmolality (Uosm) less than 100 mOsm/kg H2O can indicate low dietary solute intake, primary polydipsia, or a reset osmostat after suppression of AVP release by a decrease in plasma osmolality below the osmotic threshold for AVP secretion, usually as a result of increased water loading.

  • Urine sodium concentration. Excretion of sodium, as measured by a spot urine [Na+] (UNa), can indicate depletional hyponatremia if the concentration is less than 30 mmol/L.15 A low UNa reflects a volume depleted state unless the patient has secondary hyperaldosteronism from heart failure or cirrhosis. Patients with a low UNa are more likely to respond to isotonic saline. Euvolemic patients who have a normal dietary sodium intake will generally have spot UNa 30 mmol/L and will not benefit from isotonic saline administration.15 In fact, in SIADH, these patients may respond to isotonic saline with a worsening of hyponatremia, since the sodium from the isotonic saline will be excreted in a concentrated urine while the free water is reabsorbed in the kidney collecting ducts. If the patient is on diuretic therapy, urine sodium values cannot always be accurately interpreted, since a UNa 30 mmol/L may reflect the natriuretic effect of the diuretic and not a volume replete state.

  • Blood tests. Additional indicators of volume status include serum blood nitrogen (BUN) and uric acid levels. A BUN <10 mg/dL and uric acid <4 mg/dL are generally consistent with a euvolemic state, particularly when there is glomerular hyperfiltration, which is often present in SIADH. Elevated serum BUN and uric acid levels (BUN >20 mg/dL and uric acid >6 mg/dL), especially if prior values are available for comparison, can also help to establish whether ineffective vascular volume status may be contributing to the pathophysiology of the hyponatremia. In certain clinical scenarios, the B‐type natriuretic protein (BNP) can be helpful to support a clinical impression of congestive heart failure.

The criteria necessary for a diagnosis of SIADH remain essentially as defined by Bartter and Schwartz16 in 1967 (Table 1), but several points deserve emphasis.17 First, true ECF hypoosmolality must be present and hyponatremia secondary to pseudohyponatremia or hyperglycemia excluded. Second, urinary osmolality must be inappropriate for plasma hypoosmolality (Posm). This does not require a Uosm>Posm, but simply that the urine osmolality is greater than maximally dilute (ie, Uosm>100 mOsm/kg H2O in adults). Furthermore, urine osmolality need not be inappropriately elevated at all levels of Posm but simply at some level under 275 mOsm/kg H2O, since in patients with a reset osmostat, AVP secretion can be suppressed at some level of osmolality resulting in maximal urinary dilution and free water excretion at plasma osmolalities below this level.18 Although some consider a reset osmostat to be a separate disorder rather than a variant of SIADH, such cases nonetheless illustrate that some hypoosmolar patients can exhibit an appropriately dilute urine at some, though not all, plasma osmolalities. Third, clinical euvolemia must be present to diagnose SIADH, and this diagnosis cannot be made in a hypovolemic or edematous patient. Importantly, this does not mean that patients with SIADH cannot become hypovolemic for other reasons, but in such cases it is impossible to diagnose the underlying SIADH until the patient is rendered euvolemic. The fourth criterion, renal salt wasting, has probably caused the most confusion in the diagnosis of SIADH. As noted above, the importance of this criterion lies in its usefulness in differentiating hypoosmolality caused by a decreased effective intravascular volume with high aldosterone levels in which case renal Na+ conservation occurs, from dilutional disorders in which urine Na+ excretion is normal or increased due to ECF volume expansion and a suppressed renin‐angiotensin‐aldosterone system. However, UNa can also be high in renal causes of solute depletion such as diuretic use or Addison's disease, and conversely patients with SIADH can have a low UNa if they subsequently become hypovolemic or solute depleted, conditions sometimes produced by imposed salt and water restriction. Consequently, although high urinary Na+ excretion is generally the rule in most patients with SIADH, its presence does not necessarily confirm this diagnosis, nor does its absence rule out the diagnosis. The final criterion emphasizes that SIADH remains a diagnosis of exclusion, and the absence of other potential causes of hypoosmolality must always be verified. Glucocorticoid deficiency and SIADH can be especially difficult to distinguish, since both primary and secondary hypocortisolism can cause elevated plasma AVP levels in addition to direct renal effects that prevent maximal urinary dilution.19 Therefore, no patient with chronic hyponatremia should be diagnosed as having SIADH without a thorough evaluation of adrenal function, preferably via a rapid adrenocorticotropic hormone (ACTH) stimulation test. Acute hyponatremia of obvious etiology, such as postoperatively or in association with pneumonitis, may be treated without adrenal testing as long as there are no other clinical signs or symptoms suggestive of adrenal dysfunction.20

Criteria for the Diagnosis of SIADH
  • Abbreviations: AVP, arginine vasopressin; SIADH, syndrome of inappropriate antidiuretic hormone secretion.

Essential
Decreased effective osmolality of the extracellular fluid (Posm< 275 mOsm/kg H2O).
Inappropriate urinary concentration (Uosm >100 mOsm/kg H2O with normal renal function) at some level of hypoosmolality.
Clinical euvolemia, as defined by the absence of signs of hypovolemia (orthostasis, tachycardia, decreased skin turgor, dry mucous membranes) or hypervolemia (subcutaneous edema, ascites).
Elevated urinary sodium excretion while on a normal salt and water intake.
Absence of other potential causes of euvolemic hypoosmolality: hypothyroidism, hypocortisolism (Addison's disease or secondary adrenal insufficiency) and diuretic use.
Supplemental
Abnormal water load test (inability to excrete at least 90% of a 20 mL/kg water load in 4 hours and/or failure to dilute Uosm to <100 mOsm/kg H2O).
Plasma AVP level inappropriately elevated relative to plasma osmolality.
No significant correction of serum [Na+] with volume expansion but improvement after fluid restriction.

Hyponatremia is a particularly common complication in elderly hospitalized patients, increasing in prevalence from approximately 7% in the general older population to 18% to 22% among elderly patients in chronic care facilities.21 Despite the many known causes of SIADH (Figure 1), hyponatremia is often associated with idiopathic SIADH in the elderly population. In a study of 119 nursing home residents aged 60 to 103 years, 53% had at least 1 episode of hyponatremia during the previous 12 months.22 Of these patients, 26% were diagnosed with idiopathic SIADH. In another study of elderly patients with hyponatremia and SIADH, 60% were diagnosed with idiopathic SIADH. Among remaining patients, the 2 main causes identified were pneumonia (9 cases/18%) and medications (6 cases/12%).23 Therefore, more than half of elderly patients who present with hyponatremia due to SIADH may have an idiopathic form, with no detectable underlying treatable disease.

Which Hospital Patients With SIADH are Candidates for Treatment of Hyponatremia?

Correction of hyponatremia is associated with markedly improved neurological outcomes in patients with severely symptomatic hyponatremia. In a retrospective review of patients who presented with severe neurological symptoms and serum [Na+] <125 mmol/L, prompt therapy with isotonic or hypertonic saline resulted in a correction in the range of 20 mmol/L over several days and neurological recovery in almost all cases. In contrast, in patients who were treated with fluid restriction alone, there was very little correction over the study period (<5 mmol/L over 72 hours), and the neurological outcomes were much worse, with most of these patients either dying or entering a persistently vegetative state.24 Consequently, prompt therapy to rapidly increase the serum [Na+] represents the standard‐of‐care for treatment of patients presenting with severe life‐threatening symptoms of hyponatremia.

As discussed earlier, chronic hyponatremia is much less symptomatic as a result of the process of brain volume regulation. Because of this adaptation process, chronic hyponatremia is arguably a condition that clinicians feel they may not need to be as concerned about, and in some publications this has been called asymptomatic hyponatremia. However, such patients often do have neurological symptoms, even if milder and more subtle in nature, including headaches, nausea, mood disturbances, depression, difficulty concentrating, slowed reaction times, unstable gait, increased falls, confusion, and disorientation. Consequently, any patient with hyponatremia secondary to SIADH who manifests any neurological symptoms that could be related to the hyponatremia should be considered as appropriate candidates for treatment of the hyponatremia, regardless of the chronicity of the hyponatremia or the level of serum [Na+].

What Therapies are Currently Available to Manage SIADH in Hospitalized Patients?

Conventional management strategies for euvolemic hyponatremia range from saline infusion and fluid restriction to pharmacologic adjustment of fluid balance. Consideration of treatment options should include an evaluation of the benefits as well as the potential toxicities of any therapy (Table 2). Sometimes, simply stopping treatment with an agent that is associated with hyponatremia is sufficient to reverse a low serum [Na+].

Therapeutic Options for the Management of Hyponatremia in Patients With SIADH
Therapy Targets Underlying Pathophysiology Limitations
  • Abbreviations: AVP, arginine vasopressin; CYP3A4, cytochrome P450 3A4; FDA, Food and Drug Administration; SIADH, syndrome of inappropriate antidiuretic hormone secretion.

Isotonic saline Ineffective in dilutional hyponatremias; exacerbates the volume overload if used in edema‐forming disorders; no controlled safety database.
Hypertonic saline No consensus regarding appropriate infusion rates; overcorrection can cause osmotic demyelination; exacerbates the volume overload if used in edema‐forming disorders; no controlled safety database.
Fluid restriction Slow to correct over many days; poorly tolerated due to thirst; can not be used effectively in patients with high AVP levels and urine osmolalities.
Demeclocycline Not FDA approved for hyponatremia; slow to correct; nephrotoxic in cirrhosis and heart failure.
Mineralocorticoids Only one report in elderly patients with SIADH; no safety database; exacerbates the volume overload if used in edema‐forming disorders.
Urea Not FDA‐approved for hyponatremia; poor palatability.
AVP receptor antagonists (vaptans) Conivaptan approved only for in‐hospital use secondary to CYP3A4 inhibition; infusion‐site reactions with intravenous use. Tolvaptan must be initiated and reinitiated in the hospital, as serum sodium needs to be monitored closely to avoid overly rapid correction of hyponatremia.

Isotonic Saline

The treatment of choice for depletional hyponatremia (ie, hypovolemic hyponatremia) is isotonic saline ([Na+] = 154 mmol/L) to restore ECF volume and ensure adequate organ perfusion. This initial therapy is appropriate for patients who either have clinical signs of hypovolemia, or in whom a spot UNa+ is <30 mmol/L. However, this therapy is ineffective for dilutional hyponatremias such as SIADH,25 and continued inappropriate administration of isotonic saline to a euvolemic patient may worsen their hyponatremia,26 and/or cause fluid overload. Although isotonic saline may improve the serum [Na+] in patients with hypervolemic hyponatremia, their volume status will generally worsen with this therapy, so unless the hyponatremia is profound isotonic saline should be avoided.

Hypertonic Saline

Acute hyponatremia presenting with severe neurological symptoms is life‐threatening, and should be treated promptly with hypertonic solutions, typically 3% NaCl ([Na+] = 513 mmol/L), as this represents the most reliable method to quickly raise the serum [Na+]. A continuous infusion of hypertonic NaCl is usually utilized in inpatient settings. Various formulae have been suggested for calculating the initial rate of infusion of hypertonic solutions,27 but perhaps the simplest utilizes the following relationship:

An alternative option for more emergent situations is administration of a 100 mL bolus of 3% NaCl, repeated once if no clinical improvement, which has been recommended by a consensus conference organized to develop guidelines for prevention and treatment of exercise‐induced hyponatremia, an acute and potentially lethal condition.28 Injecting this amount of hypertonic saline intravenously raises the serum [Na+] by an average of 2 mmol/L to 4 mmol/L, which is well below the recommended maximal daily rate of change of 10 to 12 mmol/24 hours or 18 mmol/48 hours.29 Because the brain can only accommodate an average increase of approximately 8% in brain volume before herniation occurs, quickly increasing the serum [Na+] by as little as 2 mmol/L to 4 mmol/L in acute hyponatremia can effectively reduce brain swelling and intracranial pressure.30

Unfortunately, until now there has been no consensus regarding appropriate infusion rates of 3% NaCl, and many physicians are hesitant to use it in patients with chronic hyponatremia because it can cause an overly rapid correction of serum sodium levels that can lead to the osmotic demyelination syndrome (ODS).31 Nonetheless, this remains the treatment of choice for patients with severe neurological symptoms, even when the time course of the hyponatremia is nonacute or unknown. The administration of hypertonic saline is generally not recommended for most patients with edema‐forming disorders because it acts as a volume expander and may exacerbate volume overload.

Fluid Restriction

For patients with chronic hyponatremia, fluid restriction has been the most popular and most widely accepted treatment. When SIADH is present, generally fluids should be limited to 500 to 1000 mL/24 hours. Because fluid restriction increases the serum [Na+] largely by under‐replacing the excretion of fluid by the kidneys, some have advocated an initial restriction to 500 mL less than the 24‐hour urine output.32 When instituting a fluid restriction, it is important for the nursing staff and the patient to understand that this includes all fluids that are consumed, not just water. Generally the water content of ingested food is not included in the restriction because this is balanced by insensible water losses (perspiration, exhaled air, feces, etc.), but caution should be exercised with foods that have high fluid concentrations (such as fruits and soups). Restricting fluid intake is effective when properly applied and managed, but serum sodium levels are increased only slowly (1‐2 mmol/L/day) even with severe restriction.25 In addition, this therapy is often poorly tolerated because of an associated increase in thirst. However, it is economically favorable, and some patients do respond well to this option. Fluid restriction should not be used with hypovolemic patients, and is particularly difficult to maintain in patients with very elevated urine osmolalities secondary to high AVP levels; in general, if the sum of urine Na+ and K+ exceeds the serum [Na+], most patients will not respond to a fluid restriction since an electrolyte‐free water clearance will be difficult to achieve,33, 34 and in patients in intensive care settings who often require administration of fluids as part of their therapies.

Demeclocycline

Demeclocycline, a tetracycline antibiotic, inhibits adenylyl cyclase activation after AVP binds to its V2 receptor in the kidney, and thus targets the underlying pathophysiology of SIADH. This therapy is typically used when patients find severe fluid restriction unacceptable and the underlying disorder cannot be corrected. However, demeclocycline is not approved by the U.S. Food and Drug Administration (FDA) to treat hyponatremia, and can cause nephrotoxicity in patients with heart failure and cirrhosis, although this is usually reversible if caught quickly enough.35

Mineralocorticoids

Administration of mineralocorticoids, such as fludrocortisone, has been shown to be useful in a small number of elderly patients.36 However, the initial studies of SIADH did not show it to be of benefit in patients with SIADH, and it carries the risk of fluid overload and hypertension. Consequently, it is rarely used to treat hyponatremia in the U.S.

Urea

Administration of urea has been successfully used to treat hyponatremia because it induces osmotic diuresis and augments free water excretion. Effective doses of urea for treatment of hyponatremia are 30 gm to 60 gm daily in divided doses.37 Unfortunately, its use is limited because there is no United States Pharmacopeia (USP) formulation for urea, and it is not approved by the FDA for treatment of hyponatremia. As such, urea has not been used extensively in the United States, and there are limited data to support its long‐term use. Furthermore, urea is associated with poor palatability; however, patients with feeding tubes may be excellent candidates for urea therapy since palatability is not a concern, and the use of fluid restriction may be difficult in some patients with high obligate intake of fluids as part of their nutritional and medication therapy. Although mild azotemia can be seen with urea therapy, this rarely reaches clinically significant levels.

Clinicians have used all of the above conventional therapies for hyponatremia over the past decades. However, conventional therapies for hyponatremia, although effective in specific circumstances, are suboptimal for many different reasons, including variable efficacy, slow responses, intolerable side effects, and serious toxicities, as summarized in Table 2. But perhaps the most striking deficiency of most conventional therapies is that with the exception of demeclocycline, these therapies do not directly target the underlying cause of most all dilutional hyponatremias, namely inappropriately elevated plasma AVP levels. A new class of pharmacological agents, vasopressin receptor antagonists, that directly block AVP‐mediated receptor activation have recently been approved by the FDA for treatment of euvolemic and hypervolemic hyponatremia.38

AVP Receptor (AVPR) Antagonists

Conivaptan and tolvaptan are antagonists of the AVP V2 (antidiuretic) receptor and have been approved by the FDA for the treatment of euvolemic and hypervolemic hyponatremia. These agents, also known as vaptans, compete with AVP/ADH for binding at its site of action in the kidney, thereby blocking the antidiuresis caused by elevated AVP levels and directly attacking the underlying pathophysiology of dilutional hyponatremia. AVPR antagonists produce electrolyte free water excretion (called aquaresis) without affecting renal sodium and potassium excretion.39 The overall result is a reduction in body water without natriuresis, which leads to an increase in the serum [Na+]. One of the major benefits of this class of drugs is that serum [Na+] is significantly increased within 24 to 48 hours,40, 41 which is considerably faster than the effects of fluid restriction that can take many days. Also, compliance has not been shown to be problem for vaptans, whereas this is a major problem with attempted long‐term use of fluid restriction.

Conivaptan is FDA‐approved for euvolemic and hypervolemic hyponatremia in hospitalized patients. It is available only as an intravenous preparation, and is given as a 20 mg loading dose over 30 minutes, followed by a continuous infusion of 20 or 40 mg.42 Generally, the 20 mg continuous infusion is used for the first 24 hours to gauge the initial response. If the correction of serum [Na+] is felt to be inadequate (eg, <5 mmol/L), then the infusion rate can be increased to 40 mg/day. Therapy is limited to a maximum duration of 4 days because of drug‐interaction effects with other agents metabolized by the cytochrome P450 3A4 (CYP3A4) hepatic isoenzymes. Importantly, for conivaptan and all other vaptans, it is critical that the serum [Na+] concentration is measured frequently during the active phase of correction of the hyponatremia (a minimum of every 6 hours, but more frequently in patients with risk factors for development of osmotic demyelination, such as severely low serum [Na+], malnutrition, alcoholism and hypokalemia).43 If the correction approaches 12 mmol/L in the first 24 hours, the infusion should be stopped and the patient monitored on a fluid restriction. If the correction exceeds 12 mmol/L, consideration should be given to administering sufficient water, either orally or as intravenous D5W to bring the overall correction below 12 mmol/L. The maximum correction limit should be reduced to 8 mmol/L over the first 24 hours in patients with risk factors for development of osmotic demyelination. The most common adverse effects include injection‐site reactions, which are generally mild and usually do not lead to treatment discontinuation, headache, thirst, and hypokalemia.40

Tolvaptan, an oral AVPR antagonist, is FDA‐approved for treatment of dilutional hyponatremias. In contrast to conivaptan, oral administration allows it to be used for both short‐term and long‐term treatment of hyponatremia.41 Similar to conivaptan, tolvaptan treatment must be initiated in the hospital so that the rate of correction can be monitored carefully. Patients with a serum [Na+] <125 mmol/L are eligible for therapy with tolvaptan as primary therapy; if the serum [Na+] is 125 mmol/L, tolvaptan therapy is only indicated if the patient has symptoms that could be attributable to the hyponatremia and the patient is resistant to attempts at fluid restriction.44 The starting dose of tolvaptan is 15 mg on the first day, and the dose can be titrated to 30 mg and 60 mg at 24‐hour intervals if the serum [Na+] remains <135 mmol/L or the increase in serum [Na+] has been 5 mmol/L in the previous 24 hours. As with conivaptan, it is essential that the serum [Na+] concentration is measured frequently during the active phase of correction of the hyponatremia (a minimum of every 8 hrs, but more frequently in patients with risk factors for development of osmotic demyelination). Limits for safe correction of hyponatremia and methods to compensate for overly rapid corrections are the same as described previously for conivaptan. Common side effects include dry mouth, thirst, increased urinary frequency, dizziness, nausea and orthostatic hypotension, which were relatively similar between placebo and tolvaptan groups in clinical trials.41, 44

Because inducing increased renal fluid excretion via either a diuresis or an aquaresis can cause or worsen hypotension in patients with hypovolemic hyponatremia, vaptans are contraindicated in this patient population.43 However, clinically significant hypotension was not observed in either the conivaptan or tolvaptan clinical trials in euvolemic and hypervolemic hyponatremic patients. Although vaptans are not contraindicated with decreased renal function, these agents generally will not be effective if the serum creatinine is >2.5 mg/dL.

Hyponatremia Treatment Guidelines for Hospitalized Patients With SIADH

Although various authors have published recommendations on the treatment of hyponatremia,27, 43, 45‐47 no standardized treatment algorithms have yet been widely accepted. A synthesis of existing expert recommendations for treatment of hyponatremia is illustrated in Figure 2. This algorithm is based primarily on the symptomatology of hyponatremic patients, rather than the serum [Na+] or the chronicity of the hyponatremia, which are often difficult to ascertain. A careful neurological history and assessment should always be done to identify potential causes for the patient's symptoms other than hyponatremia, although it will not always be possible to exclude an additive contribution from the hyponatremia to an underlying neurological condition. In this model, patients are divided into three groups based on their presenting symptoms.

Figure 2
Algorithm for treating patients with euvolemic hyponatremia.

Level 1 symptoms include seizures, coma, respiratory arrest, obtundation, and vomiting, and usually imply a more acute onset or worsening of hyponatremia requiring immediate active treatment. Therapies that will quickly raise serum sodium levels are required to reduce cerebral edema and decrease the risk of potentially fatal herniation.

Level 2 symptoms, which are more moderate, include nausea, confusion, disorientation, and altered mental status. These symptoms may be either chronic or acute, but allow time to elaborate a more deliberate approach to treatment.

Level 3 symptoms range from minimal symptoms such as a headache, irritability, inability to concentrate, altered mood, and depression, to a virtual absence of discernable symptoms, and indicate that the patient may have chronic or slowly evolving hyponatremia. These symptoms necessitate a cautious approach, especially when patients have underlying comorbidities.

Patients with severe symptoms (Level 1) should be treated with hypertonic saline as first‐line therapy, followed by fluid restriction with or without AVPR antagonist therapy. Patients with moderate symptoms will benefit from a more aggressive regimen of vaptan therapy or limited hypertonic saline administration, followed by fluid restriction or long‐term vaptan therapy. Although moderate neurological symptoms can indicate that a patient is in an early stage of acute hyponatremia, they more often indicate a chronically hyponatremic state with sufficient brain volume adaptation to prevent marked symptomatology from cerebral edema. Regardless, close monitoring of these patients in a hospital setting is warranted until the symptoms improve or stabilize. Patients with no or minimal symptoms should be managed initially with fluid restriction, although treatment with vaptans may be appropriate for a wide range of specific clinical conditions, foremost of which is a failure to improve the serum [Na+] despite reasonable attempts at fluid restriction (Figure 2).

Although this classification is based on presenting symptoms at the time of initial evaluation, it should be remembered that in some cases patients initially exhibit more moderate symptoms because they are in the early stages of hyponatremia. In addition, some patients with minimal symptoms are prone to develop more symptomatic hyponatremia during periods of increased fluid ingestion. In support of this, approximately 70% of 31 patients presenting to a university hospital with symptomatic hyponatremia and a mean serum [Na+] of 119 mmol/L had preexisting asymptomatic hyponatremia as the most common risk factor identified.48 Consequently, therapy of hyponatremia should also be considered to prevent progression from lower to higher levels of symptomatic hyponatremia, particularly in patients with a past history of repeated presentations of symptomatic hyponatremia.

How Often Should Serum [Na+] Be Monitored in Hospitalized Patients With SIADH?

The frequency of serum [Na+] monitoring is dependent on both the severity of the hyponatremia and the therapy chosen. In all hyponatremic patients neurological symptomatology should be carefully assessed very early in the diagnostic evaluation to assess the symptomatic severity of the hyponatremia and to determine whether the patient requires more urgent therapy. All patients undergoing active treatment with hypertonic saline for level 1 or 2 symptomatic hyponatremia should have frequent monitoring of serum [Na+] and ECF volume status (every 2‐4 hours) to ensure that the serum [Na+] does not exceeded the recommended levels during the active phase of correction,43 since overly rapid correction of serum sodium can cause damage to the myelin sheath of nerve cells, resulting in central pontine myelinolysis, also called the ODS.31 Patients treated with vaptans for level 2 or 3 symptoms should have serum [Na+] monitored every 6 to 8 hours during the active phase of correction, which will generally be the first 24 to 48 hours of therapy. Active treatment with hypertonic saline or vaptans should be stopped when the patient's symptoms are no longer present, a safe serum [Na+] (usually >120 mmol/L) has been achieved, or the rate of correction has reached 12 mmol/L within 24 hours or 18 mmol/L within 48 hours.29, 43 Importantly, ODS has not been reported either in clinical trials or with therapeutic use of any vaptan to date. In patients with a stable level of serum [Na+] treated with fluid restriction or therapies other than hypertonic saline, measurement of serum [Na+] daily is generally sufficient, since levels will not change that quickly in the absence of active therapy or large changes in fluid intake or administration.

Potential Future Indications for Treatment of Hyponatremia

Correction of hyponatremia improves other symptoms, such as gait stability, in patients who may be considered to be asymptomatic by virtue of a normal neurological exam. In 1 study, 16 patients with hyponatremia secondary to SIADH in the range of 124 mmol/L to 130 mmol/L demonstrated a significant gait instability that normalized after correction of the hyponatremia to normal ranges.49 The functional significance of the gait instability was illustrated in a study of 122 Belgian patients with a variety of levels of hyponatremia, all judged to be asymptomatic at the time of visit to an emergency department (ED). These patients were compared with 244 age‐matched, sex‐matched, and disease‐matched controls also presenting to the ED during the same time period. Researchers found that 21% of the hyponatremic patients presented to the ED because of a recent fall, compared to only 5% of the controls, resulting in an adjusted odds ratio (OR) for presenting to the ED because of a recent fall of 67 for hyponatremia (P < 0.001).49 Consequently, this study clearly documented an increased incidence of falls in so‐called asymptomatic hyponatremic patients.

The clinical significance of the gait instability and fall data were further evaluated in a study that compared 553 patients with fractures to an equal number of age‐matched and sex‐matched controls. Hyponatremia was found in 13% of the patients presenting with fractures compared to only 4% of the controls.50 Similar findings have been reported in a 364 elderly patients with large‐bone fractures in New York.51 More recently published studies have shown that hyponatremia is associated with increased bone loss in experimental animals and a significant increased OR for osteoporosis of the femoral neck (OR, 2.87; P < 0.003) in humans over the age of 50 in the NHANES III database.52 Thus, the major clinical significance of chronic hyponatremia may be the increased morbidity and mortality associated with falls and fractures in our elderly population.

Summary

Disorders of sodium and water metabolism are commonly encountered in the hospital setting due to the wide range of disease states that can disrupt the balanced control of water and solute intake and output. In particular, the prompt identification and appropriate management of abnormally low serum [Na+] is critical if we are to reduce the increased morbidity and mortality that accompany hyponatremia in hospitalized patients. Use of an algorithm that is based primarily on the symptomatology of hyponatremic patients, rather than the chronicity of the hyponatremia or the serum [Na+], will help to choose the correct initial therapy in hospitalized hyponatremic patients. However, careful monitoring of serum [Na+] responses is required in all cases to adjust therapy appropriately in response to changing clinical conditions. Although this approach will enable efficacious and safe treatment of hyponatremic patients with SIADH at the present time, evolving knowledge of the consequences of chronic hyponatremia will likely alter treatment indications and guidelines in the future.

References
  1. Hawkins RC.Age and gender as risk factors for hyponatremia and hypernatremia.Clin Chim Acta.2003;337(1‐2):169172.
  2. Upadhyay A,Jaber BL,Madias NE.Incidence and prevalence of hyponatremia.Am J Med.2006;119(7 Suppl 1):S30S35.
  3. Terzian C,Frye EB,Piotrowski ZH.Admission hyponatremia in the elderly: factors influencing prognosis.J Gen Intern Med1994;9:8991.
  4. Bennani SL,Abouqal R,Zeggwagh AA, et al.[Incidence, causes and prognostic factors of hyponatremia in intensive care].Rev Med Interne.2003;24(4):224229.
  5. Chung HM,Kluge R,Schrier RW,Anderson RJ.Postoperative hyponatremia. A prospective study.Arch Int Med.1986;146:333336.
  6. Verbalis JG.Whole‐body volume regulation and escape from antidiuresis.Am J Med.2006;119(7 Suppl 1):S21S29.
  7. Robertson GL,Aycinena P,Zerbe RL.Neurogenic disorders of osmoregulation.Am J Med.1982;72:339353.
  8. Zerbe R,Stropes L,Robertson G.Vasopressin function in the syndrome of inappropriate antidiuresis.Annu Rev Med.1980;31:315327.
  9. Szatalowicz VL,Arnold PE,Chaimovitz C,Bichet D,Berl T,Schrier RW.Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure.N Eng J Med.1981;305:263266.
  10. Fraser CL,Arieff AI.Epidemiology, pathophysiology, and management of hyponatremic encephalopathy.Am J Med.1997;102:6777.
  11. Ayus JC,Arieff AI.Pulmonary complications of hyponatremic encephalopathy. noncardiogenic pulmonary edema and hypercapnic respiratory failure [see comments].Chest.1995;107(2):517521.
  12. Gullans SR,Verbalis JG.Control of brain volume during hyperosmolar and hypoosmolar conditions.Annu Rev Med.1993;44:289301.
  13. Verbalis JG.Control of brain volume during hypoosmolality and hyperosmolality.Adv Exp Med Biol.2006;576:113129.
  14. Chow KM,Kwan BC,Szeto CC.Clinical studies of thiazide‐induced hyponatremia.J Natl Med Assoc.2004;96(10):13051308.
  15. Chung HM,Kluge R,Schrier RW,Anderson RJ.Clinical assessment of extracellular fluid volume in hyponatremia.Am J Med.1987;83:905908.
  16. Bartter FC,Schwartz WB.The syndrome of inappropriate secretion of antidiuretic hormone.Am J Med.1967;42:790806.
  17. Verbalis JG.Hyponatremia and Hypo‐osmolar Disorders. In: Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC, eds.Primer on Kidney Diseases.Philadelphia:Saunders Elsevier,2009:5259.
  18. Michelis MF,Fusco RD,Bragdon RW,Davis BB.Reset of osmoreceptors in association with normovolemic hyponatremia.Am J Med Sci.1974;267:267273.
  19. Oelkers W.Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism.N Eng J Med.1989;321:492496.
  20. Verbalis JG.The Syndrome of Inappropriate Antidiuretic Hormone Secretion and Other Hypoosmolar Disorders. In: Schrier RW, ed.Diseases of the Kidney and Urinary Tract.Philadelphia:Lippincott Williams 27:156161.
  21. Miller M,Morley JE,Rubenstein LZ.Hyponatremia in a nursing home population.J Am Geriatr Soc.1995;43(12):14101413.
  22. Hirshberg B,Ben‐Yehuda A.The syndrome of inappropriate antidiuretic hormone secretion in the elderly.Am J Med.1997;103(4):270273.
  23. Ayus JC.Diuretic‐induced hyponatremia [editorial].Arch Intern Med.1986;146(7):12951296.
  24. Schwartz WB,Bennett S,Curelop S,Bartter FC.A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone.Am J Med.1957;23:529542.
  25. Steele A,Gowrishankar M,Abrahamson S,Mazer CD,Feldman RD,Halperin ML.Postoperative hyponatremia despite near‐isotonic saline infusion: a phenomenon of desalination [see comments].Ann Intern Med.1997;126(1):2025.
  26. Adrogue HJ,Madias NE.Hyponatremia.N Engl J Med.2000;342(21):15811589.
  27. Hew‐Butler T,Ayus JC,Kipps C, et al.Statement of the Second International Exercise‐Associated Hyponatremia Consensus Development Conference, New Zealand, 2007.Clin J Sport Med.2008;18(2):111121.
  28. Sterns RH,Cappuccio JD,Silver SM,Cohen EP.Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective.J Am Soc Nephrol.1994;4:15221530.
  29. Battison C,Andrews PJ,Graham C,Petty T.Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury.Crit Care Med.2005;33(1):196202.
  30. Sterns RH,Riggs JE,Schochet SS.Osmotic demyelination syndrome following correction of hyponatremia.N Engl J Med.1986;314:15351542.
  31. Robertson GL.Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis.Am J Med.2006;119(7 Suppl 1):S36S42.
  32. Decaux G.The syndrome of inappropriate secretion of antidiuretic hormone (SIADH).Semin Nephrol.2009;29(3):239256.
  33. Berl T.Impact of solute intake on urine flow and water excretion.J Am Soc Nephrol.2008;19(6):10761078.
  34. Singer I,Rotenberg D.Demeclocycline‐induced nephrogenic diabetes insipidus. In‐vivo and in‐ vitro studies.Ann Intern Med.1973;79(5):679683.
  35. Ishikawa S,Fujita N,Fujisawa G, et al.Involvement of arginine vasopressin and renal sodium handling in pathogenesis of hyponatremia in elderly patients.Endocr J.1996;43(1):101108.
  36. Decaux G,Genette F.Urea for long‐term treatment of syndrome of inappropriate secretion of antidiuretic hormone.Br Med J (Clin Res Ed).1981;283:10811083.
  37. Greenberg A,Verbalis JG.Vasopressin receptor antagonists.Kidney Int.2006;69(12):21242130.
  38. Ohnishi A,Orita Y,Okahara R, et al.Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC‐31260) in men.J Clin Invest.1993;92(6):26532659.
  39. Zeltser D,Rosansky S,van Rensburg H,Verbalis JG,Smith N.Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.Am J Nephrol.2007;27(5):447457.
  40. Schrier RW,Gross P,Gheorghiade M, et al.Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia.N Engl J Med.2006;355(20):20992112.
  41. Vaprisol (conivaptan hydrochloride injection) prescribing information.Deerfield, IL:Astellas Pharma US, Inc.,2006.
  42. Verbalis JG,Goldsmith SR,Greenberg A,Schrier RW,Sterns RH.Hyponatremia treatment guidelines 2007: expert panel recommendations.Am J Med.2007;120(11 Suppl 1):S1S21.
  43. Otsuka Pharmaceutical Co L, Tokyo J. Samsca (tolvaptan) prescribing information.2009.
  44. Ellison DH,Berl T.Clinical practice. The syndrome of inappropriate antidiuresis.N Engl J Med.2007;356(20):20642072.
  45. Sterns RH,Nigwekar SU,Hix JK.The treatment of hyponatremia.Semin Nephrol.2009;29(3):282299.
  46. Verbalis JG.Hyponatremia and Hypo‐osmolar Disorders. In: Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC, eds.Primer on Kidney Diseases.Philadelphia. PA:Saunders Elsevier;2009:5259.
  47. Bissram M,Scott FD,Liu L,Rosner MH.Risk factors for symptomatic hyponatraemia: the role of pre‐existing asymptomatic hyponatraemia.Intern Med J.2007;37(3):149155.
  48. Renneboog B,Musch W,Vandemergel X,Manto MU,Decaux G.Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits.Am J Med.2006;119(1):71.
  49. Gankam KF,Andres C,Sattar L,Melot C,Decaux G.Mild hyponatremia and risk of fracture in the ambulatory elderly.QJM.2008;101(7):583588.
  50. Sandhu HS,Gilles E,DeVita MV,Panagopoulos G,Michelis MF.Hyponatremia associated with large‐bone fracture in elderly patients.Int Urol Nephrol.2009;41(3):733737.
  51. Verbalis JG,Barsony J,Sugimura Y, et al.Hyponatremia‐induced osteoporosis.J Bone Miner Res.2010;25(3):554563.
Article PDF
Issue
Journal of Hospital Medicine - 5(3)
Page Number
S18-S26
Sections
Article PDF
Article PDF

Why is SIADH Important to Hospitalists?

Disorders of body fluids, and particularly hyponatremia, are among the most commonly encountered problems in clinical medicine, affecting up to 30% of hospitalized patients. In a study of 303,577 laboratory samples collected from 120,137 patients, the prevalence of hyponatremia (serum [Na+] <135 mmol/L) on initial presentation to a healthcare provider was 28.2% among those treated in an acute hospital care setting, 21% among those treated in an ambulatory hospital care setting, and 7.2% in community care centers.1 Numerous other studies have corroborated a high prevalence of hyponatremia in hospitalized patients,2 which reflects the increased vulnerability of this patient population to disruptions of body fluid homeostasis. Recognizing the many possible causes of hyponatremia in hospitalized patients and implementing appropriate treatment strategies therefore are critical steps toward optimizing care and improving outcomes in hospitalized patients with hyponatremia.

In addition to its frequency, hyponatremia is also important because it has been associated with worse clinical outcomes across the entire range of inpatient care, from the general hospital population to those treated in the intensive care unit (ICU). In a study of 4123 patients age 65 years or older who were admitted to a community hospital, 3.5% had clinically significant hyponatremia (serum [Na+] <130 mmol/L) at admission. Compared with nonhyponatremic patients, those with hyponatremia were twice as likely to die during their hospital stay (relative risk [RR], 1.95; P < 0.05).3 In another study of 2188 patients admitted to a medical ICU over a 5‐year period, 13.7% had hyponatremia. The overall rate of in‐hospital mortality among all ICU patients was high at 37.7%. However, severe hyponatremia (serum [Na+] <125 mmol/L) more than doubled the risk of in‐hospital mortality (RR, 2.10; P < 0.001).4 In addition to the general hospital population, in virtually every disease ever studied, the presence of hyponatremia has been found to be an independent risk factor for increased mortality, from congestive heart failure to tuberculosis to liver failure.2

What Causes Hyponatremia in Patients with SIADH?

Hyponatremia can be caused by 1 of 2 potential disruptions in fluid balance: dilution from retained water, or depletion from electrolyte losses in excess of water. Dilutional hyponatremias are associated with either a normal (euvolemic) or an increased (hypervolemic) extracellular fluid (ECF) volume, whereas depletional hyponatremias generally are associated with a decreased ECF volume (hypovolemic). Dilutional hyponatremia can arise from a primary defect in osmoregulation, such as in SIADH, or as a result of ECF volume expansion, as seen in conditions associated with concomitant secondary hyperaldosteronism such as heart failure, hepatic cirrhosis, or nephrotic syndrome. Among some hospitalized patient groups, euvolemic hyponatremia is the most common presentation of abnormally low serum [Na+]. In a study of patients who developed clinically significant postoperative hyponatremia (defined as a serum [Na+] <130 mmol/L) in a large teaching hospital, only 8% were hypovolemic, whereas 42% were euvolemic and 21% were hypervolemic.5

Euvolemic hyponatremia results from an increase in total body water, but with normal or near‐normal total body sodium. As a result, there is an absence of clinical manifestations of ECF volume expansion, such as subcutaneous edema or ascites. It is important to recognize that although SIADH clearly represents a state of volume expansion due to water retention, it rarely causes clinically recognizable hypervolemia since the retained water is distributed across the intracellular fluid (ICF) as well as the ECF, and because volume regulatory processes act to decrease the actual degree of ECF volume expansion.6 Euvolemic hyponatremia can accompany a wide variety of pathological processes, but the most common cause by far is SIADH. Normally, increased plasma osmolality activates osmoreceptors located in the anterior hypothalamus and stimulates the secretion of arginine vasopressin (AVP), also called antidiuretic hormone (ADH), a key neurohormone that regulates fluid homeostasis. In patients with euvolemic hyponatremia due to SIADH, plasma AVP levels are not suppressed despite normal or decreased plasma osmolality.7 This can be a result of ectopic production of AVP by tumors, or stimulation of endogenous pituitary AVP secretion as a result of nonosmotic stimuli that also stimulate vasopressinergic neurons, which include hypovolemia, hypotension, angiotensin II, nausea, hypoxia, hypercarbia, hypoglycemia, stress, and physical activity. Nonsuppressed AVP levels have been documented in the majority of hyponatremic patients, including those with SIADH8 and heart failure.9

SIADH can develop as the result of many different disease processes that disrupt the normal mechanisms that regulate AVP secretion, including pneumonias and other lung infections, thoracic and extrathoracic tumors, a variety of different central nervous system disorders, the postoperative state, human immunodeficiency virus (HIV), and many different drugs (Figure 1). Given the multiplicity of disorders and drugs that can cause disrupted AVP secretion, it is not surprising that hyponatremia is the most common electrolyte abnormality seen in clinical practice.

Figure 1
Etiologies of syndrome of inappropriate antidiuretic hormone secretion.

What Symptoms are Associated With SIADH?

Symptoms of hyponatremia correlate both with the degree of decrease in the serum [Na+] and with the chronicity of the hyponatremia. Acute hyponatremia, defined as <48 hours in duration, is often associated with life‐threatening clinical features such as obtundation, seizures, coma, and respiratory arrest. These symptoms can occur abruptly, sometimes with little warning.10 In the most severe cases, death can occur as a result of cerebral edema with tentorial herniation. Hypoxia secondary to neurogenic pulmonary edema can increase the severity of brain swelling.11

In contrast, chronic hyponatremia is much less symptomatic, and the reason for the profound differences between the symptoms of acute and chronic hyponatremia is now well understood to be due to the process of brain volume regulation.12 It is essential that this process be understood in order to understand the full spectrum of hyponatremic symptoms. As the ECF [Na+] decreases, regardless of whether due to a loss of sodium or a gain of water, there is an obligate movement of water into the brain along osmotic gradients. That water shift causes swelling of the brain, or cerebral edema. If the increased brain water reaches approximately 8% in adults, it exceeds the capacity of the skull to accommodate brain expansion, leading to tentorial herniation and death from respiratory arrest and/or ischemic brain damage. However, if the patient survives the initial hyponatremia, a very strong volume regulatory process follows, consisting of loss of electrolytes and small organic molecules called osmolytes from brain cells into brain ECF, and eventually the peripheral ECF.12, 13 As the solute content of the brain decreases, the water content is allowed to normalize, eventually reaching a state in which brain edema is virtually absent, and as a result symptoms are markedly less than with acute hyponatremia. Although the time required for the brain to acieve a volume‐regulated state varies across patients, this process is completed within 48 hours in experinmental animal studies, and probably follows a similar time course in humans.

Despite this powerful adaptation process, chronic hyponatremia is frequently associated with neurological symptomatology, albeit milder and more subtle in nature. A recent report found a fairly high incidence of symptoms in 223 patients with chronic hyponatremia as a result of thiazide administration: 49% had malaise/lethargy, 47% had dizzy spells, 35% had vomiting, 17% had confusion/obtundation, 17% experienced falls, 6% had headaches, and 0.9% had seizures.14 Although dizziness can potentially be attributed to a diuretic‐induced hypovolemia, symptoms such as confusion, obtundation and seizures are more consistent with hyponatremic symptomatology. Because thiazide‐induced hyponatremia can be readily corrected by stopping the thiazide and/or administering sodium, this represents an ideal situation in which to assess improvement in hyponatremia symptomatology with normalization of the serum [Na+]; in this study, all of these symptoms improved with correction of the hyponatremia. This represents one of the best examples demonstrating reversal of the symptoms associated with chronic hyponatremia by correction of the hyponatremia, because the patients in this study did not in general have severe underlying comorbidities that might complicate interpretation of their symptoms, as is often the case in patients with SIADH.

What Is Required for Making a Diagnosis of SIADH in Hospitalized Patients?

In patients with hypotonic hypoosmolality, ascertainment of their ECF volume status (ie, hypovolemic, euvolemic, or hypervolemic) is an essential first step, as this will segregate patients into different treatment paradigms. For example, in patients who are truly clinically hypovolemic with a decreased ECF volume by clinical parameters, treatment would generally consist of solute repletion with sodium, generally isotonic saline infusion with or without potassium, until the sodium levels normalize. In patients who are hypervolemic, treatment should focus first on the underlying disease rather than addressing the serum [Na+] directly. In patients with clinical euvolemia, the standard diagnostic pathway should be followed to confirm a diagnosis of SIADH as described below.

Assessing ECF volume status can be difficult, even for the most experienced clinicians. Physical signs such as orthostatic decreases in blood pressure and increases in pulse rate, dry mucus membranes, and skin tenting indicate hypovolemic hyponatremia, while signs such as subcutaneous edema, ascites, or anasarca indicate hypervolemic hyponatremia. Patients without any of these findings are generally considered to be euvolemic. However, in any situation these signs are only applicable if there are no other reasons to suspect an altered ECF volume. Along with a complete history and physical examination that includes a careful neurological evaluation, several laboratory tests can help to assess the etiology of the hyponatremia, once serum sodium concentrations have been shown to be below normal ([Na+] <135 mmol/L):

  • Urine osmolality. A urine osmolality (Uosm) less than 100 mOsm/kg H2O can indicate low dietary solute intake, primary polydipsia, or a reset osmostat after suppression of AVP release by a decrease in plasma osmolality below the osmotic threshold for AVP secretion, usually as a result of increased water loading.

  • Urine sodium concentration. Excretion of sodium, as measured by a spot urine [Na+] (UNa), can indicate depletional hyponatremia if the concentration is less than 30 mmol/L.15 A low UNa reflects a volume depleted state unless the patient has secondary hyperaldosteronism from heart failure or cirrhosis. Patients with a low UNa are more likely to respond to isotonic saline. Euvolemic patients who have a normal dietary sodium intake will generally have spot UNa 30 mmol/L and will not benefit from isotonic saline administration.15 In fact, in SIADH, these patients may respond to isotonic saline with a worsening of hyponatremia, since the sodium from the isotonic saline will be excreted in a concentrated urine while the free water is reabsorbed in the kidney collecting ducts. If the patient is on diuretic therapy, urine sodium values cannot always be accurately interpreted, since a UNa 30 mmol/L may reflect the natriuretic effect of the diuretic and not a volume replete state.

  • Blood tests. Additional indicators of volume status include serum blood nitrogen (BUN) and uric acid levels. A BUN <10 mg/dL and uric acid <4 mg/dL are generally consistent with a euvolemic state, particularly when there is glomerular hyperfiltration, which is often present in SIADH. Elevated serum BUN and uric acid levels (BUN >20 mg/dL and uric acid >6 mg/dL), especially if prior values are available for comparison, can also help to establish whether ineffective vascular volume status may be contributing to the pathophysiology of the hyponatremia. In certain clinical scenarios, the B‐type natriuretic protein (BNP) can be helpful to support a clinical impression of congestive heart failure.

The criteria necessary for a diagnosis of SIADH remain essentially as defined by Bartter and Schwartz16 in 1967 (Table 1), but several points deserve emphasis.17 First, true ECF hypoosmolality must be present and hyponatremia secondary to pseudohyponatremia or hyperglycemia excluded. Second, urinary osmolality must be inappropriate for plasma hypoosmolality (Posm). This does not require a Uosm>Posm, but simply that the urine osmolality is greater than maximally dilute (ie, Uosm>100 mOsm/kg H2O in adults). Furthermore, urine osmolality need not be inappropriately elevated at all levels of Posm but simply at some level under 275 mOsm/kg H2O, since in patients with a reset osmostat, AVP secretion can be suppressed at some level of osmolality resulting in maximal urinary dilution and free water excretion at plasma osmolalities below this level.18 Although some consider a reset osmostat to be a separate disorder rather than a variant of SIADH, such cases nonetheless illustrate that some hypoosmolar patients can exhibit an appropriately dilute urine at some, though not all, plasma osmolalities. Third, clinical euvolemia must be present to diagnose SIADH, and this diagnosis cannot be made in a hypovolemic or edematous patient. Importantly, this does not mean that patients with SIADH cannot become hypovolemic for other reasons, but in such cases it is impossible to diagnose the underlying SIADH until the patient is rendered euvolemic. The fourth criterion, renal salt wasting, has probably caused the most confusion in the diagnosis of SIADH. As noted above, the importance of this criterion lies in its usefulness in differentiating hypoosmolality caused by a decreased effective intravascular volume with high aldosterone levels in which case renal Na+ conservation occurs, from dilutional disorders in which urine Na+ excretion is normal or increased due to ECF volume expansion and a suppressed renin‐angiotensin‐aldosterone system. However, UNa can also be high in renal causes of solute depletion such as diuretic use or Addison's disease, and conversely patients with SIADH can have a low UNa if they subsequently become hypovolemic or solute depleted, conditions sometimes produced by imposed salt and water restriction. Consequently, although high urinary Na+ excretion is generally the rule in most patients with SIADH, its presence does not necessarily confirm this diagnosis, nor does its absence rule out the diagnosis. The final criterion emphasizes that SIADH remains a diagnosis of exclusion, and the absence of other potential causes of hypoosmolality must always be verified. Glucocorticoid deficiency and SIADH can be especially difficult to distinguish, since both primary and secondary hypocortisolism can cause elevated plasma AVP levels in addition to direct renal effects that prevent maximal urinary dilution.19 Therefore, no patient with chronic hyponatremia should be diagnosed as having SIADH without a thorough evaluation of adrenal function, preferably via a rapid adrenocorticotropic hormone (ACTH) stimulation test. Acute hyponatremia of obvious etiology, such as postoperatively or in association with pneumonitis, may be treated without adrenal testing as long as there are no other clinical signs or symptoms suggestive of adrenal dysfunction.20

Criteria for the Diagnosis of SIADH
  • Abbreviations: AVP, arginine vasopressin; SIADH, syndrome of inappropriate antidiuretic hormone secretion.

Essential
Decreased effective osmolality of the extracellular fluid (Posm< 275 mOsm/kg H2O).
Inappropriate urinary concentration (Uosm >100 mOsm/kg H2O with normal renal function) at some level of hypoosmolality.
Clinical euvolemia, as defined by the absence of signs of hypovolemia (orthostasis, tachycardia, decreased skin turgor, dry mucous membranes) or hypervolemia (subcutaneous edema, ascites).
Elevated urinary sodium excretion while on a normal salt and water intake.
Absence of other potential causes of euvolemic hypoosmolality: hypothyroidism, hypocortisolism (Addison's disease or secondary adrenal insufficiency) and diuretic use.
Supplemental
Abnormal water load test (inability to excrete at least 90% of a 20 mL/kg water load in 4 hours and/or failure to dilute Uosm to <100 mOsm/kg H2O).
Plasma AVP level inappropriately elevated relative to plasma osmolality.
No significant correction of serum [Na+] with volume expansion but improvement after fluid restriction.

Hyponatremia is a particularly common complication in elderly hospitalized patients, increasing in prevalence from approximately 7% in the general older population to 18% to 22% among elderly patients in chronic care facilities.21 Despite the many known causes of SIADH (Figure 1), hyponatremia is often associated with idiopathic SIADH in the elderly population. In a study of 119 nursing home residents aged 60 to 103 years, 53% had at least 1 episode of hyponatremia during the previous 12 months.22 Of these patients, 26% were diagnosed with idiopathic SIADH. In another study of elderly patients with hyponatremia and SIADH, 60% were diagnosed with idiopathic SIADH. Among remaining patients, the 2 main causes identified were pneumonia (9 cases/18%) and medications (6 cases/12%).23 Therefore, more than half of elderly patients who present with hyponatremia due to SIADH may have an idiopathic form, with no detectable underlying treatable disease.

Which Hospital Patients With SIADH are Candidates for Treatment of Hyponatremia?

Correction of hyponatremia is associated with markedly improved neurological outcomes in patients with severely symptomatic hyponatremia. In a retrospective review of patients who presented with severe neurological symptoms and serum [Na+] <125 mmol/L, prompt therapy with isotonic or hypertonic saline resulted in a correction in the range of 20 mmol/L over several days and neurological recovery in almost all cases. In contrast, in patients who were treated with fluid restriction alone, there was very little correction over the study period (<5 mmol/L over 72 hours), and the neurological outcomes were much worse, with most of these patients either dying or entering a persistently vegetative state.24 Consequently, prompt therapy to rapidly increase the serum [Na+] represents the standard‐of‐care for treatment of patients presenting with severe life‐threatening symptoms of hyponatremia.

As discussed earlier, chronic hyponatremia is much less symptomatic as a result of the process of brain volume regulation. Because of this adaptation process, chronic hyponatremia is arguably a condition that clinicians feel they may not need to be as concerned about, and in some publications this has been called asymptomatic hyponatremia. However, such patients often do have neurological symptoms, even if milder and more subtle in nature, including headaches, nausea, mood disturbances, depression, difficulty concentrating, slowed reaction times, unstable gait, increased falls, confusion, and disorientation. Consequently, any patient with hyponatremia secondary to SIADH who manifests any neurological symptoms that could be related to the hyponatremia should be considered as appropriate candidates for treatment of the hyponatremia, regardless of the chronicity of the hyponatremia or the level of serum [Na+].

What Therapies are Currently Available to Manage SIADH in Hospitalized Patients?

Conventional management strategies for euvolemic hyponatremia range from saline infusion and fluid restriction to pharmacologic adjustment of fluid balance. Consideration of treatment options should include an evaluation of the benefits as well as the potential toxicities of any therapy (Table 2). Sometimes, simply stopping treatment with an agent that is associated with hyponatremia is sufficient to reverse a low serum [Na+].

Therapeutic Options for the Management of Hyponatremia in Patients With SIADH
Therapy Targets Underlying Pathophysiology Limitations
  • Abbreviations: AVP, arginine vasopressin; CYP3A4, cytochrome P450 3A4; FDA, Food and Drug Administration; SIADH, syndrome of inappropriate antidiuretic hormone secretion.

Isotonic saline Ineffective in dilutional hyponatremias; exacerbates the volume overload if used in edema‐forming disorders; no controlled safety database.
Hypertonic saline No consensus regarding appropriate infusion rates; overcorrection can cause osmotic demyelination; exacerbates the volume overload if used in edema‐forming disorders; no controlled safety database.
Fluid restriction Slow to correct over many days; poorly tolerated due to thirst; can not be used effectively in patients with high AVP levels and urine osmolalities.
Demeclocycline Not FDA approved for hyponatremia; slow to correct; nephrotoxic in cirrhosis and heart failure.
Mineralocorticoids Only one report in elderly patients with SIADH; no safety database; exacerbates the volume overload if used in edema‐forming disorders.
Urea Not FDA‐approved for hyponatremia; poor palatability.
AVP receptor antagonists (vaptans) Conivaptan approved only for in‐hospital use secondary to CYP3A4 inhibition; infusion‐site reactions with intravenous use. Tolvaptan must be initiated and reinitiated in the hospital, as serum sodium needs to be monitored closely to avoid overly rapid correction of hyponatremia.

Isotonic Saline

The treatment of choice for depletional hyponatremia (ie, hypovolemic hyponatremia) is isotonic saline ([Na+] = 154 mmol/L) to restore ECF volume and ensure adequate organ perfusion. This initial therapy is appropriate for patients who either have clinical signs of hypovolemia, or in whom a spot UNa+ is <30 mmol/L. However, this therapy is ineffective for dilutional hyponatremias such as SIADH,25 and continued inappropriate administration of isotonic saline to a euvolemic patient may worsen their hyponatremia,26 and/or cause fluid overload. Although isotonic saline may improve the serum [Na+] in patients with hypervolemic hyponatremia, their volume status will generally worsen with this therapy, so unless the hyponatremia is profound isotonic saline should be avoided.

Hypertonic Saline

Acute hyponatremia presenting with severe neurological symptoms is life‐threatening, and should be treated promptly with hypertonic solutions, typically 3% NaCl ([Na+] = 513 mmol/L), as this represents the most reliable method to quickly raise the serum [Na+]. A continuous infusion of hypertonic NaCl is usually utilized in inpatient settings. Various formulae have been suggested for calculating the initial rate of infusion of hypertonic solutions,27 but perhaps the simplest utilizes the following relationship:

An alternative option for more emergent situations is administration of a 100 mL bolus of 3% NaCl, repeated once if no clinical improvement, which has been recommended by a consensus conference organized to develop guidelines for prevention and treatment of exercise‐induced hyponatremia, an acute and potentially lethal condition.28 Injecting this amount of hypertonic saline intravenously raises the serum [Na+] by an average of 2 mmol/L to 4 mmol/L, which is well below the recommended maximal daily rate of change of 10 to 12 mmol/24 hours or 18 mmol/48 hours.29 Because the brain can only accommodate an average increase of approximately 8% in brain volume before herniation occurs, quickly increasing the serum [Na+] by as little as 2 mmol/L to 4 mmol/L in acute hyponatremia can effectively reduce brain swelling and intracranial pressure.30

Unfortunately, until now there has been no consensus regarding appropriate infusion rates of 3% NaCl, and many physicians are hesitant to use it in patients with chronic hyponatremia because it can cause an overly rapid correction of serum sodium levels that can lead to the osmotic demyelination syndrome (ODS).31 Nonetheless, this remains the treatment of choice for patients with severe neurological symptoms, even when the time course of the hyponatremia is nonacute or unknown. The administration of hypertonic saline is generally not recommended for most patients with edema‐forming disorders because it acts as a volume expander and may exacerbate volume overload.

Fluid Restriction

For patients with chronic hyponatremia, fluid restriction has been the most popular and most widely accepted treatment. When SIADH is present, generally fluids should be limited to 500 to 1000 mL/24 hours. Because fluid restriction increases the serum [Na+] largely by under‐replacing the excretion of fluid by the kidneys, some have advocated an initial restriction to 500 mL less than the 24‐hour urine output.32 When instituting a fluid restriction, it is important for the nursing staff and the patient to understand that this includes all fluids that are consumed, not just water. Generally the water content of ingested food is not included in the restriction because this is balanced by insensible water losses (perspiration, exhaled air, feces, etc.), but caution should be exercised with foods that have high fluid concentrations (such as fruits and soups). Restricting fluid intake is effective when properly applied and managed, but serum sodium levels are increased only slowly (1‐2 mmol/L/day) even with severe restriction.25 In addition, this therapy is often poorly tolerated because of an associated increase in thirst. However, it is economically favorable, and some patients do respond well to this option. Fluid restriction should not be used with hypovolemic patients, and is particularly difficult to maintain in patients with very elevated urine osmolalities secondary to high AVP levels; in general, if the sum of urine Na+ and K+ exceeds the serum [Na+], most patients will not respond to a fluid restriction since an electrolyte‐free water clearance will be difficult to achieve,33, 34 and in patients in intensive care settings who often require administration of fluids as part of their therapies.

Demeclocycline

Demeclocycline, a tetracycline antibiotic, inhibits adenylyl cyclase activation after AVP binds to its V2 receptor in the kidney, and thus targets the underlying pathophysiology of SIADH. This therapy is typically used when patients find severe fluid restriction unacceptable and the underlying disorder cannot be corrected. However, demeclocycline is not approved by the U.S. Food and Drug Administration (FDA) to treat hyponatremia, and can cause nephrotoxicity in patients with heart failure and cirrhosis, although this is usually reversible if caught quickly enough.35

Mineralocorticoids

Administration of mineralocorticoids, such as fludrocortisone, has been shown to be useful in a small number of elderly patients.36 However, the initial studies of SIADH did not show it to be of benefit in patients with SIADH, and it carries the risk of fluid overload and hypertension. Consequently, it is rarely used to treat hyponatremia in the U.S.

Urea

Administration of urea has been successfully used to treat hyponatremia because it induces osmotic diuresis and augments free water excretion. Effective doses of urea for treatment of hyponatremia are 30 gm to 60 gm daily in divided doses.37 Unfortunately, its use is limited because there is no United States Pharmacopeia (USP) formulation for urea, and it is not approved by the FDA for treatment of hyponatremia. As such, urea has not been used extensively in the United States, and there are limited data to support its long‐term use. Furthermore, urea is associated with poor palatability; however, patients with feeding tubes may be excellent candidates for urea therapy since palatability is not a concern, and the use of fluid restriction may be difficult in some patients with high obligate intake of fluids as part of their nutritional and medication therapy. Although mild azotemia can be seen with urea therapy, this rarely reaches clinically significant levels.

Clinicians have used all of the above conventional therapies for hyponatremia over the past decades. However, conventional therapies for hyponatremia, although effective in specific circumstances, are suboptimal for many different reasons, including variable efficacy, slow responses, intolerable side effects, and serious toxicities, as summarized in Table 2. But perhaps the most striking deficiency of most conventional therapies is that with the exception of demeclocycline, these therapies do not directly target the underlying cause of most all dilutional hyponatremias, namely inappropriately elevated plasma AVP levels. A new class of pharmacological agents, vasopressin receptor antagonists, that directly block AVP‐mediated receptor activation have recently been approved by the FDA for treatment of euvolemic and hypervolemic hyponatremia.38

AVP Receptor (AVPR) Antagonists

Conivaptan and tolvaptan are antagonists of the AVP V2 (antidiuretic) receptor and have been approved by the FDA for the treatment of euvolemic and hypervolemic hyponatremia. These agents, also known as vaptans, compete with AVP/ADH for binding at its site of action in the kidney, thereby blocking the antidiuresis caused by elevated AVP levels and directly attacking the underlying pathophysiology of dilutional hyponatremia. AVPR antagonists produce electrolyte free water excretion (called aquaresis) without affecting renal sodium and potassium excretion.39 The overall result is a reduction in body water without natriuresis, which leads to an increase in the serum [Na+]. One of the major benefits of this class of drugs is that serum [Na+] is significantly increased within 24 to 48 hours,40, 41 which is considerably faster than the effects of fluid restriction that can take many days. Also, compliance has not been shown to be problem for vaptans, whereas this is a major problem with attempted long‐term use of fluid restriction.

Conivaptan is FDA‐approved for euvolemic and hypervolemic hyponatremia in hospitalized patients. It is available only as an intravenous preparation, and is given as a 20 mg loading dose over 30 minutes, followed by a continuous infusion of 20 or 40 mg.42 Generally, the 20 mg continuous infusion is used for the first 24 hours to gauge the initial response. If the correction of serum [Na+] is felt to be inadequate (eg, <5 mmol/L), then the infusion rate can be increased to 40 mg/day. Therapy is limited to a maximum duration of 4 days because of drug‐interaction effects with other agents metabolized by the cytochrome P450 3A4 (CYP3A4) hepatic isoenzymes. Importantly, for conivaptan and all other vaptans, it is critical that the serum [Na+] concentration is measured frequently during the active phase of correction of the hyponatremia (a minimum of every 6 hours, but more frequently in patients with risk factors for development of osmotic demyelination, such as severely low serum [Na+], malnutrition, alcoholism and hypokalemia).43 If the correction approaches 12 mmol/L in the first 24 hours, the infusion should be stopped and the patient monitored on a fluid restriction. If the correction exceeds 12 mmol/L, consideration should be given to administering sufficient water, either orally or as intravenous D5W to bring the overall correction below 12 mmol/L. The maximum correction limit should be reduced to 8 mmol/L over the first 24 hours in patients with risk factors for development of osmotic demyelination. The most common adverse effects include injection‐site reactions, which are generally mild and usually do not lead to treatment discontinuation, headache, thirst, and hypokalemia.40

Tolvaptan, an oral AVPR antagonist, is FDA‐approved for treatment of dilutional hyponatremias. In contrast to conivaptan, oral administration allows it to be used for both short‐term and long‐term treatment of hyponatremia.41 Similar to conivaptan, tolvaptan treatment must be initiated in the hospital so that the rate of correction can be monitored carefully. Patients with a serum [Na+] <125 mmol/L are eligible for therapy with tolvaptan as primary therapy; if the serum [Na+] is 125 mmol/L, tolvaptan therapy is only indicated if the patient has symptoms that could be attributable to the hyponatremia and the patient is resistant to attempts at fluid restriction.44 The starting dose of tolvaptan is 15 mg on the first day, and the dose can be titrated to 30 mg and 60 mg at 24‐hour intervals if the serum [Na+] remains <135 mmol/L or the increase in serum [Na+] has been 5 mmol/L in the previous 24 hours. As with conivaptan, it is essential that the serum [Na+] concentration is measured frequently during the active phase of correction of the hyponatremia (a minimum of every 8 hrs, but more frequently in patients with risk factors for development of osmotic demyelination). Limits for safe correction of hyponatremia and methods to compensate for overly rapid corrections are the same as described previously for conivaptan. Common side effects include dry mouth, thirst, increased urinary frequency, dizziness, nausea and orthostatic hypotension, which were relatively similar between placebo and tolvaptan groups in clinical trials.41, 44

Because inducing increased renal fluid excretion via either a diuresis or an aquaresis can cause or worsen hypotension in patients with hypovolemic hyponatremia, vaptans are contraindicated in this patient population.43 However, clinically significant hypotension was not observed in either the conivaptan or tolvaptan clinical trials in euvolemic and hypervolemic hyponatremic patients. Although vaptans are not contraindicated with decreased renal function, these agents generally will not be effective if the serum creatinine is >2.5 mg/dL.

Hyponatremia Treatment Guidelines for Hospitalized Patients With SIADH

Although various authors have published recommendations on the treatment of hyponatremia,27, 43, 45‐47 no standardized treatment algorithms have yet been widely accepted. A synthesis of existing expert recommendations for treatment of hyponatremia is illustrated in Figure 2. This algorithm is based primarily on the symptomatology of hyponatremic patients, rather than the serum [Na+] or the chronicity of the hyponatremia, which are often difficult to ascertain. A careful neurological history and assessment should always be done to identify potential causes for the patient's symptoms other than hyponatremia, although it will not always be possible to exclude an additive contribution from the hyponatremia to an underlying neurological condition. In this model, patients are divided into three groups based on their presenting symptoms.

Figure 2
Algorithm for treating patients with euvolemic hyponatremia.

Level 1 symptoms include seizures, coma, respiratory arrest, obtundation, and vomiting, and usually imply a more acute onset or worsening of hyponatremia requiring immediate active treatment. Therapies that will quickly raise serum sodium levels are required to reduce cerebral edema and decrease the risk of potentially fatal herniation.

Level 2 symptoms, which are more moderate, include nausea, confusion, disorientation, and altered mental status. These symptoms may be either chronic or acute, but allow time to elaborate a more deliberate approach to treatment.

Level 3 symptoms range from minimal symptoms such as a headache, irritability, inability to concentrate, altered mood, and depression, to a virtual absence of discernable symptoms, and indicate that the patient may have chronic or slowly evolving hyponatremia. These symptoms necessitate a cautious approach, especially when patients have underlying comorbidities.

Patients with severe symptoms (Level 1) should be treated with hypertonic saline as first‐line therapy, followed by fluid restriction with or without AVPR antagonist therapy. Patients with moderate symptoms will benefit from a more aggressive regimen of vaptan therapy or limited hypertonic saline administration, followed by fluid restriction or long‐term vaptan therapy. Although moderate neurological symptoms can indicate that a patient is in an early stage of acute hyponatremia, they more often indicate a chronically hyponatremic state with sufficient brain volume adaptation to prevent marked symptomatology from cerebral edema. Regardless, close monitoring of these patients in a hospital setting is warranted until the symptoms improve or stabilize. Patients with no or minimal symptoms should be managed initially with fluid restriction, although treatment with vaptans may be appropriate for a wide range of specific clinical conditions, foremost of which is a failure to improve the serum [Na+] despite reasonable attempts at fluid restriction (Figure 2).

Although this classification is based on presenting symptoms at the time of initial evaluation, it should be remembered that in some cases patients initially exhibit more moderate symptoms because they are in the early stages of hyponatremia. In addition, some patients with minimal symptoms are prone to develop more symptomatic hyponatremia during periods of increased fluid ingestion. In support of this, approximately 70% of 31 patients presenting to a university hospital with symptomatic hyponatremia and a mean serum [Na+] of 119 mmol/L had preexisting asymptomatic hyponatremia as the most common risk factor identified.48 Consequently, therapy of hyponatremia should also be considered to prevent progression from lower to higher levels of symptomatic hyponatremia, particularly in patients with a past history of repeated presentations of symptomatic hyponatremia.

How Often Should Serum [Na+] Be Monitored in Hospitalized Patients With SIADH?

The frequency of serum [Na+] monitoring is dependent on both the severity of the hyponatremia and the therapy chosen. In all hyponatremic patients neurological symptomatology should be carefully assessed very early in the diagnostic evaluation to assess the symptomatic severity of the hyponatremia and to determine whether the patient requires more urgent therapy. All patients undergoing active treatment with hypertonic saline for level 1 or 2 symptomatic hyponatremia should have frequent monitoring of serum [Na+] and ECF volume status (every 2‐4 hours) to ensure that the serum [Na+] does not exceeded the recommended levels during the active phase of correction,43 since overly rapid correction of serum sodium can cause damage to the myelin sheath of nerve cells, resulting in central pontine myelinolysis, also called the ODS.31 Patients treated with vaptans for level 2 or 3 symptoms should have serum [Na+] monitored every 6 to 8 hours during the active phase of correction, which will generally be the first 24 to 48 hours of therapy. Active treatment with hypertonic saline or vaptans should be stopped when the patient's symptoms are no longer present, a safe serum [Na+] (usually >120 mmol/L) has been achieved, or the rate of correction has reached 12 mmol/L within 24 hours or 18 mmol/L within 48 hours.29, 43 Importantly, ODS has not been reported either in clinical trials or with therapeutic use of any vaptan to date. In patients with a stable level of serum [Na+] treated with fluid restriction or therapies other than hypertonic saline, measurement of serum [Na+] daily is generally sufficient, since levels will not change that quickly in the absence of active therapy or large changes in fluid intake or administration.

Potential Future Indications for Treatment of Hyponatremia

Correction of hyponatremia improves other symptoms, such as gait stability, in patients who may be considered to be asymptomatic by virtue of a normal neurological exam. In 1 study, 16 patients with hyponatremia secondary to SIADH in the range of 124 mmol/L to 130 mmol/L demonstrated a significant gait instability that normalized after correction of the hyponatremia to normal ranges.49 The functional significance of the gait instability was illustrated in a study of 122 Belgian patients with a variety of levels of hyponatremia, all judged to be asymptomatic at the time of visit to an emergency department (ED). These patients were compared with 244 age‐matched, sex‐matched, and disease‐matched controls also presenting to the ED during the same time period. Researchers found that 21% of the hyponatremic patients presented to the ED because of a recent fall, compared to only 5% of the controls, resulting in an adjusted odds ratio (OR) for presenting to the ED because of a recent fall of 67 for hyponatremia (P < 0.001).49 Consequently, this study clearly documented an increased incidence of falls in so‐called asymptomatic hyponatremic patients.

The clinical significance of the gait instability and fall data were further evaluated in a study that compared 553 patients with fractures to an equal number of age‐matched and sex‐matched controls. Hyponatremia was found in 13% of the patients presenting with fractures compared to only 4% of the controls.50 Similar findings have been reported in a 364 elderly patients with large‐bone fractures in New York.51 More recently published studies have shown that hyponatremia is associated with increased bone loss in experimental animals and a significant increased OR for osteoporosis of the femoral neck (OR, 2.87; P < 0.003) in humans over the age of 50 in the NHANES III database.52 Thus, the major clinical significance of chronic hyponatremia may be the increased morbidity and mortality associated with falls and fractures in our elderly population.

Summary

Disorders of sodium and water metabolism are commonly encountered in the hospital setting due to the wide range of disease states that can disrupt the balanced control of water and solute intake and output. In particular, the prompt identification and appropriate management of abnormally low serum [Na+] is critical if we are to reduce the increased morbidity and mortality that accompany hyponatremia in hospitalized patients. Use of an algorithm that is based primarily on the symptomatology of hyponatremic patients, rather than the chronicity of the hyponatremia or the serum [Na+], will help to choose the correct initial therapy in hospitalized hyponatremic patients. However, careful monitoring of serum [Na+] responses is required in all cases to adjust therapy appropriately in response to changing clinical conditions. Although this approach will enable efficacious and safe treatment of hyponatremic patients with SIADH at the present time, evolving knowledge of the consequences of chronic hyponatremia will likely alter treatment indications and guidelines in the future.

Why is SIADH Important to Hospitalists?

Disorders of body fluids, and particularly hyponatremia, are among the most commonly encountered problems in clinical medicine, affecting up to 30% of hospitalized patients. In a study of 303,577 laboratory samples collected from 120,137 patients, the prevalence of hyponatremia (serum [Na+] <135 mmol/L) on initial presentation to a healthcare provider was 28.2% among those treated in an acute hospital care setting, 21% among those treated in an ambulatory hospital care setting, and 7.2% in community care centers.1 Numerous other studies have corroborated a high prevalence of hyponatremia in hospitalized patients,2 which reflects the increased vulnerability of this patient population to disruptions of body fluid homeostasis. Recognizing the many possible causes of hyponatremia in hospitalized patients and implementing appropriate treatment strategies therefore are critical steps toward optimizing care and improving outcomes in hospitalized patients with hyponatremia.

In addition to its frequency, hyponatremia is also important because it has been associated with worse clinical outcomes across the entire range of inpatient care, from the general hospital population to those treated in the intensive care unit (ICU). In a study of 4123 patients age 65 years or older who were admitted to a community hospital, 3.5% had clinically significant hyponatremia (serum [Na+] <130 mmol/L) at admission. Compared with nonhyponatremic patients, those with hyponatremia were twice as likely to die during their hospital stay (relative risk [RR], 1.95; P < 0.05).3 In another study of 2188 patients admitted to a medical ICU over a 5‐year period, 13.7% had hyponatremia. The overall rate of in‐hospital mortality among all ICU patients was high at 37.7%. However, severe hyponatremia (serum [Na+] <125 mmol/L) more than doubled the risk of in‐hospital mortality (RR, 2.10; P < 0.001).4 In addition to the general hospital population, in virtually every disease ever studied, the presence of hyponatremia has been found to be an independent risk factor for increased mortality, from congestive heart failure to tuberculosis to liver failure.2

What Causes Hyponatremia in Patients with SIADH?

Hyponatremia can be caused by 1 of 2 potential disruptions in fluid balance: dilution from retained water, or depletion from electrolyte losses in excess of water. Dilutional hyponatremias are associated with either a normal (euvolemic) or an increased (hypervolemic) extracellular fluid (ECF) volume, whereas depletional hyponatremias generally are associated with a decreased ECF volume (hypovolemic). Dilutional hyponatremia can arise from a primary defect in osmoregulation, such as in SIADH, or as a result of ECF volume expansion, as seen in conditions associated with concomitant secondary hyperaldosteronism such as heart failure, hepatic cirrhosis, or nephrotic syndrome. Among some hospitalized patient groups, euvolemic hyponatremia is the most common presentation of abnormally low serum [Na+]. In a study of patients who developed clinically significant postoperative hyponatremia (defined as a serum [Na+] <130 mmol/L) in a large teaching hospital, only 8% were hypovolemic, whereas 42% were euvolemic and 21% were hypervolemic.5

Euvolemic hyponatremia results from an increase in total body water, but with normal or near‐normal total body sodium. As a result, there is an absence of clinical manifestations of ECF volume expansion, such as subcutaneous edema or ascites. It is important to recognize that although SIADH clearly represents a state of volume expansion due to water retention, it rarely causes clinically recognizable hypervolemia since the retained water is distributed across the intracellular fluid (ICF) as well as the ECF, and because volume regulatory processes act to decrease the actual degree of ECF volume expansion.6 Euvolemic hyponatremia can accompany a wide variety of pathological processes, but the most common cause by far is SIADH. Normally, increased plasma osmolality activates osmoreceptors located in the anterior hypothalamus and stimulates the secretion of arginine vasopressin (AVP), also called antidiuretic hormone (ADH), a key neurohormone that regulates fluid homeostasis. In patients with euvolemic hyponatremia due to SIADH, plasma AVP levels are not suppressed despite normal or decreased plasma osmolality.7 This can be a result of ectopic production of AVP by tumors, or stimulation of endogenous pituitary AVP secretion as a result of nonosmotic stimuli that also stimulate vasopressinergic neurons, which include hypovolemia, hypotension, angiotensin II, nausea, hypoxia, hypercarbia, hypoglycemia, stress, and physical activity. Nonsuppressed AVP levels have been documented in the majority of hyponatremic patients, including those with SIADH8 and heart failure.9

SIADH can develop as the result of many different disease processes that disrupt the normal mechanisms that regulate AVP secretion, including pneumonias and other lung infections, thoracic and extrathoracic tumors, a variety of different central nervous system disorders, the postoperative state, human immunodeficiency virus (HIV), and many different drugs (Figure 1). Given the multiplicity of disorders and drugs that can cause disrupted AVP secretion, it is not surprising that hyponatremia is the most common electrolyte abnormality seen in clinical practice.

Figure 1
Etiologies of syndrome of inappropriate antidiuretic hormone secretion.

What Symptoms are Associated With SIADH?

Symptoms of hyponatremia correlate both with the degree of decrease in the serum [Na+] and with the chronicity of the hyponatremia. Acute hyponatremia, defined as <48 hours in duration, is often associated with life‐threatening clinical features such as obtundation, seizures, coma, and respiratory arrest. These symptoms can occur abruptly, sometimes with little warning.10 In the most severe cases, death can occur as a result of cerebral edema with tentorial herniation. Hypoxia secondary to neurogenic pulmonary edema can increase the severity of brain swelling.11

In contrast, chronic hyponatremia is much less symptomatic, and the reason for the profound differences between the symptoms of acute and chronic hyponatremia is now well understood to be due to the process of brain volume regulation.12 It is essential that this process be understood in order to understand the full spectrum of hyponatremic symptoms. As the ECF [Na+] decreases, regardless of whether due to a loss of sodium or a gain of water, there is an obligate movement of water into the brain along osmotic gradients. That water shift causes swelling of the brain, or cerebral edema. If the increased brain water reaches approximately 8% in adults, it exceeds the capacity of the skull to accommodate brain expansion, leading to tentorial herniation and death from respiratory arrest and/or ischemic brain damage. However, if the patient survives the initial hyponatremia, a very strong volume regulatory process follows, consisting of loss of electrolytes and small organic molecules called osmolytes from brain cells into brain ECF, and eventually the peripheral ECF.12, 13 As the solute content of the brain decreases, the water content is allowed to normalize, eventually reaching a state in which brain edema is virtually absent, and as a result symptoms are markedly less than with acute hyponatremia. Although the time required for the brain to acieve a volume‐regulated state varies across patients, this process is completed within 48 hours in experinmental animal studies, and probably follows a similar time course in humans.

Despite this powerful adaptation process, chronic hyponatremia is frequently associated with neurological symptomatology, albeit milder and more subtle in nature. A recent report found a fairly high incidence of symptoms in 223 patients with chronic hyponatremia as a result of thiazide administration: 49% had malaise/lethargy, 47% had dizzy spells, 35% had vomiting, 17% had confusion/obtundation, 17% experienced falls, 6% had headaches, and 0.9% had seizures.14 Although dizziness can potentially be attributed to a diuretic‐induced hypovolemia, symptoms such as confusion, obtundation and seizures are more consistent with hyponatremic symptomatology. Because thiazide‐induced hyponatremia can be readily corrected by stopping the thiazide and/or administering sodium, this represents an ideal situation in which to assess improvement in hyponatremia symptomatology with normalization of the serum [Na+]; in this study, all of these symptoms improved with correction of the hyponatremia. This represents one of the best examples demonstrating reversal of the symptoms associated with chronic hyponatremia by correction of the hyponatremia, because the patients in this study did not in general have severe underlying comorbidities that might complicate interpretation of their symptoms, as is often the case in patients with SIADH.

What Is Required for Making a Diagnosis of SIADH in Hospitalized Patients?

In patients with hypotonic hypoosmolality, ascertainment of their ECF volume status (ie, hypovolemic, euvolemic, or hypervolemic) is an essential first step, as this will segregate patients into different treatment paradigms. For example, in patients who are truly clinically hypovolemic with a decreased ECF volume by clinical parameters, treatment would generally consist of solute repletion with sodium, generally isotonic saline infusion with or without potassium, until the sodium levels normalize. In patients who are hypervolemic, treatment should focus first on the underlying disease rather than addressing the serum [Na+] directly. In patients with clinical euvolemia, the standard diagnostic pathway should be followed to confirm a diagnosis of SIADH as described below.

Assessing ECF volume status can be difficult, even for the most experienced clinicians. Physical signs such as orthostatic decreases in blood pressure and increases in pulse rate, dry mucus membranes, and skin tenting indicate hypovolemic hyponatremia, while signs such as subcutaneous edema, ascites, or anasarca indicate hypervolemic hyponatremia. Patients without any of these findings are generally considered to be euvolemic. However, in any situation these signs are only applicable if there are no other reasons to suspect an altered ECF volume. Along with a complete history and physical examination that includes a careful neurological evaluation, several laboratory tests can help to assess the etiology of the hyponatremia, once serum sodium concentrations have been shown to be below normal ([Na+] <135 mmol/L):

  • Urine osmolality. A urine osmolality (Uosm) less than 100 mOsm/kg H2O can indicate low dietary solute intake, primary polydipsia, or a reset osmostat after suppression of AVP release by a decrease in plasma osmolality below the osmotic threshold for AVP secretion, usually as a result of increased water loading.

  • Urine sodium concentration. Excretion of sodium, as measured by a spot urine [Na+] (UNa), can indicate depletional hyponatremia if the concentration is less than 30 mmol/L.15 A low UNa reflects a volume depleted state unless the patient has secondary hyperaldosteronism from heart failure or cirrhosis. Patients with a low UNa are more likely to respond to isotonic saline. Euvolemic patients who have a normal dietary sodium intake will generally have spot UNa 30 mmol/L and will not benefit from isotonic saline administration.15 In fact, in SIADH, these patients may respond to isotonic saline with a worsening of hyponatremia, since the sodium from the isotonic saline will be excreted in a concentrated urine while the free water is reabsorbed in the kidney collecting ducts. If the patient is on diuretic therapy, urine sodium values cannot always be accurately interpreted, since a UNa 30 mmol/L may reflect the natriuretic effect of the diuretic and not a volume replete state.

  • Blood tests. Additional indicators of volume status include serum blood nitrogen (BUN) and uric acid levels. A BUN <10 mg/dL and uric acid <4 mg/dL are generally consistent with a euvolemic state, particularly when there is glomerular hyperfiltration, which is often present in SIADH. Elevated serum BUN and uric acid levels (BUN >20 mg/dL and uric acid >6 mg/dL), especially if prior values are available for comparison, can also help to establish whether ineffective vascular volume status may be contributing to the pathophysiology of the hyponatremia. In certain clinical scenarios, the B‐type natriuretic protein (BNP) can be helpful to support a clinical impression of congestive heart failure.

The criteria necessary for a diagnosis of SIADH remain essentially as defined by Bartter and Schwartz16 in 1967 (Table 1), but several points deserve emphasis.17 First, true ECF hypoosmolality must be present and hyponatremia secondary to pseudohyponatremia or hyperglycemia excluded. Second, urinary osmolality must be inappropriate for plasma hypoosmolality (Posm). This does not require a Uosm>Posm, but simply that the urine osmolality is greater than maximally dilute (ie, Uosm>100 mOsm/kg H2O in adults). Furthermore, urine osmolality need not be inappropriately elevated at all levels of Posm but simply at some level under 275 mOsm/kg H2O, since in patients with a reset osmostat, AVP secretion can be suppressed at some level of osmolality resulting in maximal urinary dilution and free water excretion at plasma osmolalities below this level.18 Although some consider a reset osmostat to be a separate disorder rather than a variant of SIADH, such cases nonetheless illustrate that some hypoosmolar patients can exhibit an appropriately dilute urine at some, though not all, plasma osmolalities. Third, clinical euvolemia must be present to diagnose SIADH, and this diagnosis cannot be made in a hypovolemic or edematous patient. Importantly, this does not mean that patients with SIADH cannot become hypovolemic for other reasons, but in such cases it is impossible to diagnose the underlying SIADH until the patient is rendered euvolemic. The fourth criterion, renal salt wasting, has probably caused the most confusion in the diagnosis of SIADH. As noted above, the importance of this criterion lies in its usefulness in differentiating hypoosmolality caused by a decreased effective intravascular volume with high aldosterone levels in which case renal Na+ conservation occurs, from dilutional disorders in which urine Na+ excretion is normal or increased due to ECF volume expansion and a suppressed renin‐angiotensin‐aldosterone system. However, UNa can also be high in renal causes of solute depletion such as diuretic use or Addison's disease, and conversely patients with SIADH can have a low UNa if they subsequently become hypovolemic or solute depleted, conditions sometimes produced by imposed salt and water restriction. Consequently, although high urinary Na+ excretion is generally the rule in most patients with SIADH, its presence does not necessarily confirm this diagnosis, nor does its absence rule out the diagnosis. The final criterion emphasizes that SIADH remains a diagnosis of exclusion, and the absence of other potential causes of hypoosmolality must always be verified. Glucocorticoid deficiency and SIADH can be especially difficult to distinguish, since both primary and secondary hypocortisolism can cause elevated plasma AVP levels in addition to direct renal effects that prevent maximal urinary dilution.19 Therefore, no patient with chronic hyponatremia should be diagnosed as having SIADH without a thorough evaluation of adrenal function, preferably via a rapid adrenocorticotropic hormone (ACTH) stimulation test. Acute hyponatremia of obvious etiology, such as postoperatively or in association with pneumonitis, may be treated without adrenal testing as long as there are no other clinical signs or symptoms suggestive of adrenal dysfunction.20

Criteria for the Diagnosis of SIADH
  • Abbreviations: AVP, arginine vasopressin; SIADH, syndrome of inappropriate antidiuretic hormone secretion.

Essential
Decreased effective osmolality of the extracellular fluid (Posm< 275 mOsm/kg H2O).
Inappropriate urinary concentration (Uosm >100 mOsm/kg H2O with normal renal function) at some level of hypoosmolality.
Clinical euvolemia, as defined by the absence of signs of hypovolemia (orthostasis, tachycardia, decreased skin turgor, dry mucous membranes) or hypervolemia (subcutaneous edema, ascites).
Elevated urinary sodium excretion while on a normal salt and water intake.
Absence of other potential causes of euvolemic hypoosmolality: hypothyroidism, hypocortisolism (Addison's disease or secondary adrenal insufficiency) and diuretic use.
Supplemental
Abnormal water load test (inability to excrete at least 90% of a 20 mL/kg water load in 4 hours and/or failure to dilute Uosm to <100 mOsm/kg H2O).
Plasma AVP level inappropriately elevated relative to plasma osmolality.
No significant correction of serum [Na+] with volume expansion but improvement after fluid restriction.

Hyponatremia is a particularly common complication in elderly hospitalized patients, increasing in prevalence from approximately 7% in the general older population to 18% to 22% among elderly patients in chronic care facilities.21 Despite the many known causes of SIADH (Figure 1), hyponatremia is often associated with idiopathic SIADH in the elderly population. In a study of 119 nursing home residents aged 60 to 103 years, 53% had at least 1 episode of hyponatremia during the previous 12 months.22 Of these patients, 26% were diagnosed with idiopathic SIADH. In another study of elderly patients with hyponatremia and SIADH, 60% were diagnosed with idiopathic SIADH. Among remaining patients, the 2 main causes identified were pneumonia (9 cases/18%) and medications (6 cases/12%).23 Therefore, more than half of elderly patients who present with hyponatremia due to SIADH may have an idiopathic form, with no detectable underlying treatable disease.

Which Hospital Patients With SIADH are Candidates for Treatment of Hyponatremia?

Correction of hyponatremia is associated with markedly improved neurological outcomes in patients with severely symptomatic hyponatremia. In a retrospective review of patients who presented with severe neurological symptoms and serum [Na+] <125 mmol/L, prompt therapy with isotonic or hypertonic saline resulted in a correction in the range of 20 mmol/L over several days and neurological recovery in almost all cases. In contrast, in patients who were treated with fluid restriction alone, there was very little correction over the study period (<5 mmol/L over 72 hours), and the neurological outcomes were much worse, with most of these patients either dying or entering a persistently vegetative state.24 Consequently, prompt therapy to rapidly increase the serum [Na+] represents the standard‐of‐care for treatment of patients presenting with severe life‐threatening symptoms of hyponatremia.

As discussed earlier, chronic hyponatremia is much less symptomatic as a result of the process of brain volume regulation. Because of this adaptation process, chronic hyponatremia is arguably a condition that clinicians feel they may not need to be as concerned about, and in some publications this has been called asymptomatic hyponatremia. However, such patients often do have neurological symptoms, even if milder and more subtle in nature, including headaches, nausea, mood disturbances, depression, difficulty concentrating, slowed reaction times, unstable gait, increased falls, confusion, and disorientation. Consequently, any patient with hyponatremia secondary to SIADH who manifests any neurological symptoms that could be related to the hyponatremia should be considered as appropriate candidates for treatment of the hyponatremia, regardless of the chronicity of the hyponatremia or the level of serum [Na+].

What Therapies are Currently Available to Manage SIADH in Hospitalized Patients?

Conventional management strategies for euvolemic hyponatremia range from saline infusion and fluid restriction to pharmacologic adjustment of fluid balance. Consideration of treatment options should include an evaluation of the benefits as well as the potential toxicities of any therapy (Table 2). Sometimes, simply stopping treatment with an agent that is associated with hyponatremia is sufficient to reverse a low serum [Na+].

Therapeutic Options for the Management of Hyponatremia in Patients With SIADH
Therapy Targets Underlying Pathophysiology Limitations
  • Abbreviations: AVP, arginine vasopressin; CYP3A4, cytochrome P450 3A4; FDA, Food and Drug Administration; SIADH, syndrome of inappropriate antidiuretic hormone secretion.

Isotonic saline Ineffective in dilutional hyponatremias; exacerbates the volume overload if used in edema‐forming disorders; no controlled safety database.
Hypertonic saline No consensus regarding appropriate infusion rates; overcorrection can cause osmotic demyelination; exacerbates the volume overload if used in edema‐forming disorders; no controlled safety database.
Fluid restriction Slow to correct over many days; poorly tolerated due to thirst; can not be used effectively in patients with high AVP levels and urine osmolalities.
Demeclocycline Not FDA approved for hyponatremia; slow to correct; nephrotoxic in cirrhosis and heart failure.
Mineralocorticoids Only one report in elderly patients with SIADH; no safety database; exacerbates the volume overload if used in edema‐forming disorders.
Urea Not FDA‐approved for hyponatremia; poor palatability.
AVP receptor antagonists (vaptans) Conivaptan approved only for in‐hospital use secondary to CYP3A4 inhibition; infusion‐site reactions with intravenous use. Tolvaptan must be initiated and reinitiated in the hospital, as serum sodium needs to be monitored closely to avoid overly rapid correction of hyponatremia.

Isotonic Saline

The treatment of choice for depletional hyponatremia (ie, hypovolemic hyponatremia) is isotonic saline ([Na+] = 154 mmol/L) to restore ECF volume and ensure adequate organ perfusion. This initial therapy is appropriate for patients who either have clinical signs of hypovolemia, or in whom a spot UNa+ is <30 mmol/L. However, this therapy is ineffective for dilutional hyponatremias such as SIADH,25 and continued inappropriate administration of isotonic saline to a euvolemic patient may worsen their hyponatremia,26 and/or cause fluid overload. Although isotonic saline may improve the serum [Na+] in patients with hypervolemic hyponatremia, their volume status will generally worsen with this therapy, so unless the hyponatremia is profound isotonic saline should be avoided.

Hypertonic Saline

Acute hyponatremia presenting with severe neurological symptoms is life‐threatening, and should be treated promptly with hypertonic solutions, typically 3% NaCl ([Na+] = 513 mmol/L), as this represents the most reliable method to quickly raise the serum [Na+]. A continuous infusion of hypertonic NaCl is usually utilized in inpatient settings. Various formulae have been suggested for calculating the initial rate of infusion of hypertonic solutions,27 but perhaps the simplest utilizes the following relationship:

An alternative option for more emergent situations is administration of a 100 mL bolus of 3% NaCl, repeated once if no clinical improvement, which has been recommended by a consensus conference organized to develop guidelines for prevention and treatment of exercise‐induced hyponatremia, an acute and potentially lethal condition.28 Injecting this amount of hypertonic saline intravenously raises the serum [Na+] by an average of 2 mmol/L to 4 mmol/L, which is well below the recommended maximal daily rate of change of 10 to 12 mmol/24 hours or 18 mmol/48 hours.29 Because the brain can only accommodate an average increase of approximately 8% in brain volume before herniation occurs, quickly increasing the serum [Na+] by as little as 2 mmol/L to 4 mmol/L in acute hyponatremia can effectively reduce brain swelling and intracranial pressure.30

Unfortunately, until now there has been no consensus regarding appropriate infusion rates of 3% NaCl, and many physicians are hesitant to use it in patients with chronic hyponatremia because it can cause an overly rapid correction of serum sodium levels that can lead to the osmotic demyelination syndrome (ODS).31 Nonetheless, this remains the treatment of choice for patients with severe neurological symptoms, even when the time course of the hyponatremia is nonacute or unknown. The administration of hypertonic saline is generally not recommended for most patients with edema‐forming disorders because it acts as a volume expander and may exacerbate volume overload.

Fluid Restriction

For patients with chronic hyponatremia, fluid restriction has been the most popular and most widely accepted treatment. When SIADH is present, generally fluids should be limited to 500 to 1000 mL/24 hours. Because fluid restriction increases the serum [Na+] largely by under‐replacing the excretion of fluid by the kidneys, some have advocated an initial restriction to 500 mL less than the 24‐hour urine output.32 When instituting a fluid restriction, it is important for the nursing staff and the patient to understand that this includes all fluids that are consumed, not just water. Generally the water content of ingested food is not included in the restriction because this is balanced by insensible water losses (perspiration, exhaled air, feces, etc.), but caution should be exercised with foods that have high fluid concentrations (such as fruits and soups). Restricting fluid intake is effective when properly applied and managed, but serum sodium levels are increased only slowly (1‐2 mmol/L/day) even with severe restriction.25 In addition, this therapy is often poorly tolerated because of an associated increase in thirst. However, it is economically favorable, and some patients do respond well to this option. Fluid restriction should not be used with hypovolemic patients, and is particularly difficult to maintain in patients with very elevated urine osmolalities secondary to high AVP levels; in general, if the sum of urine Na+ and K+ exceeds the serum [Na+], most patients will not respond to a fluid restriction since an electrolyte‐free water clearance will be difficult to achieve,33, 34 and in patients in intensive care settings who often require administration of fluids as part of their therapies.

Demeclocycline

Demeclocycline, a tetracycline antibiotic, inhibits adenylyl cyclase activation after AVP binds to its V2 receptor in the kidney, and thus targets the underlying pathophysiology of SIADH. This therapy is typically used when patients find severe fluid restriction unacceptable and the underlying disorder cannot be corrected. However, demeclocycline is not approved by the U.S. Food and Drug Administration (FDA) to treat hyponatremia, and can cause nephrotoxicity in patients with heart failure and cirrhosis, although this is usually reversible if caught quickly enough.35

Mineralocorticoids

Administration of mineralocorticoids, such as fludrocortisone, has been shown to be useful in a small number of elderly patients.36 However, the initial studies of SIADH did not show it to be of benefit in patients with SIADH, and it carries the risk of fluid overload and hypertension. Consequently, it is rarely used to treat hyponatremia in the U.S.

Urea

Administration of urea has been successfully used to treat hyponatremia because it induces osmotic diuresis and augments free water excretion. Effective doses of urea for treatment of hyponatremia are 30 gm to 60 gm daily in divided doses.37 Unfortunately, its use is limited because there is no United States Pharmacopeia (USP) formulation for urea, and it is not approved by the FDA for treatment of hyponatremia. As such, urea has not been used extensively in the United States, and there are limited data to support its long‐term use. Furthermore, urea is associated with poor palatability; however, patients with feeding tubes may be excellent candidates for urea therapy since palatability is not a concern, and the use of fluid restriction may be difficult in some patients with high obligate intake of fluids as part of their nutritional and medication therapy. Although mild azotemia can be seen with urea therapy, this rarely reaches clinically significant levels.

Clinicians have used all of the above conventional therapies for hyponatremia over the past decades. However, conventional therapies for hyponatremia, although effective in specific circumstances, are suboptimal for many different reasons, including variable efficacy, slow responses, intolerable side effects, and serious toxicities, as summarized in Table 2. But perhaps the most striking deficiency of most conventional therapies is that with the exception of demeclocycline, these therapies do not directly target the underlying cause of most all dilutional hyponatremias, namely inappropriately elevated plasma AVP levels. A new class of pharmacological agents, vasopressin receptor antagonists, that directly block AVP‐mediated receptor activation have recently been approved by the FDA for treatment of euvolemic and hypervolemic hyponatremia.38

AVP Receptor (AVPR) Antagonists

Conivaptan and tolvaptan are antagonists of the AVP V2 (antidiuretic) receptor and have been approved by the FDA for the treatment of euvolemic and hypervolemic hyponatremia. These agents, also known as vaptans, compete with AVP/ADH for binding at its site of action in the kidney, thereby blocking the antidiuresis caused by elevated AVP levels and directly attacking the underlying pathophysiology of dilutional hyponatremia. AVPR antagonists produce electrolyte free water excretion (called aquaresis) without affecting renal sodium and potassium excretion.39 The overall result is a reduction in body water without natriuresis, which leads to an increase in the serum [Na+]. One of the major benefits of this class of drugs is that serum [Na+] is significantly increased within 24 to 48 hours,40, 41 which is considerably faster than the effects of fluid restriction that can take many days. Also, compliance has not been shown to be problem for vaptans, whereas this is a major problem with attempted long‐term use of fluid restriction.

Conivaptan is FDA‐approved for euvolemic and hypervolemic hyponatremia in hospitalized patients. It is available only as an intravenous preparation, and is given as a 20 mg loading dose over 30 minutes, followed by a continuous infusion of 20 or 40 mg.42 Generally, the 20 mg continuous infusion is used for the first 24 hours to gauge the initial response. If the correction of serum [Na+] is felt to be inadequate (eg, <5 mmol/L), then the infusion rate can be increased to 40 mg/day. Therapy is limited to a maximum duration of 4 days because of drug‐interaction effects with other agents metabolized by the cytochrome P450 3A4 (CYP3A4) hepatic isoenzymes. Importantly, for conivaptan and all other vaptans, it is critical that the serum [Na+] concentration is measured frequently during the active phase of correction of the hyponatremia (a minimum of every 6 hours, but more frequently in patients with risk factors for development of osmotic demyelination, such as severely low serum [Na+], malnutrition, alcoholism and hypokalemia).43 If the correction approaches 12 mmol/L in the first 24 hours, the infusion should be stopped and the patient monitored on a fluid restriction. If the correction exceeds 12 mmol/L, consideration should be given to administering sufficient water, either orally or as intravenous D5W to bring the overall correction below 12 mmol/L. The maximum correction limit should be reduced to 8 mmol/L over the first 24 hours in patients with risk factors for development of osmotic demyelination. The most common adverse effects include injection‐site reactions, which are generally mild and usually do not lead to treatment discontinuation, headache, thirst, and hypokalemia.40

Tolvaptan, an oral AVPR antagonist, is FDA‐approved for treatment of dilutional hyponatremias. In contrast to conivaptan, oral administration allows it to be used for both short‐term and long‐term treatment of hyponatremia.41 Similar to conivaptan, tolvaptan treatment must be initiated in the hospital so that the rate of correction can be monitored carefully. Patients with a serum [Na+] <125 mmol/L are eligible for therapy with tolvaptan as primary therapy; if the serum [Na+] is 125 mmol/L, tolvaptan therapy is only indicated if the patient has symptoms that could be attributable to the hyponatremia and the patient is resistant to attempts at fluid restriction.44 The starting dose of tolvaptan is 15 mg on the first day, and the dose can be titrated to 30 mg and 60 mg at 24‐hour intervals if the serum [Na+] remains <135 mmol/L or the increase in serum [Na+] has been 5 mmol/L in the previous 24 hours. As with conivaptan, it is essential that the serum [Na+] concentration is measured frequently during the active phase of correction of the hyponatremia (a minimum of every 8 hrs, but more frequently in patients with risk factors for development of osmotic demyelination). Limits for safe correction of hyponatremia and methods to compensate for overly rapid corrections are the same as described previously for conivaptan. Common side effects include dry mouth, thirst, increased urinary frequency, dizziness, nausea and orthostatic hypotension, which were relatively similar between placebo and tolvaptan groups in clinical trials.41, 44

Because inducing increased renal fluid excretion via either a diuresis or an aquaresis can cause or worsen hypotension in patients with hypovolemic hyponatremia, vaptans are contraindicated in this patient population.43 However, clinically significant hypotension was not observed in either the conivaptan or tolvaptan clinical trials in euvolemic and hypervolemic hyponatremic patients. Although vaptans are not contraindicated with decreased renal function, these agents generally will not be effective if the serum creatinine is >2.5 mg/dL.

Hyponatremia Treatment Guidelines for Hospitalized Patients With SIADH

Although various authors have published recommendations on the treatment of hyponatremia,27, 43, 45‐47 no standardized treatment algorithms have yet been widely accepted. A synthesis of existing expert recommendations for treatment of hyponatremia is illustrated in Figure 2. This algorithm is based primarily on the symptomatology of hyponatremic patients, rather than the serum [Na+] or the chronicity of the hyponatremia, which are often difficult to ascertain. A careful neurological history and assessment should always be done to identify potential causes for the patient's symptoms other than hyponatremia, although it will not always be possible to exclude an additive contribution from the hyponatremia to an underlying neurological condition. In this model, patients are divided into three groups based on their presenting symptoms.

Figure 2
Algorithm for treating patients with euvolemic hyponatremia.

Level 1 symptoms include seizures, coma, respiratory arrest, obtundation, and vomiting, and usually imply a more acute onset or worsening of hyponatremia requiring immediate active treatment. Therapies that will quickly raise serum sodium levels are required to reduce cerebral edema and decrease the risk of potentially fatal herniation.

Level 2 symptoms, which are more moderate, include nausea, confusion, disorientation, and altered mental status. These symptoms may be either chronic or acute, but allow time to elaborate a more deliberate approach to treatment.

Level 3 symptoms range from minimal symptoms such as a headache, irritability, inability to concentrate, altered mood, and depression, to a virtual absence of discernable symptoms, and indicate that the patient may have chronic or slowly evolving hyponatremia. These symptoms necessitate a cautious approach, especially when patients have underlying comorbidities.

Patients with severe symptoms (Level 1) should be treated with hypertonic saline as first‐line therapy, followed by fluid restriction with or without AVPR antagonist therapy. Patients with moderate symptoms will benefit from a more aggressive regimen of vaptan therapy or limited hypertonic saline administration, followed by fluid restriction or long‐term vaptan therapy. Although moderate neurological symptoms can indicate that a patient is in an early stage of acute hyponatremia, they more often indicate a chronically hyponatremic state with sufficient brain volume adaptation to prevent marked symptomatology from cerebral edema. Regardless, close monitoring of these patients in a hospital setting is warranted until the symptoms improve or stabilize. Patients with no or minimal symptoms should be managed initially with fluid restriction, although treatment with vaptans may be appropriate for a wide range of specific clinical conditions, foremost of which is a failure to improve the serum [Na+] despite reasonable attempts at fluid restriction (Figure 2).

Although this classification is based on presenting symptoms at the time of initial evaluation, it should be remembered that in some cases patients initially exhibit more moderate symptoms because they are in the early stages of hyponatremia. In addition, some patients with minimal symptoms are prone to develop more symptomatic hyponatremia during periods of increased fluid ingestion. In support of this, approximately 70% of 31 patients presenting to a university hospital with symptomatic hyponatremia and a mean serum [Na+] of 119 mmol/L had preexisting asymptomatic hyponatremia as the most common risk factor identified.48 Consequently, therapy of hyponatremia should also be considered to prevent progression from lower to higher levels of symptomatic hyponatremia, particularly in patients with a past history of repeated presentations of symptomatic hyponatremia.

How Often Should Serum [Na+] Be Monitored in Hospitalized Patients With SIADH?

The frequency of serum [Na+] monitoring is dependent on both the severity of the hyponatremia and the therapy chosen. In all hyponatremic patients neurological symptomatology should be carefully assessed very early in the diagnostic evaluation to assess the symptomatic severity of the hyponatremia and to determine whether the patient requires more urgent therapy. All patients undergoing active treatment with hypertonic saline for level 1 or 2 symptomatic hyponatremia should have frequent monitoring of serum [Na+] and ECF volume status (every 2‐4 hours) to ensure that the serum [Na+] does not exceeded the recommended levels during the active phase of correction,43 since overly rapid correction of serum sodium can cause damage to the myelin sheath of nerve cells, resulting in central pontine myelinolysis, also called the ODS.31 Patients treated with vaptans for level 2 or 3 symptoms should have serum [Na+] monitored every 6 to 8 hours during the active phase of correction, which will generally be the first 24 to 48 hours of therapy. Active treatment with hypertonic saline or vaptans should be stopped when the patient's symptoms are no longer present, a safe serum [Na+] (usually >120 mmol/L) has been achieved, or the rate of correction has reached 12 mmol/L within 24 hours or 18 mmol/L within 48 hours.29, 43 Importantly, ODS has not been reported either in clinical trials or with therapeutic use of any vaptan to date. In patients with a stable level of serum [Na+] treated with fluid restriction or therapies other than hypertonic saline, measurement of serum [Na+] daily is generally sufficient, since levels will not change that quickly in the absence of active therapy or large changes in fluid intake or administration.

Potential Future Indications for Treatment of Hyponatremia

Correction of hyponatremia improves other symptoms, such as gait stability, in patients who may be considered to be asymptomatic by virtue of a normal neurological exam. In 1 study, 16 patients with hyponatremia secondary to SIADH in the range of 124 mmol/L to 130 mmol/L demonstrated a significant gait instability that normalized after correction of the hyponatremia to normal ranges.49 The functional significance of the gait instability was illustrated in a study of 122 Belgian patients with a variety of levels of hyponatremia, all judged to be asymptomatic at the time of visit to an emergency department (ED). These patients were compared with 244 age‐matched, sex‐matched, and disease‐matched controls also presenting to the ED during the same time period. Researchers found that 21% of the hyponatremic patients presented to the ED because of a recent fall, compared to only 5% of the controls, resulting in an adjusted odds ratio (OR) for presenting to the ED because of a recent fall of 67 for hyponatremia (P < 0.001).49 Consequently, this study clearly documented an increased incidence of falls in so‐called asymptomatic hyponatremic patients.

The clinical significance of the gait instability and fall data were further evaluated in a study that compared 553 patients with fractures to an equal number of age‐matched and sex‐matched controls. Hyponatremia was found in 13% of the patients presenting with fractures compared to only 4% of the controls.50 Similar findings have been reported in a 364 elderly patients with large‐bone fractures in New York.51 More recently published studies have shown that hyponatremia is associated with increased bone loss in experimental animals and a significant increased OR for osteoporosis of the femoral neck (OR, 2.87; P < 0.003) in humans over the age of 50 in the NHANES III database.52 Thus, the major clinical significance of chronic hyponatremia may be the increased morbidity and mortality associated with falls and fractures in our elderly population.

Summary

Disorders of sodium and water metabolism are commonly encountered in the hospital setting due to the wide range of disease states that can disrupt the balanced control of water and solute intake and output. In particular, the prompt identification and appropriate management of abnormally low serum [Na+] is critical if we are to reduce the increased morbidity and mortality that accompany hyponatremia in hospitalized patients. Use of an algorithm that is based primarily on the symptomatology of hyponatremic patients, rather than the chronicity of the hyponatremia or the serum [Na+], will help to choose the correct initial therapy in hospitalized hyponatremic patients. However, careful monitoring of serum [Na+] responses is required in all cases to adjust therapy appropriately in response to changing clinical conditions. Although this approach will enable efficacious and safe treatment of hyponatremic patients with SIADH at the present time, evolving knowledge of the consequences of chronic hyponatremia will likely alter treatment indications and guidelines in the future.

References
  1. Hawkins RC.Age and gender as risk factors for hyponatremia and hypernatremia.Clin Chim Acta.2003;337(1‐2):169172.
  2. Upadhyay A,Jaber BL,Madias NE.Incidence and prevalence of hyponatremia.Am J Med.2006;119(7 Suppl 1):S30S35.
  3. Terzian C,Frye EB,Piotrowski ZH.Admission hyponatremia in the elderly: factors influencing prognosis.J Gen Intern Med1994;9:8991.
  4. Bennani SL,Abouqal R,Zeggwagh AA, et al.[Incidence, causes and prognostic factors of hyponatremia in intensive care].Rev Med Interne.2003;24(4):224229.
  5. Chung HM,Kluge R,Schrier RW,Anderson RJ.Postoperative hyponatremia. A prospective study.Arch Int Med.1986;146:333336.
  6. Verbalis JG.Whole‐body volume regulation and escape from antidiuresis.Am J Med.2006;119(7 Suppl 1):S21S29.
  7. Robertson GL,Aycinena P,Zerbe RL.Neurogenic disorders of osmoregulation.Am J Med.1982;72:339353.
  8. Zerbe R,Stropes L,Robertson G.Vasopressin function in the syndrome of inappropriate antidiuresis.Annu Rev Med.1980;31:315327.
  9. Szatalowicz VL,Arnold PE,Chaimovitz C,Bichet D,Berl T,Schrier RW.Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure.N Eng J Med.1981;305:263266.
  10. Fraser CL,Arieff AI.Epidemiology, pathophysiology, and management of hyponatremic encephalopathy.Am J Med.1997;102:6777.
  11. Ayus JC,Arieff AI.Pulmonary complications of hyponatremic encephalopathy. noncardiogenic pulmonary edema and hypercapnic respiratory failure [see comments].Chest.1995;107(2):517521.
  12. Gullans SR,Verbalis JG.Control of brain volume during hyperosmolar and hypoosmolar conditions.Annu Rev Med.1993;44:289301.
  13. Verbalis JG.Control of brain volume during hypoosmolality and hyperosmolality.Adv Exp Med Biol.2006;576:113129.
  14. Chow KM,Kwan BC,Szeto CC.Clinical studies of thiazide‐induced hyponatremia.J Natl Med Assoc.2004;96(10):13051308.
  15. Chung HM,Kluge R,Schrier RW,Anderson RJ.Clinical assessment of extracellular fluid volume in hyponatremia.Am J Med.1987;83:905908.
  16. Bartter FC,Schwartz WB.The syndrome of inappropriate secretion of antidiuretic hormone.Am J Med.1967;42:790806.
  17. Verbalis JG.Hyponatremia and Hypo‐osmolar Disorders. In: Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC, eds.Primer on Kidney Diseases.Philadelphia:Saunders Elsevier,2009:5259.
  18. Michelis MF,Fusco RD,Bragdon RW,Davis BB.Reset of osmoreceptors in association with normovolemic hyponatremia.Am J Med Sci.1974;267:267273.
  19. Oelkers W.Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism.N Eng J Med.1989;321:492496.
  20. Verbalis JG.The Syndrome of Inappropriate Antidiuretic Hormone Secretion and Other Hypoosmolar Disorders. In: Schrier RW, ed.Diseases of the Kidney and Urinary Tract.Philadelphia:Lippincott Williams 27:156161.
  21. Miller M,Morley JE,Rubenstein LZ.Hyponatremia in a nursing home population.J Am Geriatr Soc.1995;43(12):14101413.
  22. Hirshberg B,Ben‐Yehuda A.The syndrome of inappropriate antidiuretic hormone secretion in the elderly.Am J Med.1997;103(4):270273.
  23. Ayus JC.Diuretic‐induced hyponatremia [editorial].Arch Intern Med.1986;146(7):12951296.
  24. Schwartz WB,Bennett S,Curelop S,Bartter FC.A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone.Am J Med.1957;23:529542.
  25. Steele A,Gowrishankar M,Abrahamson S,Mazer CD,Feldman RD,Halperin ML.Postoperative hyponatremia despite near‐isotonic saline infusion: a phenomenon of desalination [see comments].Ann Intern Med.1997;126(1):2025.
  26. Adrogue HJ,Madias NE.Hyponatremia.N Engl J Med.2000;342(21):15811589.
  27. Hew‐Butler T,Ayus JC,Kipps C, et al.Statement of the Second International Exercise‐Associated Hyponatremia Consensus Development Conference, New Zealand, 2007.Clin J Sport Med.2008;18(2):111121.
  28. Sterns RH,Cappuccio JD,Silver SM,Cohen EP.Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective.J Am Soc Nephrol.1994;4:15221530.
  29. Battison C,Andrews PJ,Graham C,Petty T.Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury.Crit Care Med.2005;33(1):196202.
  30. Sterns RH,Riggs JE,Schochet SS.Osmotic demyelination syndrome following correction of hyponatremia.N Engl J Med.1986;314:15351542.
  31. Robertson GL.Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis.Am J Med.2006;119(7 Suppl 1):S36S42.
  32. Decaux G.The syndrome of inappropriate secretion of antidiuretic hormone (SIADH).Semin Nephrol.2009;29(3):239256.
  33. Berl T.Impact of solute intake on urine flow and water excretion.J Am Soc Nephrol.2008;19(6):10761078.
  34. Singer I,Rotenberg D.Demeclocycline‐induced nephrogenic diabetes insipidus. In‐vivo and in‐ vitro studies.Ann Intern Med.1973;79(5):679683.
  35. Ishikawa S,Fujita N,Fujisawa G, et al.Involvement of arginine vasopressin and renal sodium handling in pathogenesis of hyponatremia in elderly patients.Endocr J.1996;43(1):101108.
  36. Decaux G,Genette F.Urea for long‐term treatment of syndrome of inappropriate secretion of antidiuretic hormone.Br Med J (Clin Res Ed).1981;283:10811083.
  37. Greenberg A,Verbalis JG.Vasopressin receptor antagonists.Kidney Int.2006;69(12):21242130.
  38. Ohnishi A,Orita Y,Okahara R, et al.Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC‐31260) in men.J Clin Invest.1993;92(6):26532659.
  39. Zeltser D,Rosansky S,van Rensburg H,Verbalis JG,Smith N.Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.Am J Nephrol.2007;27(5):447457.
  40. Schrier RW,Gross P,Gheorghiade M, et al.Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia.N Engl J Med.2006;355(20):20992112.
  41. Vaprisol (conivaptan hydrochloride injection) prescribing information.Deerfield, IL:Astellas Pharma US, Inc.,2006.
  42. Verbalis JG,Goldsmith SR,Greenberg A,Schrier RW,Sterns RH.Hyponatremia treatment guidelines 2007: expert panel recommendations.Am J Med.2007;120(11 Suppl 1):S1S21.
  43. Otsuka Pharmaceutical Co L, Tokyo J. Samsca (tolvaptan) prescribing information.2009.
  44. Ellison DH,Berl T.Clinical practice. The syndrome of inappropriate antidiuresis.N Engl J Med.2007;356(20):20642072.
  45. Sterns RH,Nigwekar SU,Hix JK.The treatment of hyponatremia.Semin Nephrol.2009;29(3):282299.
  46. Verbalis JG.Hyponatremia and Hypo‐osmolar Disorders. In: Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC, eds.Primer on Kidney Diseases.Philadelphia. PA:Saunders Elsevier;2009:5259.
  47. Bissram M,Scott FD,Liu L,Rosner MH.Risk factors for symptomatic hyponatraemia: the role of pre‐existing asymptomatic hyponatraemia.Intern Med J.2007;37(3):149155.
  48. Renneboog B,Musch W,Vandemergel X,Manto MU,Decaux G.Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits.Am J Med.2006;119(1):71.
  49. Gankam KF,Andres C,Sattar L,Melot C,Decaux G.Mild hyponatremia and risk of fracture in the ambulatory elderly.QJM.2008;101(7):583588.
  50. Sandhu HS,Gilles E,DeVita MV,Panagopoulos G,Michelis MF.Hyponatremia associated with large‐bone fracture in elderly patients.Int Urol Nephrol.2009;41(3):733737.
  51. Verbalis JG,Barsony J,Sugimura Y, et al.Hyponatremia‐induced osteoporosis.J Bone Miner Res.2010;25(3):554563.
References
  1. Hawkins RC.Age and gender as risk factors for hyponatremia and hypernatremia.Clin Chim Acta.2003;337(1‐2):169172.
  2. Upadhyay A,Jaber BL,Madias NE.Incidence and prevalence of hyponatremia.Am J Med.2006;119(7 Suppl 1):S30S35.
  3. Terzian C,Frye EB,Piotrowski ZH.Admission hyponatremia in the elderly: factors influencing prognosis.J Gen Intern Med1994;9:8991.
  4. Bennani SL,Abouqal R,Zeggwagh AA, et al.[Incidence, causes and prognostic factors of hyponatremia in intensive care].Rev Med Interne.2003;24(4):224229.
  5. Chung HM,Kluge R,Schrier RW,Anderson RJ.Postoperative hyponatremia. A prospective study.Arch Int Med.1986;146:333336.
  6. Verbalis JG.Whole‐body volume regulation and escape from antidiuresis.Am J Med.2006;119(7 Suppl 1):S21S29.
  7. Robertson GL,Aycinena P,Zerbe RL.Neurogenic disorders of osmoregulation.Am J Med.1982;72:339353.
  8. Zerbe R,Stropes L,Robertson G.Vasopressin function in the syndrome of inappropriate antidiuresis.Annu Rev Med.1980;31:315327.
  9. Szatalowicz VL,Arnold PE,Chaimovitz C,Bichet D,Berl T,Schrier RW.Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure.N Eng J Med.1981;305:263266.
  10. Fraser CL,Arieff AI.Epidemiology, pathophysiology, and management of hyponatremic encephalopathy.Am J Med.1997;102:6777.
  11. Ayus JC,Arieff AI.Pulmonary complications of hyponatremic encephalopathy. noncardiogenic pulmonary edema and hypercapnic respiratory failure [see comments].Chest.1995;107(2):517521.
  12. Gullans SR,Verbalis JG.Control of brain volume during hyperosmolar and hypoosmolar conditions.Annu Rev Med.1993;44:289301.
  13. Verbalis JG.Control of brain volume during hypoosmolality and hyperosmolality.Adv Exp Med Biol.2006;576:113129.
  14. Chow KM,Kwan BC,Szeto CC.Clinical studies of thiazide‐induced hyponatremia.J Natl Med Assoc.2004;96(10):13051308.
  15. Chung HM,Kluge R,Schrier RW,Anderson RJ.Clinical assessment of extracellular fluid volume in hyponatremia.Am J Med.1987;83:905908.
  16. Bartter FC,Schwartz WB.The syndrome of inappropriate secretion of antidiuretic hormone.Am J Med.1967;42:790806.
  17. Verbalis JG.Hyponatremia and Hypo‐osmolar Disorders. In: Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC, eds.Primer on Kidney Diseases.Philadelphia:Saunders Elsevier,2009:5259.
  18. Michelis MF,Fusco RD,Bragdon RW,Davis BB.Reset of osmoreceptors in association with normovolemic hyponatremia.Am J Med Sci.1974;267:267273.
  19. Oelkers W.Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism.N Eng J Med.1989;321:492496.
  20. Verbalis JG.The Syndrome of Inappropriate Antidiuretic Hormone Secretion and Other Hypoosmolar Disorders. In: Schrier RW, ed.Diseases of the Kidney and Urinary Tract.Philadelphia:Lippincott Williams 27:156161.
  21. Miller M,Morley JE,Rubenstein LZ.Hyponatremia in a nursing home population.J Am Geriatr Soc.1995;43(12):14101413.
  22. Hirshberg B,Ben‐Yehuda A.The syndrome of inappropriate antidiuretic hormone secretion in the elderly.Am J Med.1997;103(4):270273.
  23. Ayus JC.Diuretic‐induced hyponatremia [editorial].Arch Intern Med.1986;146(7):12951296.
  24. Schwartz WB,Bennett S,Curelop S,Bartter FC.A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone.Am J Med.1957;23:529542.
  25. Steele A,Gowrishankar M,Abrahamson S,Mazer CD,Feldman RD,Halperin ML.Postoperative hyponatremia despite near‐isotonic saline infusion: a phenomenon of desalination [see comments].Ann Intern Med.1997;126(1):2025.
  26. Adrogue HJ,Madias NE.Hyponatremia.N Engl J Med.2000;342(21):15811589.
  27. Hew‐Butler T,Ayus JC,Kipps C, et al.Statement of the Second International Exercise‐Associated Hyponatremia Consensus Development Conference, New Zealand, 2007.Clin J Sport Med.2008;18(2):111121.
  28. Sterns RH,Cappuccio JD,Silver SM,Cohen EP.Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective.J Am Soc Nephrol.1994;4:15221530.
  29. Battison C,Andrews PJ,Graham C,Petty T.Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury.Crit Care Med.2005;33(1):196202.
  30. Sterns RH,Riggs JE,Schochet SS.Osmotic demyelination syndrome following correction of hyponatremia.N Engl J Med.1986;314:15351542.
  31. Robertson GL.Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis.Am J Med.2006;119(7 Suppl 1):S36S42.
  32. Decaux G.The syndrome of inappropriate secretion of antidiuretic hormone (SIADH).Semin Nephrol.2009;29(3):239256.
  33. Berl T.Impact of solute intake on urine flow and water excretion.J Am Soc Nephrol.2008;19(6):10761078.
  34. Singer I,Rotenberg D.Demeclocycline‐induced nephrogenic diabetes insipidus. In‐vivo and in‐ vitro studies.Ann Intern Med.1973;79(5):679683.
  35. Ishikawa S,Fujita N,Fujisawa G, et al.Involvement of arginine vasopressin and renal sodium handling in pathogenesis of hyponatremia in elderly patients.Endocr J.1996;43(1):101108.
  36. Decaux G,Genette F.Urea for long‐term treatment of syndrome of inappropriate secretion of antidiuretic hormone.Br Med J (Clin Res Ed).1981;283:10811083.
  37. Greenberg A,Verbalis JG.Vasopressin receptor antagonists.Kidney Int.2006;69(12):21242130.
  38. Ohnishi A,Orita Y,Okahara R, et al.Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC‐31260) in men.J Clin Invest.1993;92(6):26532659.
  39. Zeltser D,Rosansky S,van Rensburg H,Verbalis JG,Smith N.Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.Am J Nephrol.2007;27(5):447457.
  40. Schrier RW,Gross P,Gheorghiade M, et al.Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia.N Engl J Med.2006;355(20):20992112.
  41. Vaprisol (conivaptan hydrochloride injection) prescribing information.Deerfield, IL:Astellas Pharma US, Inc.,2006.
  42. Verbalis JG,Goldsmith SR,Greenberg A,Schrier RW,Sterns RH.Hyponatremia treatment guidelines 2007: expert panel recommendations.Am J Med.2007;120(11 Suppl 1):S1S21.
  43. Otsuka Pharmaceutical Co L, Tokyo J. Samsca (tolvaptan) prescribing information.2009.
  44. Ellison DH,Berl T.Clinical practice. The syndrome of inappropriate antidiuresis.N Engl J Med.2007;356(20):20642072.
  45. Sterns RH,Nigwekar SU,Hix JK.The treatment of hyponatremia.Semin Nephrol.2009;29(3):282299.
  46. Verbalis JG.Hyponatremia and Hypo‐osmolar Disorders. In: Greenberg A, Cheung AK, Coffman TM, Falk RJ, Jennette JC, eds.Primer on Kidney Diseases.Philadelphia. PA:Saunders Elsevier;2009:5259.
  47. Bissram M,Scott FD,Liu L,Rosner MH.Risk factors for symptomatic hyponatraemia: the role of pre‐existing asymptomatic hyponatraemia.Intern Med J.2007;37(3):149155.
  48. Renneboog B,Musch W,Vandemergel X,Manto MU,Decaux G.Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits.Am J Med.2006;119(1):71.
  49. Gankam KF,Andres C,Sattar L,Melot C,Decaux G.Mild hyponatremia and risk of fracture in the ambulatory elderly.QJM.2008;101(7):583588.
  50. Sandhu HS,Gilles E,DeVita MV,Panagopoulos G,Michelis MF.Hyponatremia associated with large‐bone fracture in elderly patients.Int Urol Nephrol.2009;41(3):733737.
  51. Verbalis JG,Barsony J,Sugimura Y, et al.Hyponatremia‐induced osteoporosis.J Bone Miner Res.2010;25(3):554563.
Issue
Journal of Hospital Medicine - 5(3)
Issue
Journal of Hospital Medicine - 5(3)
Page Number
S18-S26
Page Number
S18-S26
Article Type
Display Headline
Managing hyponatremia in patients with syndrome of inappropriate antidiuretic hormone secretion
Display Headline
Managing hyponatremia in patients with syndrome of inappropriate antidiuretic hormone secretion
Sections
Article Source
Copyright © 2010 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
Division of Endocrinology and Metabolism, Georgetown University Medical Center, 4000 Reservoir Road NW, Bldg D, Suite 232, Washington, DC 20007
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media